Pyridizinone derivatives

ABSTRACT

The present invention provides compounds of formula (I*):  
                 
 
     their use as H 3  inhibitors, processes for their preparation, and pharmaceutical compositions thereof.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application Ser. No. 60/833,164 filed Jul. 25, 2006, the disclosure of which is incorporated herein by reference in its entirety.

FIELD OF THE INVENTION

The present invention is related to pyridizinone derivatives, their use as H₃ inhibitors, processes for their preparation, and pharmaceutical compositions thereof.

BACKGROUND OF THE INVENTION

Histamine is a well established modulator of neuronal activity. At least four subtypes of histamine receptors have been reported in the literature—H₁, H₂, H₃, H₄. The histamine H₃ receptors play a key role in neurotransmission in the central nervous system. The H₃ receptor was discovered in 1983 originally on histamine-containing neurons where it was shown to function presynaptically, regulating the release and synthesis of the biogenic amine histamine (Arrang et al, 1983) now a well established neurotransmitter. H₃ receptors are predominately expressed in the brain, localizing to the cerebral cortex, amygdala, hippocampus, striatum, thalamus and hypothalamus. H₃ receptors are also localized presynaptically on histaminergic nerve terminals and act as inhibitory autoreceptors (Alguacil and Perez-Garcia, 2003; Passani et al, 2004; Leurs at al, 2005; Celanire et al, 2005; Witkin and Nelson, 2004). When these receptors are activated by histamine, histamine release is inhibited. H₃ receptors can also be found in the periphery (skin, lung, cardiovascular system, intestine, GI tract, etc). H₃ receptors are also involved in presynaptic regulation of the release of acetylcholine, dopamine, GABA, glutamate and serotonin (see Repka-Ramirez, 2003; Chazot and Hann, 2001; Leurs et al, 1998). The H₃ receptor demonstrates a high degree of constitutive or spontaneous activity (e.g., receptor is active in the absence of agonist stimulation) in vitro and in vivo, thus, ligands to the receptor can display, agonist, neutral antagonist or inverse agonist effects.

The location and function of histaminergic neurons in the CNS suggests that compounds interacting with the H₃ receptor may have utility in a number of therapeutic applications including narcolepsy or sleep/wake disorders, feeding behavior, eating disorders, obesity, cognition, arousal, memory, mood disorders, mood attention alteration, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease/dementia, schizophrenia, pain, stress, migraine, motion sickness, depression, psychiatric disorders and epilepsy (Leurs et al, 2005; Witkin and Nelson, 2004, Hancock and Fox 2004; Esbenshade et al. 2006). An H₃ antagonist/inverse agonist could be important for gastrointestinal disorders, respiratory disorders such as asthma, inflammation, and myocardial infarction.

Ohtake et al. (US 2006/0178375 A1) disclosed compounds that reportedly exhibit histamine receptor H₃ antagonist or inverse agonist activity and may be useful for the treatment or prevention of obesity, diabetes, hormonal secretion abnormality, or sleep disorders.

Celanire et al. (WO 2006/103057 A1 and WO 2006/103045) have disclosed compounds comprising an oxazoline or thiazoline moiety, processes for preparing them, their pharmaceutical compositions and their uses as H₃ ligands.

Bertrand et al. (WO 2006/117609 A2) disclosed novel histamine H₃ receptor ligands, processes for their preparation, and their therapeutic applications.

Schwartz et al. (WO 2006/103546 A2) disclosed certain methods of treatment for Parkinson's disease, obstructive sleep apnea, narcolepsy, dementia with Lewy bodies, and/or vascular dementia using non-imidazole alkylamine derivatives that are antagonists of the H₃ receptors of histamine.

Apodaca et al. (EP 1 311 482 B1) disclosed certain non-imidazole aryloxypiperidines as H₃ receptor ligands, their synthesis, and their use for the treatment of disorders and conditions mediated by the histamine receptor.

Xu et al. disclosed certain 6-substituted phenyl-4,5-dihydro-3(2H)-pyridazinones, their synthesis, and rabbit platelet aggregation inhibitory activity induced by ADP in vitro.

Thus, there is a need for novel classes of compounds that possess the beneficial properties. It has been discovered that currently disclosed class of compounds, referred to herein as substituted pyridizinone derivatives, are useful as agents for treating or preventing various diseases or disorders disclosed herein.

SUMMARY OF THE INVENTION

Accordingly, the present invention is directed, in part, to novel pyridizinone compounds which may be useful as H₃ inhibitors, and thus may be useful, inter alia, in methods for treating diseases, disorders, and/or conditions that may be mediated or modulated by inhibition of H₃, or otherwise associated with the H₃ receptor system, including, for example, narcolepsy or sleep/wake disorders, feeding behavior, eating disorders, obesity, cognition, arousal, memory, mood disorders, mood attention alteration, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease/dementia, schizophrenia, pain, stress, migraine, motion sickness, depression, psychiatric disorders, epilepsy, gastrointestinal disorders, respiratory disorders (such as asthma), inflammation, and myocardial infarction. In preferred form, the novel compounds of the invention have the following formula I*:

or a stereoisomeric form, mixture of stereoisomeric forms, or a pharmaceutically acceptable salt forms thereof, wherein:

-   X and X^(a) are each independently CH or N; -   Y is S(O)_(q), O, or NR¹⁵; -   R¹ is NR¹⁰R¹¹ or a 4- to 9-membered heterocycloalkyl ring containing     1 or 2 nitrogen atoms and optionally substituted with 1 to 3 R²⁰     groups; -   R² is     -   wherein:         -   when X and X^(a) are both CH, then R² is meta or para to the             Y—(CHR⁴)_(m)—R¹ group; and         -   when either X or X^(a) are N, then R² is para to the             Y—(CHR⁴)_(m)—R¹ group; -   each R³ is:     -   independently H, F, Cl, Br, I, OR²¹, NR²³R²⁴, NO₂, CN, CF₃,         C₁-C₆alkyl, C(═O)R²¹, CO₂R²¹, or C(═O)NR²³R²⁴; or     -   when R³ is ortho to R², and R² is (i), (ii), (iv), (vi), or         (ix), then R³ and R¹⁴ taken together may form —(CH₂)_(s)—,         —CH₂Z-, -ZCH₂—, -ZCH₂CH₂— or CH₂CH₂Z-; wherein Z is O, S(O)_(y),         or NR²⁷ or     -   when R³ is ortho to R², and R² is (iv), (v), or (viii), then R³         and R¹³ taken together may form —(CH₂)_(s)—, —CH₂Z-, -ZCH₂—,         -ZCH₂CH₂— or CH₂CH₂Z-; or     -   when R³ is ortho to R², and R² is (viii), then R³ and R^(13b)         taken together may form —(CH₂)_(s)—, —CH₂Z-, -ZCH₂—, -ZCH₂CH₂—         or CH₂CH₂Z-; or     -   when R³ is ortho to X^(a) and R² is ortho to R³ and meta to         X^(a), then R² and R³ taken together may form: -   each R⁴ is independently H, C₁-C₆alkyl, or OR²¹, wherein the alkyl     group is optionally substituted with 1 to 3 R²⁰ groups; -   R¹⁰ and R¹¹ are each independently H, C₁-C₆alkyl, or     C₃-C₆cycloalkyl, wherein the alkyl or cycloalkyl group is optionally     substituted with 1 to 3 R²⁰ groups; -   R¹² is H, C₁-C₆alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl,     heterocycloalkyl, C(═O)R²⁷, or CO₂R²⁷, wherein the alkyl,     cycloalkyl, aryl, arylalkyl, heteroaryl, or heterocycloalkyl group     is optionally substituted with 1 to 3 R²⁰ groups; -   R¹³ and R¹⁴ are each independently H, C₁-C₆alkyl, aryl, arylalkyl     C₁-C₆alkoxyl, S(═O)_(y)—C₁-C₆alkyl, cycloalkyl, heterocycloalkyl, or     heteroaryl; -   R^(13a), R^(13b), R^(13c), and R^(14a) are each independently H,     C₁-C₆alkyl; or R¹³ and R¹⁴, taken together with the carbon atoms     through which they are connected form a fused phenyl, thienyl,     pyrrolyl, oxazolyl, pyridinyl, or C₃-C₆cycloalkyl ring; or R^(13b)     and R¹⁴, or R¹³ and ^(14a), or R^(13b) and ^(14a), or R^(13c) and     R^(14a), taken together with the carbon atoms through which they are     connected form a fused C₃-C₆cycloalkyl ring; or R¹³ and R^(13a), or     R¹⁴ and R^(14a), taken together with the carbon atom to which they     are attached form a C₃-C₈cycloalkyl ring; provided that no more than     one pair of R¹³ and R¹⁴, R^(13b) and R¹⁴, R¹³ and R^(14a), R^(13b)     and R^(14a), R^(13c) and R^(14a), R¹³ and R^(13a), and R¹⁴ and     R^(14a) are taken together with the carbon atoms through which they     are connected or to which they are attached to form a ring; and     wherein the fused phenyl, thienyl, pyrrolyl, oxazolyl, pyridinyl, or     cycloalkyl ring is optionally substituted with 1 to 3 R²⁰ groups; -   R¹⁵ is H, C₁-C₆ alkyl, C(═O)R²⁵, CO₂R²⁵; -   R²⁰ at each occurrence is independently, H, F, Cl, Br, I, OR²¹,     OR²², NR²³R²⁴, NHOH, NO₂, CN, CF₃, C₁-C₆ alkyl optionally     substituted with OR²⁶, C₂-C₆ alkenyl, C₂-C₆ alkynyl,     C₃-C₇cycloalkylC₀-C₄alkyl, 3- to 7-membered     heterocycloalkylC₀-C₄alkyl, phenyl, 5- or 6-membered     heteroarylC₀-C₄alkyl, arylalkyl, (═O), C(═O)R²¹, CO₂R²¹, OC(═O)R²¹,     C(═O)NR²³R²⁴, NR²⁷C(═O)R²¹, NR²⁷C(═O)OR²¹, OC(═O)NR²³R²⁴,     NR²⁷C(═S)R²¹, or S(O)_(q)R²¹; -   each R²¹ is independently H, C₁-C₆alkyl, aryl, or arylalkyl; -   each R²² is independently the residue of an amino acid after the     hydroxyl group of the carboxyl group is removed; -   each R²³ and R²⁴ is independently selected from H, C₁-C₆alkyl, and     aryl, or R²³ and R²⁴, together with the nitrogen atom to which they     are attached, form a 3 to 7 membered heterocyclic ring optionally     substituted with ═O; -   R²⁵ is C₁-C₆alkyl, aryl, or alkylaryl; -   R²⁶ is H, C₁-C₆alkyl, aryl, or alkylaryl; -   R²⁷ is H or C₁-C₆alkyl; -   m is 1, 2, 3, 4, or 5 when R¹ is attached via a nitrogen atom, and m     is 0, 1, 2, 3, 4, or 5 when R¹ is attached via a carbon atom; -   n is 1, 2, or 3; -   q is 0, 1, or 2; -   s is 1, 2, or 3; and -   y is 0, 1, or 2.

In another aspect, the present invention is directed to pharmaceutical compositions which comprise a pharmaceutically acceptable carrier and a compound of the present invention, preferably in a therapeutically effective amount.

In other aspects, the present invention is directed to methods for treating a disorder selected from the group consisting of narcolepsy or sleep/wake disorders, feeding behavior, eating disorders, obesity, cognition, arousal, memory, mood disorders, mood attention alteration, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease/dementia, schizophrenia, pain, stress, migraine, motion sickness, depression, psychiatric disorders, epilepsy, gastrointestinal disorders, respiratory disorders, inflammation, and myocardial infarction in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of the present invention.

These and other aspects of the invention will become more apparent from the following detailed description.

DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

The invention is generally directed to pyridizinone derivatives, processes for their preparation, and pharmaceuticals compositions their and methods of their pharmaceutical use.

As employed above and throughout the disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings.

As used herein, the term “about” refers to a range of values from ±10% of a specified value. For example, the phrase “about 50” includes ±10% of 50, or from 45 to 55. The phrase “from about 10 to 100” includes ±10% of 10 and ±10% of 100, or from 9 to 110.

As used herein, a range of values in the form “x-y” or “x to y”, or “x through y”, include integers x, y, and the integers therebetween. For example, the phrases “1-6”, or “1 to 6” or “1 through 6” are intended to include the integers 1, 2, 3, 4, 5, and 6. Preferred embodiments include each individual integer in the range, as well as any subcombination of integers. For example, preferred integers for “1-6” can include 1, 2, 3, 4, 5, 6, 1 to 2, 1 to 3, 1 to 4, 1 to 5, 2 to 3, 2 to 4, 2 to 5, 2 to 6, etc.

As used herein “stable compound” or “stable structure” refers to a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and preferably capable of formulation into an efficacious therapeutic agent. The present invention is directed only to stable compounds.

As used herein, “substituted” refers to any one or more hydrogen atoms on the indicated atom is replaced with a selected group referred to herein as a “substituent”, provided that the substituted atom's valency is not exceeded, and that the substitution results in a stable compound. A substituted group has 1 to 5, preferably 1 to 3, and more preferably 1 independently selected substituents. Preferred substituents include, but are not limited to F, Cl, Br, I, OH, OR, NH₂, NHR, NR₂, NHOH, NO₂, CN, CF₃, CF₂CF₃, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkoxy, C₃-C₇ cycloalkyl, heterocyclyl, C₆-C₁₀ aryl, heteroaryl, arylalkyl, ═O, C(═O)R, COOH, CO₂R, O—C(═O)R, C(═O)NRR′, NRC(═O)R′, NRCO₂R′, OC(═O)NRR′, —NRC(═O)NRR′, —NRC(═S)NRR′, and —SO₂NRR′, wherein R and R′ are each independently hydrogen, C₁-C₆ alkyl, or C₆-C₁₀ aryl.

As used herein, the term “alkyl” refers to a straight-chain, or branched alkyl group having 1 to 8 carbon atoms, preferably from 1 to 6, with 1 to 3 more preferred. Exemplary alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isoamyl, neopentyl, 1-ethylpropyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, hexyl, octyl, etc. The alkyl moiety of alkyl-containing groups, such as alkoxy, alkoxycarbonyl, and alkylaminocarbonyl groups, has the same meaning as alkyl defined above. Lower alkyl groups, which are preferred, are alkyl groups as defined above which contain 1 to 4 carbons. A designation such as “C₁-C₄ alkyl” refers to an alkyl radical containing from 1 to 4 carbon atoms. Alkyl groups may be optionally substituted.

As used herein, the term “alkenyl” refers to a straight chain, or branched hydrocarbon chains of 2 to 8 carbon atoms having at least one carbon-carbon double bond. A designation “C₂-C₈ alkenyl” refers to an alkenyl radical containing from 2 to 8 carbon atoms. Examples of alkenyl groups include ethenyl, propenyl, isopropenyl, 2,4-pentadienyl, etc. Alkenyl groups may be optionally substituted.

As used herein, the term “alkynyl” refers to a straight chain, or branched hydrocarbon chains of 2 to 8 carbon atoms having at least one carbon-carbon triple bond. A designation “C₂-C₈ alkynyl” refers to an alkynyl radical containing from 2 to 8 carbon atoms. Examples include ethynyl, propynyl, isopropynyl, 3,5-hexadiynyl, etc. Alkynyl groups may be optionally substituted.

As used herein, the term “cycloalkyl” refers to a saturated or partially saturated mono- or bicyclic alkyl ring system containing 3 to 10 carbon atoms. Certain embodiments contain 3 to 6 carbon atoms, preferably 3 or 4 carbon atoms, and other embodiments contain 5 or 6 carbon atoms. A designation such as “C₅-C₇ cycloalkyl” refers to a cycloalkyl radical containing from 5 to 7 ring carbon atoms. Examples of cycloalkyl groups include such groups as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, pinenyl, pinanyl, and adamantanyl. Cycloalkyl groups may be optionally substituted.

As used herein, the term “aryl” refers to a substituted or unsubstituted, mono- or bicyclic hydrocarbon aromatic ring system having 6 to 12 ring carbon atoms. Examples include phenyl and naphthyl. Preferred aryl groups include unsubstituted or substituted phenyl and naphthyl groups. Included within the definition of “aryl” are fused ring systems, including, for example, ring systems in which an aromatic ring is fused to a cycloalkyl ring. Examples of such fused ring systems include, for example, indane, indene, and tetrahydronaphthalene. Aryl groups may be optionally substituted.

As used herein, the terms “heterocycle”, “heterocyclic” or “heterocyclyl” refer to a substituted or unsubstituted carbocyclic group in which one or more ring carbon atoms are replaced by at least one hetero atom such as —O—, —N—, or —S—. Certain embodiments include 4 to 9 membered rings preferably 3 to 7 membered rings, and other embodiments include 5 or 6 membered rings. The nitrogen and sulfur heteroatoms may be optionally oxidized, and the nitrogen may be optionally substituted in non-aromatic rings. Heterocycles are intended to include heteroaryl and heterocycloalkyl groups. Heterocyclic groups may be optionally substituted.

As used herein, the term “heteroaryl” refers to an aromatic group containing 5 to 10 ring carbon atoms in which one or more ring carbon atoms are replaced by at least one hetero atom such as —O—, —N—, or —S—. Certain embodiments include 5 or 6 membered rings. Examples of heteroaryl groups include pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, isoxazolyl, oxazolyl, oxathiolyl, oxadiazolyl, triazolyl, oxatriazolyl, furazanyl, tetrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, picolinyl, indolyl, isoindolyl, indazolyl, benzofuranyl, isobenzofuranyl, purinyl, quinazolinyl, quinolyl, isoquinolyl, benzoimidazolyl, benzothiazolyl, benzothiophenyl, thianaphthenyl, benzoxazolyl, benzisoxazolyl, cinnolinyl, phthalazinyl, naphthyridinyl, and quinoxalinyl. Included within the definition of “heteroaryl” are fused ring systems, including, for example, ring systems in which an aromatic ring is fused to a heterocycloalkyl ring. Examples of such fused ring systems include, for example, phthalamide, phthalic anhydride, indoline, isoindoline, tetrahydroisoquinoline, chroman, isochroman, chromene, and isochromene. Heteroaryl groups may be optionally substituted. In certain preferred embodiments, heteroaryl is pyridinyl, more preferably pyridine-2-yl, or thienyl

As used herein, the term “heterocycloalkyl” refers to a cycloalkyl group in which one or more ring carbon atoms are replaced by at least one hetero atom such as —O—, —N—, or —S—. Certain embodiments include 4 to 9 membered rings, preferably 3 to 7, more preferably 3 to 6 membered rings, and other embodiments include 5 or 6 membered rings. Examples of heterocycloalkyl groups include pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pirazolidinyl, pirazolinyl, pyrazalinyl, piperidinyl, piperazinyl, hexahydropyrimidinyl, morpholinyl, thiomorpholinyl, tetrahydrofuranyl, dithiolyl, oxathiolyl, dioxazolyl, oxathiazolyl, pyranyl, oxazinyl, oxathiazinyl, and oxadiazinyl, preferably pyrrolidinyl, morpholinyl, piperidinyl, orazapanyl, more preferably pyrrolidinyl or piperidinyl. Heterocycloalkyl groups may be optionally substituted.

As used herein, the term “arylalkyl” refers to an alkyl group that is substituted with an aryl group. Examples of arylalkyl groups include, but are not limited to, benzyl, bromobenzyl, phenethyl, benzhydryl, diphenylmethyl, triphenylmethyl, diphenylethyl, naphthylmethyl, etc. preferably benzyl. Arylalkyl groups may be optionally substituted.

As used herein, the term “amino acid” refers to a group containing both an amino group and a carboxyl group. Embodiments of amino acids include α-amino, β-amino, γ-amino acids. The α-amino acids have a general formula HOOC—CH(side chain)-NH₂. The amino acids can be in their D, L or racemic configurations. Amino acids include naturally-occurring and non-naturally occurring moieties. The naturally-occurring amino acids include the standard 20 α-amino acids found in proteins, such as glycine, serine, tyrosine, proline, histidine, glutamine, etc. Naturally-occurring amino acids can also include non-1-amino acids (such as β-alanine, γ-aminobutyric acid, homocysteine, etc.), rare amino acids (such as 4-hydroxyproline, 5-hydroxylysine, 3-methylhistidine, etc.) and non-protein amino acids (such as citrulline, ornithine, canavanine, etc.). Non-naturally occurring amino acids are well-known in the art, and include analogs of natural amino acids. See Lehninger, A. L. Biochemistry, 2^(nd) ed.; Worth Publishers: New York, 1975; 71-77, the disclosure of which is incorporated herein by reference. Non-naturally occurring amino acids also include α-amino acids wherein the side chains are replaced with synthetic derivatives. In certain embodiments, substituent groups for the compounds of the present invention include the residue of an amino acid after removal of the hydroxyl moiety of the carboxyl group thereof; i.e., groups of formula —C(═O)CH(side chain)-NH₂. Representative side chains of naturally occurring and non-naturally occurring α-amino acids include are shown below in Table A. TABLE A H CH₃— HO—CH₂— C₆H₅—CH₂— HO—C₆H₄—CH₂—

HS—CH₂— HO₂C—CH(NH₂)—CH₂—S—S—CH₂— CH₃—CH₂— CH₃—S—CH₂—CH₂— CH₃—CH₂—S—CH₂—CH₂— HO—CH₂—CH₂— C₅H₉— C₆H₁₁— C₆H₁₁—CH₂— CH₃—CH(OH)— HO₂C—CH₂—NHC(═O)—CH₂— HO₂C—CH₂— HO₂C—CH₂—CH₂— NH₂C(═O)—CH₂— NH₂C(═O)—CH₂—CH₂— (CH₃)₂—CH— (CH₃)₂—CH—CH₂— CH₃—CH₂—CH₂— H₂N—CH₂—CH₂—CH₂— H₂N—C(═NH)—NH—CH₂—CH₂—CH₂— H₂N—C(═O)—NH—CH₂—CH₂—CH₂— CH₃—CH₂—CH(CH₃)— CH₃—CH₂—CH₂—CH₂— H₂N—CH₂—CH₂—CH₂—CH₂—

As used herein, the term “subject” or “patient” refers to a warm blooded animal such as a mammal, preferably a human, or a human child, which is afflicted with, or has the potential to be afflicted with one or more diseases and conditions described herein.

As used herein, a “therapeutically effective amount” refers to an amount of a compound of the present invention effective to prevent or treat the symptoms of particular disorder. Such disorders include, but are not limited to, those pathological and neurological disorders associated with the aberrant activity of the receptors described herein, wherein the treatment or prevention comprises inhibiting, inducing, or enhancing the activity thereof by contacting the receptor with a compound of the present invention.

As used herein, the term “pharmaceutically acceptable” refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem complications commensurate with a reasonable benefit/risk ratio.

As used herein, the term “unit dose” refers to a single dose which is capable of being administered to a patient, and which can be readily handled and packaged, remaining as a physically and chemically stable unit dose comprising either the active compound itself, or as a pharmaceutically acceptable composition, as described hereinafter.

As used herein, “pharmaceutically acceptable salts” refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like. These physiologically acceptable salts are prepared by methods known in the art, e.g., by dissolving the free amine bases with an excess of the acid in aqueous alcohol, or neutralizing a free carboxylic acid with an alkali metal base such as a hydroxide, or with an amine.

Compounds described herein throughout, can be used or prepared in alternate forms. For example, many amino-containing compounds can be used or prepared as an acid addition salt. Often such salts improve isolation and handling properties of the compound. For example, depending on the reagents, reaction conditions and the like, compounds as described herein can be used or prepared, for example, as their hydrochloride or tosylate salts. Isomorphic crystalline forms, all chiral and racemic forms, N-oxide, hydrates, solvates, and acid salt hydrates, are also contemplated to be within the scope of the present invention.

Certain acidic or basic compounds of the present invention may exist as zwitterions. All forms of the compounds, including free acid, free base and zwitterions, are contemplated to be within the scope of the present invention. It is well known in the art that compounds containing both amino and carboxy groups often exist in equilibrium with their zwitterionic forms. Thus, any of the compounds described herein throughout that contain, for example, both amino and carboxy groups, also include reference to their corresponding zwitterions.

As used herein, “prodrug” refers to compounds specifically designed to maximize the amount of active species that reaches the desired site of reaction, which are of themselves typically inactive or minimally active for the activity desired, but through biotransformation are converted into biologically active metabolites.

Accordingly, prodrugs include, for example, compounds described herein in which a hydroxy, amino, or carboxy group is bonded to any group that, when the prodrug is administered to a mammalian subject, cleaves to form a free hydroxyl, free amino, or carboxylic acid, respectively. Examples include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups; and alkyl, cycloalkyl, aryl, and alkylaryl esters such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, cyclopropyl, phenyl, benzyl, and phenethyl esters, and the like.

Compounds described herein may contain one or more asymmetrically substituted carbon atoms, and may be isolated in optically active or racemic forms. Thus, all isomeric forms of a structure, including all stereogenic (such as enantiomeric, diastereomeric, and/or meso forms, whether chiral or racemic), all achiral, all geometric, and/or all conformational isomeric forms are intended, unless the specific stereochemical or other isomeric form is specifically indicated and/or achiral. It is well known in the art how to prepare and isolate such isomeric forms of a structure including those having stereogenic centers including those stereogenic forms wherein the structure is present in optically active form. For example, mixtures of stereoisomers may be separated by standard techniques including, but not limited to, resolution of racemic forms, normal, reverse-phase, and chiral chromatography, preferential salt formation, recrystallization, and the like, or by chiral synthesis either from chiral starting materials or by deliberate synthesis of target chiral centers.

As used herein, the term “stereoisomers” refers to compounds that have identical chemical constitution, but differ as regards the arrangement of the atoms or groups in space.

The terms “treatment” and “treating” as used herein include preventative (e.g., prophylactic), curative and/or palliative treatment.

When any variable occurs more than one time in any constituent or in any formula, its definition in each occurrence is independent of its definition at every other occurrence. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

It is believed the chemical formulas and names used herein correctly and accurately reflect the underlying chemical compounds. However, the nature and value of the present invention does not depend upon the theoretical correctness of these formulae, in whole or in part. Thus it is understood that the formulas used herein, as well as the chemical names attributed to the correspondingly indicated compounds, are not intended to limit the invention in any way, including restricting it to any specific tautomeric form or to any specific optical or geometric isomer, except where such stereochemistry is clearly defined.

Accordingly, the present invention is directed, in part, to novel pyridizinone compounds which have the following formula I*:

or a stereoisomeric form, mixture of stereoisomeric forms, or a pharmaceutically acceptable salt forms thereof, wherein:

-   X and X^(a) are each independently CH or N; -   Y is S(O)_(q), O, or NR¹⁵; -   R¹ is NR¹⁰R¹¹ or a 4- to 9-membered heterocycloalkyl ring containing     1 or 2 nitrogen atoms and optionally substituted with 1 to 3 R²⁰     groups; -   R² is     -   wherein:         -   when X and X^(a) are both CH, then R² is meta or para to the             Y—(CHR⁴)_(m)—R¹ group; and         -   when either X or X^(a) are N, then R² is para to the             Y—(CHR⁴)_(m)—R¹ group; -   each R³ is:     -   independently H, F, Cl, Br, I, OR²¹, NR²³R²⁴, NO₂, CN, CF₃,         C₁-C₆alkyl, C(═O)R²¹, CO₂R²¹, or C(═O)NR²³R²⁴; or     -   when R³ is ortho to R², and R² is (i), (ii), (iv), (vi), or         (ix), then R³ and R¹⁴ taken together may form —(CH₂)_(s)—,         —CH₂Z-, -ZCH₂—, -ZCH₂CH₂— or CH₂CH₂Z-; wherein Z is O, S(O)_(y),         or NR²⁷; or     -   when R³ is ortho to R², and R² is (iv), (v), or (viii), then R³         and R¹³ taken together may form —(CH₂)_(s)—, —CH₂Z-, -ZCH₂—,         -ZCH₂CH₂— or CH₂CH₂Z-; or     -   when R³ is ortho to R², and R² is (viii), then R³ and R^(13b)         taken together may form —(CH₂)_(s)—, —CH₂Z-, -ZCH₂—, -ZCH₂CH₂—         or CH₂CH₂Z-; or     -   when R³ is ortho to X^(a) and R² is ortho to R³ and meta to         X^(a), then R² and R³ taken together may form: -   each R⁴ is independently H, C₁-C₆alkyl, or OR²¹, wherein the alkyl     group is optionally substituted with 1 to 3 R²⁰ groups; -   R¹⁰ and R¹¹ are each independently H, C₁-C₆alkyl, or     C₃-C₆cycloalkyl, wherein the alkyl or cycloalkyl group is optionally     substituted with 1 to 3 R²⁰ groups; -   R¹² is H, C₁-C₆alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl,     heterocycloalkyl, C(═O)R²⁷, or CO₂R²⁷, wherein the alkyl,     cycloalkyl, aryl, arylalkyl, heteroaryl, or heterocycloalkyl group     is optionally substituted with 1 to 3 R²⁰ groups; -   R¹³ and R¹⁴ are each independently H, C₁-C₆alkyl, aryl, arylalkyl     C₁-C₆alkoxyl, S(═O)_(y)—C₁-C₆alkyl, cycloalkyl, heterocycloalkyl, or     heteroaryl; -   R^(13a), R^(13b), R^(13c), and R^(14a) are each independently H,     C₁-C₆alkyl; or R¹³ and R¹⁴, taken together with the carbon atoms     through which they are connected form a fused phenyl, thienyl,     pyrrolyl, oxazolyl, pyridinyl, or C₃-C₆cycloalkyl ring; or R^(13b)     and R¹⁴, or R¹³ and ^(14a), or R^(13b) and ^(14a), or R^(13c) and     R^(14a), taken together with the carbon atoms through which they are     connected form a fused C₃-C₆cycloalkyl ring; or R¹³ and R^(13a), or     R¹⁴ and R^(14a), taken together with the carbon atom to which they     are attached form a C₃-C₈cycloalkyl ring; provided that no more than     one pair of R¹³ and R¹⁴, R^(13b) and R¹⁴, R¹³ and R^(14a), R^(13b)     and R^(14a), R^(13c) and R^(14a), R¹³ and R^(13a), and R¹⁴ and     R^(14a) are taken together with the carbon atoms through which they     are connected or to which they are attached to form a ring; and     wherein the fused phenyl, thienyl, pyrrolyl, oxazolyl, pyridinyl, or     cycloalkyl ring is optionally substituted with 1 to 3 R²⁰ groups; -   R¹⁵ is H, C₁-C₆ alkyl, C(═O)R²⁵, CO₂R²⁵; -   R²⁰ at each occurrence is independently, H, F, Cl, Br, I, OR²¹,     OR²², NR²³R²⁴, NHOH, NO₂, CN, CF₃, C₁-C₆ alkyl optionally     substituted with OR²⁶, C₂-C₆ alkenyl, C₂-C₆ alkynyl,     C₃-C₇cycloalkylC₀-C₄alkyl, 3- to 7-membered     heterocycloalkylC₀-C₄alkyl, phenyl, 5- or 6-membered     heteroarylC₀-C₄alkyl, arylalkyl, (═O), C(═O)R²¹, CO₂R²¹, OC(═O)R²¹,     C(═O)NR²³R²⁴, NR²⁷C(═O)R²¹, NR²⁷C(═O)OR²¹, OC(═O)NR²³R²⁴,     NR²⁷C(═S)R², or S(O)_(q)R²¹; -   each R²¹ is independently H, C₁-C₆alkyl, aryl, or arylalkyl; -   each R²² is independently the residue of an amino acid after the     hydroxyl group of the carboxyl group is removed; -   each R²³ and R²⁴ is independently selected from H, C₁-C₆alkyl, and     aryl, or R²³ and R²⁴, together with the nitrogen atom to which they     are attached, form a 3 to 7 membered heterocyclic ring optionally     substituted with ═O; -   R²⁵ is C₁-C₆alkyl, aryl, or alkylaryl; -   R²⁶ is H, C₁-C₆alkyl, aryl, or alkylaryl; -   R²⁷ is H or C₁-C₆alkyl; -   m is 1, 2, 3, 4, or 5 when R¹ is attached via a nitrogen atom, and m     is 0, 1, 2, 3, 4, or 5 when R¹ is attached via a carbon atom; -   n is 1, 2, or 3; -   q is 0, 1, or 2; -   s is 1, 2, or 3; and

y is 0, 1, or 2.

In certain preferred embodiments, the compounds of formula I or I* are other than 6-[4-(3-Diethylamino-propoxy)-phenyl]-4,5-dihydro-2H-pyridazin-3-one. In other preferred embodiments of the compounds of formula I or I*; when X^(a) and X are each CH, Y is O, n is 0, each R⁴ is H, m is 2, 3, or 4, R¹ is methylamino, hydroxyethylamino, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, and R² is para to the Y—(CHR⁴)_(m)—R¹ group, then R² is other than 4,5-dihydro-2H-pyridazin-3-one-6-yl.

In some preferred embodiments, the present invention provides a novel of formula I:

and stereoisomeric forms, mixtures of stereoisomeric forms or pharmaceutically acceptable salt forms thereof, wherein:

-   X and X^(a) are each independently CH or N; -   Y is selected from S(O)_(q), O, and NR¹⁵; -   R¹ is NR¹⁰R¹¹ or a 4 to 9 membered heterocycloalkyl ring containing     1 or 2 nitrogen atoms and optionally substituted with 1 to 3 R²⁰     groups; -   R² is     -   wherein:         -   when X and X^(a) are both CH, then R² is meta or para to the             Y—(CHR⁴)_(m)—R¹ group; and         -   when either X or X^(a) are N, then R² is para to the             Y—(CHR⁴)_(m)—R¹ group; -   R³ is:     -   at each occurrence is independently, H, F, Cl, Br, I, OR²¹,         NR²³R²⁴, NO₂, CN, CF₃, C₁-C₆ alkyl, C(═O)R²¹, CO₂R²¹, or         C(═O)NR²³R²⁴; or     -   when R³ is ortho to R², then R³ and R¹⁴ can combine to form         —(CH₂)_(s)—, —CH₂Z-, CH₂CH₂Z-; wherein Z is O, S(O)_(y), NR²⁷;         or     -   when R³ is ortho to X^(a) and R² is ortho to R³ and meta to         X^(a), then R² and R³ combine to form: -   R⁴ is H, C₁-C₆ alkyl, or OR²¹, wherein the alkyl group is optionally     substituted with 1 to 3 R²⁰ groups; -   R¹⁰ and R¹¹ are each, independently H or C₁-C₆ alkyl, wherein the     alkyl group is optionally substituted with 1 to 3 R²⁰ groups; -   R¹² is H, C₁-C₆ alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl,     heterocycloalkyl, C(═O)R²⁷, or CO₂R²⁷, wherein the alkyl,     cycloalkyl, aryl, arylalkyl, heteroaryl, and heterocycloalkyl groups     are optionally substituted with 1 to 3 R²⁰ groups; -   R¹³ and R¹⁴ are independently H, C₁-C₆ alkyl, aryl, or arylalkyl or     R¹³ and R¹⁴ can combine to form a fused phenyl, thienyl, pyrrolyl,     cyclopentyl or cyclohexyl ring; wherein the phenyl, thienyl,     pyrrolyl, cyclopentyl or cyclohexyl rings are optionally substituted     with 1 to 3 R²⁰ groups; -   R¹⁵ is H, C₁-C₆ alkyl, C(═O)R²⁵, CO₂R²⁵; -   R²⁰ at each occurrence is independently, H, F, Cl, Br, I, OR²¹,     OR²², NR²³R²⁴, NHOH, NO₂, CN, CF₃, C₁-C₆ alkyl optionally     substituted with OR²⁶, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₇     cycloalkyl, 3-7 membered heterocycloalkyl, phenyl, 5 or 6 membered     heteroaryl, arylalkyl, (═O), C(═O)R²¹, CO₂R²¹, OC(═O)R²¹,     C(═O)NR²³R²⁴, NR²⁷C(═O)R²¹, NR²⁷C(═O)OR²¹, OC(═O)NR²³R²⁴,     NR²⁷C(═S)R²¹, or S(O)_(q)R²¹; -   R²¹ at each occurrence is independently H, C₁-C₆ alkyl, aryl, or     arylalkyl; -   R²² at each occurrence is independently the residue of an amino acid     after the hydroxyl group of the carboxyl group is removed; -   R²³ and R²⁴ at each occurrence are each independently selected from     H, C₁-C₆ alkyl, and aryl, or R²³ and R²⁴, together with the nitrogen     atom to which they are attached, form a 3 to 7 membered heterocyclic     ring optionally substituted with ═O; -   R²⁵ is C₁-C₆ alkyl, aryl, or alkylaryl; -   R²⁶ is H, C₁-C₆ alkyl, aryl, or alkylaryl; -   R²⁷ is H or C₁-C₆ alkyl; -   m is 1, 2, 3, 4, or 5 when R¹ is attached via a nitrogen atom, and m     is 0, 1, 2, 3, 4, or 5 when R¹ is attached via a carbon atom; -   n is 0, 1, 2, or 3; -   q is 0, 1, or 2; -   s is 1, 2, or 3.

Embodiments of the present invention include those compounds of formula I having the structure I**:

wherein:

-   Y is O; -   R¹ is NR¹⁰R¹¹ or a 5 to 6 membered heterocycloalkyl ring containing     1 or 2 nitrogen atoms and optionally substituted with 1 to 3 R²⁰     groups; or R¹ is NR¹⁰R¹¹, pyrrolidinyl or piperidyl, wherein the     pyrrolidinyl and piperidyl groups are optionally substituted with 1     to 3 R²⁰ groups; or R¹ is pyrrolidinyl or piperidyl, wherein the     pyrrolidinyl and piperidyl groups are optionally substituted with 1     to 3 R²⁰ groups; -   R⁴ is H or C₁-C₆ alkyl, wherein the alkyl group is optionally     substituted with 1 to 3 R²⁰ groups; -   R¹⁰ and R¹¹ are each, independently H or C₁-C₆ alkyl, wherein the     alkyl group is optionally substituted with 1 to 3 R²⁰ groups; -   R¹² is H, C₁-C₆ alkyl, phenyl, or benzyl, wherein the alkyl, phenyl     and benzyl groups are optionally substituted with 1 to 3 R²⁰ groups; -   R²⁰ at each occurrence is independently, H, F, Cl, Br, I, OR²¹,     OR²², NR²³R²⁴, NHOH, NO₂, CN, CF₃, C₁-C₆ alkyl optionally     substituted with OR²⁶, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₇     cycloalkyl, 3-7 membered heterocycloalkyl, phenyl, 5 or 6 membered     heteroaryl, arylalkyl, (═O), C(═O)R²¹, CO₂R²¹, OC(═O)R²¹,     C(═O)NR²³R²⁴, NR²⁷C(═O)R²¹, NR²⁷C(═O)OR²¹, OC(═O)NR²³R²⁴,     NR²⁷C(═S)R²¹, or S(O)R²¹; -   R²¹ at each occurrence is independently H, C₁-C₆ alkyl, aryl, or     arylalkyl; -   R²² at each occurrence is independently the residue of an amino acid     after the hydroxyl group of the carboxyl group is removed; -   R²³ and R²⁴ at each occurrence are each independently selected from     H, C₁-C₆ alkyl, and aryl, or R²³ and R²⁴, together with the nitrogen     atom to which they are attached, form a 3 to 7 membered heterocyclic     ring optionally substituted with ═O; -   R²⁶ is H, C₁-C₆ alkyl, aryl, or alkylaryl; -   R²⁷ is H or C₁-C₆ alkyl; -   m is 3 when R¹ is attached via a nitrogen atom, and m is 0 or 1 when     R¹ is attached via a carbon atom; -   n is 0 or 1; -   q is 0, 1, or 2.     In another embodiment, the present invention includes compounds of     formula (Ia):     wherein each variable is defined in formula I. Additional aspects of     the present invention include compounds of formula (Ia) which     incorporate the embodiments described above for compounds of formula     I, as is appropriate. For example, additional embodiments include     compound of formula (Ia) with the preferred moieties of groups R¹     and R²; or R¹ and Y; or R¹, R² and Y; etc.

In another embodiment, the present invention includes compounds of formula (Ib):

wherein each variable is defined in formula I. Additional aspects of the present invention include compounds of formula (Ib) which incorporate the embodiments described above for compounds of formula I, as is appropriate. For example, additional embodiments include compound of formula (Ib) with the preferred moieties of groups R¹ and R²; or R¹ and Y; or R¹, R² and Y; etc.

In another embodiment, the present invention includes compounds of formula (Ic):

wherein each variable is defined in formula I. Additional aspects of the present invention include compounds of formula (Ic) which incorporate the embodiments described above for compounds of formula I, as is appropriate. For example, additional embodiments include compound of formula (Ic) with the preferred moieties of groups R¹ and R²; or R¹ and Y; or R¹, R² and Y; etc.

In another embodiment, the present invention includes compounds of formula (Id):

wherein each variable is defined in formula I. Additional aspects of the present invention include compounds of formula (Id) which incorporate the embodiments described above for compounds of formula I, as is appropriate. For example, additional embodiments include compound of formula (Id) with the preferred moieties of groups R¹; or R¹ and m; or R¹, R¹³ and R¹⁴; etc.

In another embodiment, the present invention includes compounds of formula (Ie):

wherein each variable is defined in formula I. Additional aspects of the present invention include compounds of formula (Ie) which incorporate the embodiments described above for compounds of formula I, as is appropriate. For example, additional embodiments include compound of formula (Ie) with the preferred moieties of groups R¹; or R¹, R¹³ and R¹⁴; etc.

In another embodiment, the present invention includes compounds of formula (If):

wherein each variable is defined in formula I. Additional aspects of the present invention include compounds of formula (If) which incorporate the embodiments described above for compounds of formula I, as is appropriate. For example, additional embodiments include compound of formula (If) with the preferred moieties of groups R¹; or R¹²; or R¹ and R¹².

In another embodiment, the present invention includes compounds of formula (Ig):

wherein each variable is defined in formula I. Additional aspects of the present invention include compounds of formula (Ig) which incorporate the embodiments described above for compounds of formula I, as is appropriate. For example, additional embodiments include compound of formula (Ig) with the preferred moieties of groups R¹; or R¹²; or R¹ and R¹².

In another embodiment, the present invention includes compounds of formula (Ih):

wherein each variable is defined in formula I. Additional aspects of the present invention include compounds of formula (Ih) which incorporate the embodiments described above for compounds of formula I, as is appropriate. For example, additional embodiments include compound of formula (Ih) with the preferred moieties of groups R¹; or R¹ and R¹³; or R¹, R²³ and R²⁴.

In another embodiment, the present invention includes compounds of formula (Ii):

wherein each variable is defined in formula I. Additional aspects of the present invention include compounds of formula (Ii) which incorporate the embodiments described above for compounds of formula I, as is appropriate. For example, additional embodiments include compound of formula (Ii) with the preferred moieties of the R¹ and R¹² groups.

In a further embodiment of the present invention, there are included compounds having a structure of Formula II:

and stereoisomeric forms, mixtures of stereoisomeric forms or pharmaceutically acceptable salt forms thereof, wherein:

-   R¹ is NR¹⁰R¹¹ or a 5 to 6 membered heterocycloalkyl ring containing     1 or 2 nitrogen atoms and optionally substituted with 1 to 3 R²⁰     groups; -   R² is -   R³ is:     -   at each occurrence is independently, H, F, Cl, Br, I, OR²¹,         NR²³R²⁴, NO₂, CN, CF₃, C₁-C₆ alkyl, C(═O)R²¹, CO₂R²¹, or         C(═O)NR²³R²⁴; or     -   when R³ is ortho to R², then R³ and R¹⁴ can combine to form         —CH₂CH₂—; or     -   when R³ is ortho to X^(a) and R² is ortho to R³ and meta to         X^(a), then R² and R³ combine to form: -   R⁴ is H or C₁-C₆ alkyl, wherein the alkyl group is optionally     substituted with 1 to 3 R²⁰ groups; -   R¹⁰ and R¹¹ are each, independently H or C₁-C₆ alkyl, wherein the     alkyl group is optionally substituted with 1 to 3 R²⁰ groups; -   R¹² is H, C₁-C₆ alkyl, phenyl, or benzyl, wherein the alkyl, phenyl     and benzyl groups are optionally substituted with 1 to 3 R²⁰ groups; -   R¹³ and R¹⁴ are independently H, C₁-C₆ alkyl, phenyl, or benzyl, or     R¹³ and R¹⁴ can combine to form a fused phenyl, thienyl, cyclopentyl     or cyclohexyl ring; wherein the phenyl, thienyl, pyrrolyl,     cyclopentyl or cyclohexyl rings are optionally substituted with 1 to     3 R²⁰ groups; -   R²⁰ at each occurrence is independently, H, F, Cl, Br, I, OR²¹,     OR²², NR²³R²⁴, NHOH, NO₂, CN, CF₃, C₁-C₆ alkyl optionally     substituted with OR²⁶, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₇     cycloalkyl, 3-7 membered heterocycloalkyl, phenyl, 5 or 6 membered     heteroaryl, arylalkyl, (═O), C(═O)R²¹, CO₂R²¹, OC(═O)R²¹,     C(═O)NR²³R²⁴, NR²⁷C(═O(O)R²¹, NR²⁷C(═O)OR²¹, OC(═O)NR²³R²⁴,     NR²⁷C(═S)R²¹, or S(O)_(q)R²¹; -   R²¹ at each occurrence is independently H, C₁-C₆ alkyl, aryl, or     arylalkyl; -   R²² at each occurrence is independently the residue of an amino acid     after the hydroxyl group of the carboxyl group is removed; -   R²³ and R²⁴ at each occurrence are each independently selected from     H, C₁-C₆ alkyl, and aryl, or R²³ and R²⁴, together with the nitrogen     atom to which they are attached, form a 3 to 7 membered heterocyclic     ring optionally substituted with ═O; -   R²⁶ is H, C₁-C₆ alkyl, aryl, or alkylaryl; -   R²⁷ is H or C₁-C₆ alkyl; -   m is 3 when R¹ is attached via a nitrogen atom, and m is 0 or 1 when     R¹ is attached via a carbon atom; -   n is 0 or 1; -   q is 0, 1, or 2.

As used herein, “embodiments of the present invention” is intended to include the full scope of compounds of any of formulas I, I*, I**, I(a-i), and II, or any combination or subcombination thereof, unless specifically otherwise provided.

Embodiments of the present invention include those compounds where Y is O. In other embodiments Y is S(O)_(q), or Y is NR¹⁵.

Embodiments of the present invention include those compounds where R¹ is NR¹⁰R¹¹, and those compounds where R¹⁰ and R¹¹ are each, independently H or C₁-C₆ alkyl, preferably both are C₁-C₆ alkyl.

Embodiments of the present invention include those compounds where R¹ is a 4- to 9-membered heterocycloalkyl ring, preferably a 5- to 6-membered heterocycloalkyl ring containing 1 or 2 nitrogen atoms, more preferably 1 nitrogen atom, and optionally substituted with 1 to 3 R²⁰ groups. In certain embodiments R¹ is an optionally substituted 5-membered heterocycloalkyl ring containing 1 or 2 nitrogen atoms, such as pyrrolidinyl, imidazolidinyl, or pyrazolidinyl. In other embodiments, R¹ is an optionally substituted 6-membered heterocycloalkyl ring containing 1 or 2 nitrogen atoms, such as piperidinyl, piperazinyl, or hexahydropyrimidinyl. In certain preferred embodiments, R¹ is attached to Y through a ring nitrogen atom. In other preferred embodiments, R¹ is attached to Y through a ring carbon atom.

In other preferred embodiments, R¹ is:

; more preferably:

In certain preferred embodiments of the moiety Y—(CHR⁴)_(m)—R¹, one or more of the carbon centers [(i.e., the subgroup “—CHR⁴)_(m)—”), said subgroup which is present in the Y—(CHR⁴)_(m)—R¹ moiety “m” times] may have the potential to be chiral in nature. That is to say, there may be 4 different groups attached to a carbon center in the subgroup. Each —(CHR⁴)— independently may be chiral and all possible stereoisomeric combinations are within the scope of the present invention. In certain more preferable embodiments, m is 3, more preferably the moiety Y—(CHR⁴)_(m)—R¹ is

Embodiments of the present invention include those compounds where R² is

In certain embodiments R² is

In other embodiments, R² is

In other embodiments, R² is

In other embodiments, R² is

In other embodiments, the R² can be a combination of R^(2A) through R^(2E). For example, such combinations include: R^(2A), R^(2C), R^(2D), and R^(2E); R^(2A), R^(2B), R^(2D), and R^(2E); R^(2A), R^(2B) and R^(2C); R^(2A), R^(2D), and R^(2E); R^(2A), R^(2D), and R^(2E); R^(2A) and R^(2B); R^(2B) and R^(2C); R^(2D) and R^(2E); etc.

In other embodiments, R² is:

-   -   wherein:         -   when X and X^(a) are both CH, then R² is meta or para to the             Y—(CHR⁴)_(m)—R¹ group; and         -   when either X or X^(a) are N, then R² is para to the             Y—(CHR⁴)_(m)—R¹ group;             each R³ is:     -   independently H, F, Cl, Br, I, OR²¹, NR²³R²⁴, NO₂, CN, CF₃,         C₁-C₆alkyl, C(═O)R²¹, CO₂R²¹, or C(═O)NR²³R²⁴; or     -   when R³ is ortho to R², and R² is (i), (ii), (iv), (vi), or         (ix), then R³ and R¹⁴ taken together may form —(CH₂)_(s)—,         —CH₂Z-, -ZCH₂—, -ZCH₂CH₂— or CH₂CH₂Z-; wherein Z is O, S(O)_(y),         or NR²⁷; or     -   when R³ is ortho to R², and R² is (iv), (v), or (viii), then R³         and R¹³ taken together may form —(CH₂)_(s)—, —CH₂Z-, -ZCH₂—,         -ZCH₂CH₂— or CH₂CH₂Z-; or     -   when R³ is ortho to R², and R² is (viii), then R³ and R^(13b)         taken together may form —(CH₂)_(s)—, —CH₂Z-, -ZCH₂—, -ZCH₂CH₂—         or CH₂CH₂Z-; or     -   when R³ is ortho to X^(a) and R² is ortho to R³ and meta to         X^(a), then R² and R³ taken together may form:     -    preferably wherein R² is (i), (ii), (iv), (vi), (viii), or         (ix). In certain more preferred embodiments, R² is (iv); or it         is (i); more preferably     -    or it is (iii) and one of R¹³ is cyclopropyl. In other         alternatively preferred embodiments, R2 is (vi), (viii), or         (ix).         In some preferred embodiments, R² is:         more preferably         still more preferably         Alternatively preferred in some embodiments, R² is:         In still other embodiments, R² is:

In further embodiments of the present invention, R² is para to the Y—(CHR⁴)—R¹ group. In certain embodiments when X and X^(a) are both CH, then R² is meta to the Y—(CHR⁴)—R¹ group, or R² is para to the Y—(CHR⁴)—R¹ group. In other embodiments when X and X^(a) are both CH, then R² is meta or para to the Y—(CHR⁴)—R¹ group. In other embodiments in combination with any of the three R² groups, R¹³ and R¹⁴ are independently H, or they are each independently C₁-C₆ alkyl, or they are each independently aryl, or they are each independently arylalkyl. In further embodiments of R², R¹³ and R¹⁴ can combine to form a fused phenyl ring, or they can form a fused thienyl ring, or they can form a fused pyrrolyl ring, or they can form a fused cyclopentyl ring or they can form a fused cyclohexyl ring. An example of R¹³ and R¹⁴ combining to form a fused thienyl ring has the following structure:

Embodiments of the present invention include those compounds where n is 0. Certain embodiments include those compounds where n is 1. Still other embodiments include those compounds where n is 2.

Embodiments of the present invention include those compounds where R³ at each occurrence is independently, H, F, Cl, Br, I, OR²¹, NR²³R²⁴, NO₂, CN, CF₃, C₁-C₆ alkyl, C(═O)R², CO₂R²¹, or C(═O)NR²³R²⁴, preferably F, Cl, Br, or C₁-C₆alkyl, more preferably F. In other preferred embodiments when R³ is ortho to R², then R³ and R¹⁴ can combine to form —CH₂CH₂—. In certain embodiments R³ at each occurrence is independently, H, F, Cl, Br, I, OR²¹, NR²³R²⁴, NO₂, CN, CF₃, C₁-C₆ alkyl, C(═O)R²¹, CO₂R²¹, or C(═O)NR²³R²⁴. In other embodiments, R³ is ortho to R², then R³ and R¹⁴ can combine to form —(CH₂)_(s)—. An example includes a compound where s is 2, which has the following structure:

In certain embodiments of the present invention, s is 2, or s is 3. In other embodiments, R³ and R¹⁴ can combine to form —CH₂Z- or CH₂CH₂Z-; wherein Z is O, S(O)_(y), NR²⁷. In particular, R³ and R¹⁴ can combine to form —CH₂Z- or they can combine to form CH₂CH₂Z-. In particular embodiments, Z is O and in others, Z is —S—.

In further embodiments of the present invention, R³ is ortho to X^(a) and R² is ortho to R³ and meta to X^(a), then R² and R³ combine to form:

An example includes a compound of the following structure:

Embodiments of the present invention include those compounds where R⁴ is H, optionally substituted C₁-C₆alkyl, or optionally substituted C₁-C₆ alkoxyl, preferably H or optionally substituted C₁-C₆alkyl. In certain embodiments. R⁴ is optionally substituted C₁-C₆ alkyl. In embodiments where R⁴ is alkyl, it is preferably C₁-C₃alkyl, more preferably, C₁C₆alkyl, with methyl being even more preferred.

Embodiments of the present invention include those compounds where m is 1, 2, 3, 4, or 5 when R¹ is attached via a nitrogen atom. In particular, m is 1, or m is 2, or m is 3, or m is 4, or m is 5, or m can be any combination of the above including, 1 and 2; 1 and 3; 2 and 3; 1, 2, and 3; etc. Other embodiments include those compounds where m is 0, 1, 2, 3, 4, or 5 when R¹ is attached via a carbon atom. In particular, m is 0, or m is 1, or m is 2, or m is 3, or m is 4, or m is 5, or m can be any combination of the above including, 0 and 1; 0 and 2; 0, 1, and 2; 1, 2, and 3; etc.

In certain preferred embodiments of the present invention, s is 2.

In other preferred embodiments of the present invention, R¹² is H, C₁-C₆alkyl, cycloalkyl, aryl, arylalkyl, or heteroaryl, more preferably H or heteroaryl, with heteroaryl being even more preferred. Alternatively, C₁-C₆alkyl, aryl, arylalkyl, or heteroaryl is preferred in some embodiments.

In certain preferred embodiments of the present invention, R¹³, R¹⁴R^(13a), R^(13b), R^(13c), and R^(14a) are each independently H or C₁-C₆alkyl, more preferably wherein at least one of is R¹³, R¹⁴R^(13a), R^(13b), R^(13c), and R^(14a) is C₁-C₆alkyl. In other alternatively preferred embodiments, R^(13a) and R¹³ are each independently C₁-C₃ alkyl; or R^(14a) and R¹⁴ are each independently C₁-C₃ alkyl.

In still other preferred embodiments of the present invention, R¹³ and R¹⁴, taken together with the carbon atoms through which they are connected form a fused phenyl, thienyl, oxazolyl, pyridinyl, or C₃-C₆cycloalkyl ring; or R^(13b) and R¹⁴, or R¹³ and ^(14a), or R^(13b) and ^(14a), or R^(13c) and R^(14a), taken together with the carbon atoms through which they are connected form a fused C₃-C₆cycloalkyl ring; or R¹³ and R^(13a), or R¹⁴ and R^(14a), taken together with the carbon atom to which they are attached form a C₃-C₈cycloalkyl ring; provided that no more than one pair of R¹³ and R¹⁴, R^(13b) and R¹⁴, R¹³ and R^(14a), R^(13b) and R^(14a), R^(13c) and R^(14a), R¹³ and R^(13a), and R¹⁴ and R^(14a) are taken together with the carbon atoms through which they are connected or to which they are attached to form a ring; and wherein the fused phenyl, thienyl, pyrrolyl, oxazolyl, pyridinyl, or cycloalkyl ring is optionally substituted with 1 to 3 R²⁰ groups. More preferably, R¹³ and R¹⁴, R^(13b) and R¹⁴, or R¹³ and ^(14a), or R^(13b) and ^(14a), or R^(13c) and R^(14a), taken together with the carbon atoms through which they are connected form a fused C₃-C₆cycloalkyl ring; or R¹³ and R^(13a), or R¹⁴ and R^(14a), taken together with the carbon atom to which they are attached form a C₃-C₈cycloalkyl ring; then the cycloalkyl ring is a is C₃-C₄cycloalkyl ring.

In some preferred embodiments of the present invention, R¹⁴ is heteroaryl.

In some preferred embodiments of the present invention, R²⁰ is alkyl; in others it is cycloalkyl, more preferably cyclobutyl. In still others, R²⁰ is F, Cl, CF₃, NR²³R²⁴, or C₁-C₆alkyl optionally substituted with OR²⁶, cycloalkylC₀-C₄alkyl, or heterocycloalkylC₀-C₄alkyl, more preferably C₁-C₆alkyl optionally substituted with OR²⁶.

In certain other preferred embodiments of the present invention, R²¹ is H or C₁-C₆alkyl.

In some preferred embodiments of the present invention, R²³ and R²⁴ are each independently C₁-C₆alkyl.

In yet other preferred embodiments of the present invention, R²⁶ is H or C₁-C₆alkyl.

In some preferred embodiments of the present invention, at least one of X and X_(a) is CH, more preferably X and X_(a) are each CH.

Embodiments of the present invention include those compounds of formula I wherein:

-   X and X^(a) are CH; -   Y is O; -   R¹ is NR¹⁰R¹¹ or a 5 to 6 membered heterocycloalkyl ring containing     1 or 2 nitrogen atoms and optionally substituted with 1 to 3 R²⁰     groups; or R¹ is NR¹⁰R¹¹, pyrrolidinyl or piperidyl, wherein the     pyrrolidinyl and piperidyl groups are optionally substituted with 1     to 3 R²⁰ groups; or R¹ is pyrrolidinyl or piperidyl, wherein the     pyrrolidinyl and piperidyl groups are optionally substituted with 1     to 3 R²⁰ groups; -   R² is -   R² is -   R³ at each occurrence is independently, H, F, Cl, Br, I, OR²¹,     NR²³R²⁴, NO₂, CN, CF₃, C₁-C₆ alkyl, C(═O)R²¹, CO₂R²¹, or     C(═O)NR²³R²⁴; or -   when R³ is ortho to R², then R³ and R¹⁴ can combine to form     —CH₂CH₂—; or R³ at each occurrence is independently, H; F; Cl; Br;     I; OR²¹; NR²³R²⁴; NO₂; CN; CF₃; C₁-C₆ alkyl; C(═O)R²¹; CO₂R²¹; or     C(═O)NR²³R²⁴; -   R⁴ is H or C₁-C₆ alkyl, wherein the alkyl group is optionally     substituted with 1 to 3 R²⁰ groups; -   R¹⁰ and R¹¹ are each, independently H or C₁-C₆ alkyl, wherein the     alkyl group is optionally substituted with 1 to 3 R²⁰ groups; -   R¹² is H, C₁-C₆ alkyl, phenyl, or benzyl, wherein the alkyl, phenyl     and benzyl groups are optionally substituted with 1 to 3 R²⁰ groups; -   R¹³ and R¹⁴ are independently H, C₁-C₆ alkyl, phenyl, or benzyl, or     R¹³ and R¹⁴ can combine to form a fused phenyl, thienyl, cyclopentyl     or cyclohexyl ring; wherein the phenyl, thienyl, pyrrolyl,     cyclopentyl or cyclohexyl rings are optionally substituted with 1 to     3 R²⁰ groups; or     -   R¹³ and R¹⁴ are independently H, C₁-C₆ alkyl, phenyl, or benzyl;         or     -   R¹³ and R¹⁴ can combine to form a fused phenyl, thienyl,         cyclopentyl or cyclohexyl ring; -   R²⁰ at each occurrence is independently, H, F, Cl, Br, I, OR²¹,     OR²², NR²³R²⁴, NHOH, NO₂, CN, CF₃, C₁-C₆ alkyl optionally     substituted with OR²⁶, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₇     cycloalkyl, 3-7 membered heterocycloalkyl, phenyl, 5 or 6 membered     heteroaryl, arylalkyl, (═O), C(═O)R²¹, CO₂R²¹, OC(═O)R²¹,     C(═O)NR²³R²⁴, NR²⁷C(═O)R²¹, NR²⁷C(═O)OR²¹, OC(═O)NR²³R²⁴,     NR²⁷C(═S)R²¹, or S(O)_(q)R²¹; -   R²¹ at each occurrence is independently H, C₁-C₆ alkyl, aryl, or     arylalkyl; -   R²² at each occurrence is independently the residue of an amino acid     after the hydroxyl group of the carboxyl group is removed; -   R²³ and R²⁴ at each occurrence are each independently selected from     H, C₁-C₆ alkyl, and aryl, or R²³ and R²⁴, together with the nitrogen     atom to which they are attached, form a 3 to 7 membered heterocyclic     ring optionally substituted with ═O; -   R²⁶ is H, C₁-C₆ alkyl, aryl, or alkylaryl; -   R²⁷ is H or C₁-C₆ alkyl; -   m is 3 when R¹ is attached via a nitrogen atom, and m is 0 or 1 when     R¹ is attached via a carbon atom; -   n is 0 or 1; -   q is 0, 1, or 2.

Embodiments of the present invention include those compounds of formula I wherein:

-   X is N and X^(a) is N or CH; or X and X^(a) are each N; or X is N     and X^(a) is CH; -   Y is O; -   R¹ is NR¹⁰R¹¹ or a 5 to 6 membered heterocycloalkyl ring containing     1 or 2 nitrogen atoms and optionally substituted with 1 to 3 R²⁰     groups; or R¹ is NR¹⁰R¹¹, pyrrolidinyl or piperidyl, wherein the     pyrrolidinyl and piperidinyl groups are optionally substituted with     1 to 3 R²⁰ groups; or R¹ is pyrrolidinyl or piperidinyl, wherein the     pyrrolidinyl and piperidyl groups are optionally substituted with 1     to 3 R²⁰ groups; -   R² is -   R² is -   R³ at each occurrence is independently, H, F, Cl, Br, I, OR²¹,     NR²³R²⁴, NO₂, CN, CF₃, C₁-C₆ alkyl, C(═O)R²¹, CO₂R²¹, or     C(═O)NR²³R²⁴; or     -   when R³ is ortho to R², then R³ and R¹⁴ can combine to form         —CH₂CH₂—; or     -   R³ at each occurrence is independently, H; F; Cl; Br; I; OR²¹;         NR²³R²⁴; NO₂; CN; CF₃; C₁-C₆ alkyl; C(═O)R²¹; CO₂R²¹; or         C(═O)NR²³R²⁴; -   R⁴ is H or C₁-C₆ alkyl, wherein the alkyl group is optionally     substituted with 1 to 3 R²⁰ groups; -   R¹⁰ and R¹¹ are each, independently H or C₁-C₆ alkyl, wherein the     alkyl group is optionally substituted with 1 to 3 R²⁰ groups; -   R¹² is H, C₁-C₆ alkyl, phenyl, or benzyl, wherein the alkyl, phenyl     and benzyl groups are optionally substituted with 1 to 3 R²⁰ groups; -   R¹³ and R¹⁴ are independently H, C₁-C₆ alkyl, phenyl, or benzyl, or     R¹³ and R¹⁴ can combine to form a fused phenyl, thienyl, cyclopentyl     or cyclohexyl ring; wherein the phenyl, thienyl, pyrrolyl,     cyclopentyl or cyclohexyl rings are optionally substituted with 1 to     3 R²⁰ groups; or     -   R¹³ and R¹⁴ are independently H, C₁-C₆ alkyl, phenyl, or benzyl;         or     -   R¹³ and R¹⁴ can combine to form a fused phenyl, thienyl,         cyclopentyl or cyclohexyl ring; -   R²⁰ at each occurrence is independently, H, F, Cl, Br, I, OR²¹,     OR²², NR²³R²⁴, NHOH, NO₂, CN, CF₃, C₁-C₆ alkyl optionally     substituted with OR²⁶, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₇     cycloalkyl, 3-7 membered heterocycloalkyl, phenyl, 5 or 6 membered     heteroaryl, arylalkyl, (═O), C(═O)R²¹, CO₂R²¹, OC(═O)R²¹,     C(═O)NR²³R²⁴, NR²⁷C(═O)R²¹, NR²⁷C(═O)OR²¹, OC(═O)NR²³R²⁴,     NR²⁷C(═S)R², or S(O)_(q)R²¹; -   R²¹ at each occurrence is independently H, C₁-C₆ alkyl, aryl, or     arylalkyl; -   R²² at each occurrence is independently the residue of an amino acid     after the hydroxyl group of the carboxyl group is removed; -   R²³ and R²⁴ at each occurrence are each independently selected from     H, C₁-C₆ alkyl, and aryl, or R²³ and R²⁴, together with the nitrogen     atom to which they are attached, form a 3 to 7 membered heterocyclic     ring optionally substituted with ═O; -   R²⁶ is H, C₁-C₆ alkyl, aryl, or alkylaryl; -   R²⁷ is H or C₁-C₆ alkyl; -   m is 3 when R¹ is attached via a nitrogen atom, and m is 0 or 1 when     R¹ is attached via a carbon atom; -   n is 0 or 1; -   q is 0, 1, or 2.

Embodiments of the present invention include those compounds of formula I wherein:

-   -   X and X^(a) are CH;     -   Y is O;     -   R¹ is NR¹⁰R¹¹, pyrrolidinyl or piperidyl, wherein the         pyrrolidinyl and piperidyl groups are optionally substituted         with 1 to 3 R²⁰ groups;     -   R² is para to the Y—(CHR⁴)_(m)—R¹ group;     -   R³ at each occurrence is independently, H, F, Cl, Br, I, OR²¹,         NR²³R²⁴, NO₂, CN, CF₃, C₁-C₆ alkyl, C(═O)R²¹, CO₂R²¹, or         C(═O)NR²³R²⁴; or     -   when R³ is ortho to R², then R³ and R¹⁴ can combine to form         —CH₂CH₂—;     -   m is 3 when R¹ is attached via a nitrogen atom, and m is 0 or 1         when R¹ is attached via a carbon atom;     -   n is 0 or 1.         In particular, a first embodiment includes those compounds         wherein:     -   R¹ is attached by the nitrogen atom;         R² is:     -   R¹³ and R¹⁴ combine to form a fused phenyl or thienyl ring; and     -   m is 3.         In other embodiments, R² is:         In further embodiments, R² is:         In a second particular embodiment:     -   R¹ is attached by the nitrogen atom;     -   R² is:     -   R¹³ and R¹⁴ combine to form a fused cyclopentyl or cyclohexyl         ring; and     -   m is 3.         In a third particular embodiment:     -   R¹ is attached by the nitrogen atom;     -   R² is:     -   R¹³ and R¹⁴ are independently H, C₁-C₆ alkyl, phenyl, or benzyl;         and     -   m is 3.         In a fourth particular embodiment:     -   R¹ is pyrrolidinyl or piperidyl, wherein the pyrrolidinyl and         piperidyl groups are attached by a ring carbon atom and each are         optionally substituted with 1 to 3 R²⁰ groups;     -   R² is:     -   R⁴ is H;     -   R¹³ and R¹⁴ are independently H, C₁-C₆ alkyl, phenyl, or benzyl;     -   m is 0 or 1.         In a fifth particular embodiment:     -   R¹ is attached by the nitrogen atom;     -   R² is:     -   R¹³ and R¹⁴ are independently H, C₁-C₆ alkyl, phenyl, or benzyl;     -   m is 3.         In a sixth particular embodiment:     -   R¹ is attached by the nitrogen atom;     -   R² is:     -   R¹³ and R¹⁴ are independently H, C₁-C₆ alkyl, phenyl, or benzyl;     -   m is 3.         In a seventh particular embodiment:     -   R¹ is attached by the nitrogen atom;     -   R² is ortho to R³, and R² is:     -   R³ and R¹⁴ combine to form —CH₂CH₂—;     -   m is 3.

Embodiments of the present invention include those compounds of formula I wherein:

-   X and X^(a) are CH; -   Y is O; -   R¹ is NR¹⁰R¹¹, pyrrolidinyl or piperidyl, wherein the pyrrolidinyl     and piperidyl groups are optionally substituted with 1 to 3 R²⁰     groups; -   R² is para to the Y—(CHR⁴)_(m)—R¹ group; -   R³ at each occurrence is independently, H, F, Cl, Br, I, OR²¹,     NR²³R²⁴, NO₂, CN, CF₃, C₁-C₆ alkyl, C(═O)R²¹, CO₂R²¹, or     C(═O)NR²³R²⁴; or     -   when R³ is ortho to R², then R³ and R¹⁴ can combine to form         —CH₂CH₂—; -   m is 3 when R¹ is attached via a nitrogen atom, and m is 0 or 1 when     R¹ is attached via a carbon atom; -   n is 0 or 1.

Additional aspects of the present invention include compounds of formula II which incorporate the embodiments described above for compounds of formula I, as is appropriate. For example, additional embodiments include compound of formula II with the preferred moieties of groups R¹; or R¹ and R¹³; or R¹, R²³ and R²⁴, etc.

For example, in certain embodiments of compounds of formula II:

-   R¹ is NR¹⁰R¹¹, pyrrolidinyl or piperidyl, wherein the pyrrolidinyl     and piperidyl groups are optionally substituted with 1 to 3 R²⁰     groups.

For example, in other embodiments of compounds of formula II:

-   R³ at each occurrence is independently, H, F, Cl, Br, I, OR²¹,     NR²³R²⁴, NO₂, CN, CF₃, C₁-C₆ alkyl, C(═O)R²¹, CO₂R²¹, or     C(═O)NR²³R²⁴; or -   when R³ is ortho to R², then R³ and R¹⁴ can combine to form     —CH₂CH₂—.

In certain embodiments, the compounds of the formula I*:

are selected from the group consisting of:

-   2-methyl-6-{4-[(R)-2-methyl-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   6-[4-(1-cyclopentyl-piperidin-4-yloxy)-phenyl]-2-methyl-2H-pyridazin-3-one; -   6-{3,5-difluoro-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-methyl-2H-pyridazin-3-one; -   6-{3-chloro-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-methyl-2H-pyridazin-3-one; -   2,6-dimethyl-5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   2,6-dimethyl-5-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; -   6-methyl-5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   6-methyl-5-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; -   5-[4-(3-azepan-1-yl-propoxy)-phenyl]-6-methyl-2H-pyridazin-3-one; -   2-methyl-5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   2-methyl-5-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; -   5-[4-(3-azepan-1-yl-propoxy)-phenyl]-2-methyl-2H-pyridazin-3-one; -   5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-pyridin-2-yl-2H-pyridazin-3-one; -   5-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2-pyridin-2-yl-2H-pyridazin-3-one; -   5-[4-(3-azepan-1-yl-propoxy)-phenyl]-2-pyridin-2-yl-2H-pyridazin-3-one; -   2-methyl-5-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; -   2-(6-methyl-pyridin-2-yl)-5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   2-(3-methyl-pyridin-2-yl)-5-{4-[3-((R)-2-methylpyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   6-methyl-5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-pyridin-2-yl-2H-pyridazin-3-one; -   6-methyl-2-(3-methyl-pyridin-2-yl)-5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   6-methyl-5-[4-(piperidin-4-yloxy)-phenyl]-2H-pyridazin-3-one;     hydrochloride; -   5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-6-methyl-2H-pyridazin-3-one; -   5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-6-methyl-2-pyridin-2-yl-2H-pyridazin-3-one; -   5-[4-(piperidin-4-yloxy)-phenyl]-2H-pyridazin-3-one; -   5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-2H-pyridazin-3-one; -   5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-6-methyl-2-thiophen-3-yl-2H-pyridazin-3-one; -   6-methyl-5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-thiophen-3-yl-2H-pyridazin-3-one; -   5-{4-[3-((S)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-pyridin-2-yl-2H-pyridazin-3-one; -   5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-6-methyl-4,5-dihydro-2H-pyridazin-3-one; -   6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-5-pyridin-2-yl-4,5-dihydro-2H-pyridazin-3-one; -   6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-5-pyridin-2-yl-2H-pyridazin-3-one; -   6-[4-(piperidin-4-yloxy)-phenyl]-5-pyridin-2-yl-4,5-dihydro-2H-pyridazin-3-one; -   6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-5-pyridin-2-yl-4,5-dihydro-2H-pyridazin-3-one; -   6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-5-pyridin-2-yl-2H-pyridazin-3-one; -   6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-4-methyl-4,5-dihydro-2H-pyridazin-3-one; -   5-[6-(1-cyclobutyl-piperidin-4-yloxy)-pyridin-3-yl]-2H-pyridazin-3-one; -   2-(2-fluoro-ethyl)-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   6-{3-fluoro-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   6-[3-fluoro-4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; -   4-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one; -   4-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   4-methyl-6-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; -   4-{4-[3-((S)-2-hydroxymethyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-methyl-5,6,7,8-tetrahydro-2H-phthalazin-1-one; -   2-methyl-4-{3-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2,5,6,7-tetrahydro-cyclopenta[d]pyridazin-1-one; -   2-methyl-4-[3-(3-piperidin-1-yl-propoxy)-phenyl]-2,5,6,7-tetrahydro-cyclopenta[d]pyridazin-1-one; -   4-{3-[3-((S)-2-hydroxymethyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-methyl-2,5,6,7-tetrahydro-cyclopenta[d]pyridazin-1-one; -   2-isopropyl-5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   2-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-5-(6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile; -   2-[3-(piperidin-1-yl)-propoxy]-5-(6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile; -   2-(2-hydroxyethyl)-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   6-{4-[(S)-2-methyl-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   4-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2,5,6,7-tetrahydro-cyclopenta[d]pyridazin-1-one; -   6-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; -   6-[3-methoxy-4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; -   6-{3-methoxy-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   6-[2-methyl-4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; -   6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-pyrimidin-2-yl-2H-pyridazin-3-one; -   6-[6-(1-cyclopentyl-piperidin-4-yloxy)-pyridin-3-yl]-2H-pyridazin-3-one; -   6-[6-(1-isopropyl-piperidin-4-ylmethoxy)-pyridin-3-yl]-2H-pyridazin-3-one; -   6-[6-(1-cyclobutyl-piperidin-4-yloxy)-pyridin-3-yl]-2H-pyridazin-3-one; -   6-[6-(1-isopropyl-piperidin-4-yloxy)-pyridin-3-yl]-2H-pyridazin-3-one; -   6-[6-(1-cyclopentyl-piperidin-4-yloxy)-pyridin-3-yl]-2-methyl-2H-pyridazin-3-one; -   6-[6-(1-cyclobutyl-piperidin-4-yloxy)-pyridin-3-yl]-2-methyl-2H-pyridazin-3-one; -   6-[6-(1-cyclobutyl-piperidin-4-yloxy)-pyridin-3-yl]-2-isopropyl-2H-pyridazin-3-one; -   6-{6-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-pyridin-3-yl}-2H-pyridazin-3-one; -   6-[6-(3-piperidin-1-yl-propoxy)-pyridin-3-yl]-2H-pyridazin-3-one; -   6-[6-(1-cyclobutyl-piperidin-4-yloxy)-pyridin-3-yl]-4,4-dimethyl-4,5-dihydro-2H-pyridazin-3-one; -   6-[6-(1-cyclobutyl-piperidin-4-yloxy)-pyridin-3-yl]-2-pyridin-2-yl-2H-pyridazin-3-one; -   6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-4,5-dihydro-2H-pyridazin-3-one; -   6-[4-(1-cyclobutyl-piperidin-4-yloxy)-3-fluoro-phenyl]-4,5-dihydro-2H-pyridazin-3-one; -   6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-4,4-dimethyl-4,5-dihydro-2H-pyridazin-3-one; -   6-[4-(1-cyclobutyl-piperidin-4-yloxy)-3-fluoro-phenyl]-4,4-dimethyl-4,5-dihydro-2H-pyridazin-3-one; -   6-[4-(1-cyclopentyl-piperidin-4-yloxy)-phenyl]-2H-pyridazin-3-one; -   6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-2H-pyridazin-3-one; -   6-[4-(1-cyclobutyl-piperidin-4-yloxy)-3-fluoro-phenyl]-2H-pyridazin-3-one; -   6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-2-pyridin-2-yl-2H-pyridazin-3-one; -   6-[4-(piperidin-4-yloxy)-phenyl]-2-pyridin-2-yl-4,5-dihydro-2H-pyridazin-3-one; -   6-[4-((R)-1-cyclohexyl-pyrrolidin-3-yloxy)-phenyl]-4,5-dihydro-2H-pyridazin-3-one; -   6-[4-((R)-1-cyclohexyl-pyrrolidin-3-yloxy)-phenyl]-2H-pyridazin-3-one; -   6-[4-((R)-1-cyclobutyl-pyrrolidin-3-yloxy)-phenyl]-2H-pyridazin-3-one; -   6-[4-((R)-1-cyclopentyl-pyrrolidin-3-yloxy)-phenyl]-4,5-dihydro-2H-pyridazin-3-one; -   2-cyclobutyl-6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-4,5-dihydro-2H-pyridazin-3-one; -   2-cyclobutyl-6-[4-(1-cyclopentyl-piperidin-4-yloxy)-phenyl]-4,5-dihydro-2H-pyridazin-3-one; -   2-cyclobutyl-6-[4-(piperidin-4-yloxy)-phenyl]-4,5-dihydro-2H-pyridazin-3-one; -   6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-2-(2,2,2-trifluoro-ethyl)-4,5-dihydro-2H-pyridazin-3-one; -   6-[4-(1-cyclopentyl-piperidin-4-yloxy)-phenyl]-2-(2,2,2-trifluoro-ethyl)-4,5-dihydro-2H-pyridazin-3-one; -   6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-(2,2,2-trifluoro-ethyl)-4,5-dihydro-2H-pyridazin-3-one; -   6-{4-[3-piperidin-1-yl-propoxy]-phenyl}-2-(2,2,2-trifluoro-ethyl)-4,5-dihydro-2H-pyridazin-3-one; -   6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-(2,2,2-trifluoro-ethyl)-2H-pyridazin-3-one; -   6-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2-(2,2,2-trifluoro-ethyl)-2H-pyridazin-3-one; -   5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.2.0]oct-4-en-2-one; -   5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.2.0]oct-4-en-2-one; -   4-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-2,4a,5,6,7,7a-hexahydro-cyclopenta[d]pyridazin-1-one; -   4-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2,4a,5,6,7,7a-hexahydro-cyclopenta[d]pyridazin-1-one; -   4-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-2,5,6,7-tetrahydro-cyclopenta[d]pyridazin-1-one; -   2-cyclobutyl-6-[6-(1-cyclobutyl-piperidin-4-yloxy)-pyridin-3-yl]-4,5-dihydro-2H-pyridazin-3-one; -   6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one; -   4,4-dimethyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one; -   6-{3-fluoro-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one; -   6-[3-fluoro-4-(3-piperidin-1-yl-propoxy)-phenyl]-4,5-dihydro-2H-pyridazin-3-one; -   5,5-dimethyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one; -   6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-pyridin-2-yl-4,5-dihydro-2H-pyridazin-3-one; -   6-{3,5-difluoro-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   6-{3,5-dibromo-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   6-{3,5-difluoro-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one; -   6-[4-(1-cyclobutyl-piperidin-4-yloxy)-3,5-difluoro-phenyl]-4,5-dihydro-2H-pyridazin-3-one; -   6-[4-(1-cyclobutyl-piperidin-4-yloxy)-3,5-difluoro-phenyl]-2H-pyridazin-3-one; -   6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one; -   (R)-6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one; -   (S)-6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one; -   6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-5-ethyl-4,5-dihydro-2H-pyridazin-3-one; -   6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-5-methyl-2-pyridin-2-yl-4,5-dihydro-2H-pyridazin-3-one; -   5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one     racemate; -   5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one     diastereomer; -   5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one     diastereomer; -   5-methyl-6-[4-(3-piperidin-1-yl-propoxy)-phenyl]-4,5-dihydro-2H-pyridazin-3-one; -   5-methyl-6-[4-(3-pyrrolidin-1-yl-propoxy)-phenyl]-4,5-dihydro-2H-pyridazin-3-one; -   6-{(R)-2-methyl-4-[3-(2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one; -   2-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-6-phenyl-2H-pyridazin-3-one; -   6-methyl-2-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   2-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-phthalazin-1-one; -   2-[6-(1-cyclobutyl-piperidin-4-yloxy)-pyridin-3-yl]-6-phenyl-2H-pyridazin-3-one; -   2-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-6-pyridin-3-yl-2H-pyridazin-3-one; -   4-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3-methyl-6H-isoxazolo[3,4-d]pyridazin-7-one; -   3-methyl-4-[4-(piperidin-4-yloxy)-phenyl]-6H-isoxazolo[3,4-d]pyridazin-7-one; -   3-methyl-4-[4-(3-piperidin-1-yl-propoxy)-phenyl]-6H-isoxazolo[3,4-d]pyridazin-7-one; -   3-methyl-4-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-6H-isoxazolo[3,4-d]pyridazin-7-one; -   8-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-5,6-dihydro-2H-benzo[h]cinnolin-3-one; -   5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   5-ethyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   8-[3-(2-methyl-pyrrolidin-1-yl)-propoxy]-4,4a,5,6-tetrahydro-2H-benzo[h]cinnolin-3-one; -   6-{2-methoxy-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   6-{2-fluoro-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-pyridin-2-yl-2H-pyridazin-3-one; -   6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4-pyridin-2-yl-4,5-dihydro-2H-pyridazin-3-one; -   6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4-pyridin-2-yl-2H-pyridazin-3-one; -   8-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-5,6-dihydro-3H-benzo[f]cinnolin-2-one; -   6-[4-(1-cyclobutyl-piperidin-4-yloxy)-2-fluoro-phenyl]-4,5-dihydro-2H-pyridazin-3-one; -   8-(1-cyclobutyl-piperidin-4-yloxy)-4,4a,5,6-tetrahydro-2H-benzo[h]cinnolin-3-one; -   6-[4-(1-cyclobutyl-piperidin-4-yloxy)-2-fluoro-phenyl]-2H-pyridazin-3-one; -   6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-5-methyl-2H-pyridazin-3-one; -   5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   2-methoxymethyl-5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   5-{4-[(S)-2-methyl-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   5-{4-[(R)-2-methyl-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   5-[4-((S)-2-methyl-3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; -   5-[4-((R)-2-methyl-3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; -   5-{3,5-dibromo-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   2-methoxymethyl-5-{2-methyl-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   5-{2-methyl-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   2-methoxymethyl-5-[2-methyl-4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; -   5-[2-methyl-4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; -   5-[4-(1-cyclobutyl-piperidin-4-yloxy)-2-methyl-phenyl]-2-methoxymethyl-2H-pyridazin-3-one; -   4-methoxy-2-methoxymethyl-5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   5-methoxy-2-methoxymethyl-4-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   5-methoxy-4-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   6-[4-(3-morpholin-4-yl-propoxy)-phenyl]-2H-pyridazin-3-one; -   6-{4-[3-((S)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   6-[4-(3-pyrrolidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; -   6-{4-[3-(cyclobutyl-methyl-amino)-propoxy]-phenyl}-2H-pyridazin-3-one; -   6-{4-[3-(cyclopentyl-methyl-amino)-propoxy]-phenyl}-2H-pyridazin-3-one; -   5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; -   5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; -   5-{4-[(S)-2-methyl-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; -   5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one     single isomer; -   5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one     single isomer; -   5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one     single isomer; -   5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one     single isomer; -   5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3-ethyl-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; -   5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3-isopropyl-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; -   5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3-methyl-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; -   5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3-(4-fluoro-phenyl)-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; -   5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3-(2,2,2-trifluoro-ethyl)-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; -   6-[4-(2-hydroxy-3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; -   6-{4-[2-hydroxy-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   6-{4-[(S)-2-hydroxy-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   6-{4-[(R)-2-hydroxy-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   6-[4-((R)-2-hydroxy-3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; -   5-[4-(1-cyclopentyl-piperidin-4-yloxy)-phenyl]-3-methyl-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; -   5-[4-(1-cyclopentyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one;     and -   6-cyclopropyl-2-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one;

or a stereoisomeric form, mixture of stereoisomeric forms, or a pharmaceutically acceptable salt thereof.

More preferably, they are selected from the group consisting of:

-   5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-6-methyl-2H-pyridazin-3-one; -   6-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; -   6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one; -   6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-4,4-dimethyl-4,5-dihydro-2H-pyridazin-3-one; -   6-[4-(1-cyclobutyl-piperidin-4-yloxy)-3-fluoro-phenyl]-4,4-dimethyl-4,5-dihydro-2H-pyridazin-3-one; -   6-[6-(1-cyclobutyl-piperidin-4-yloxy)-pyridin-3-yl]-4,4-dimethyl-4,5-dihydro-2H-pyridazin-3-one; -   5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-pyridin-2-yl-2H-pyridazin-3-one; -   5-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2-pyridin-2-yl-2H-pyridazin-3-one; -   6-{4-[(S)-2-Methyl-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   4,4-dimethyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one; -   5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; -   5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; -   5-{4-[(S)-2-methyl-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; -   5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; -   5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; -   5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; -   5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; -   5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.2.0]oct-4-en-2-one; -   5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one     one diastereomer; -   5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one     one diastereomer; -   5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one;     and -   6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one;

or a stereoisomeric form, mixture of stereoisomeric forms, or a pharmaceutically acceptable salt thereof.

Still more preferably, they are selected from the group consisting of:

-   5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-pyridin-2-yl-2H-pyridazin-3-one; -   5-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2-pyridin-2-yl-2H-pyridazin-3-one; -   6-{4-[(S)-2-methyl-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   4,4-dimethyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one; -   5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; -   5-;[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; -   5-{4-[(S)-2-methyl-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; -   5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; -   5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; -   5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; -   5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; -   5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.2.0]oct-4-en-2-one; -   5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one     one diastereomer; -   5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one     one diastereomer; -   5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one;     and -   6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one;

or a stereoisomeric form, mixture of stereoisomeric forms, or a pharmaceutically acceptable salt thereof.

Even more preferably, they are selected from the group consisting of:

-   4,4-dimethyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one; -   5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; -   5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; -   5-{4-[(S)-2-methyl-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; -   5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; -   5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; -   5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; -   5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; -   5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.2.0]oct-4-en-2-one; -   5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one     one diastereomer; -   5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one     one diastereomer; -   5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one;     and -   6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one;

or a stereoisomeric form, mixture of stereoisomeric forms, or a pharmaceutically acceptable salt thereof; with the compound 6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one, or a stereoisomeric form, mixture of stereoisomeric forms, or a pharmaceutically acceptable salt thereof being most preferred.

In certain alternatively preferred embodiments, the compounds of formula I are selected from the group consisting of:

-   2-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   2-methyl-6-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; -   2-isopropyl-6-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; -   2-isopropyl-6-[4-(3-piperidin-1-yl-propoxy)-phenyl]-4,5-dihydro-2H-pyridazin-3-one; -   2-isopropyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   2-ethyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   6-{3-fluoro-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-methyl-2H-pyridazin-3-one; -   2-(2,4-dichloro-benzyl)-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one; -   2-(3,5-dichloro-phenyl)-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   6-[3-fluoro-4-(3-piperidin-1-yl-propoxy)-phenyl]-2-phenyl-2H-pyridazin-3-one; -   6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   4-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2,5,6,7-tetrahydro-cyclopenta[d]pyridazin-1-one; -   2-methyl-6-{4-[(S)-2-methyl-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   6-{4-[3-((S)-2-hydroxymethyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-methyl-2H-pyridazin-3-one; -   6-{4-[3-((R)-2-hydroxymethyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-methyl-2H-pyridazin-3-one; -   2-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one; -   2-benzyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one; -   2-benzyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-phenyl-2H-pyridazin-3-one; -   6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-phenyl-2H-pyridazin-3-one; -   2-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   5-Isopropyl-7-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-5H-thieno[2,3-d]pyridazin-4-one; -   7-{4-[3-(2,5-dimethyl-pyrrolidin-1-yl)-propoxy]-phenyl}-5-isopropyl-5H-thieno[2,3-d]pyridazin-4-one; -   5-isopropyl-7-[4-(3-piperidin-1-yl-propoxy)-phenyl]-5H-thieno[2,3-d]pyridazin-4-one; -   7-{4-[3-(3,3-dimethyl-piperidin-1-yl)-propoxy]-phenyl}-5-isopropyl-5H-thieno[2,3-d]pyridazin-4-one; -   5-isopropyl-7-{4-[3-((S)-2-methoxymethyl-pyrrolidin-1-yl)-propoxy]-phenyl}-5H-thieno[2,3-d]pyridazin-4-one; -   5-isopropyl-7-{4-[3-((R)-2-methoxymethyl-pyrrolidin-1-yl)-propoxy]-phenyl}-5H-thieno[2,3-d]pyridazin-4-one; -   7-[4-(3-diethylamino-propoxy)-phenyl]-5-isopropyl-5H-thieno[2,3-d]pyridazin-4-one; -   5-isopropyl-7-[4-(3-pyrrolidin-1-yl-propoxy)-phenyl]-5H-thieno[2,3-d]-pyridazin-4-one; -   5-isopropyl-7-{4-[3-(4-pyrrolidin-1-yl-piperidin-1-yl)-propoxy]-phenyl}-5H-thieno[2,3-d]pyridazin-4-one; -   7-{4-[3-((2R,5R)-2,5-dimethyl-pyrrolidin-1-yl)-propoxy]-phenyl}-5-isopropyl-5H-thieno[2,3-d]pyridazin-4-one; -   7-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-5-propyl-5H-thieno[2,3-d]pyridazin-4-one; -   7-{4-[3-((2R,5R)-2,5-dimethyl-pyrrolidin-1-yl)-propoxy]-phenyl}-5-propyl-5H-thieno[2,3-d]pyridazin-4-one; -   7-{4-[3-(4-methyl-piperidin-1-yl)-propoxy]-phenyl}-5-propyl-5H-thieno[2,3-d]pyridazin-4-one; -   7-{4-[3-(4-dimethylamino-piperidin-1-yl)-propoxy]-phenyl}-5-propyl-5H-thieno[2,3-d]pyridazin-4-one; -   5-propyl-7-{4-[3-((S)-2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-propoxy]-phenyl}-5H-thieno[2,3-d]pyridazin-4-one; -   5-(4-chloro-benzyl)-7-[4-(3-piperidin-1-yl-propoxy)-phenyl]-5H-thieno[2,3-d]pyridazin-4-one; -   5-(4-chloro-benzyl)-7-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-5H-thieno[2,3-d]pyridazin-4-one; -   2,4-dimethyl-6-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; -   2,4-dimethyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   2-isopropyl-4-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   2-isopropyl-4-methyl-6-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; -   2-benzyl-4-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   2-benzyl-4-methyl-6-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; -   4-benzyl-2-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; -   4-benzyl-2-methyl-6-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; -   2-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-5-phenyl-2H-pyridazin-3-one; -   2-methyl-5-phenyl-6-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; -   2-methyl-4-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-phthalazin-1-one; -   2-methyl-4-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-phthalazin-1-one; -   2-methyl-4-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-2H-phthalazin-1-one; -   2-methyl-4-[4-(3-pyrrolidin-1-yl-propoxy)-phenyl]-2H-phthalazin-1-one; -   4-[4-(3-azepan-1-yl-propoxy)-phenyl]-2-methyl-2H-phthalazin-1-one; -   2-(4-chloro-benzyl)-4-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-phthalazin-1-one; -   2-(4-chloro-benzyl)-4-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-phthalazin-1-one; -   2-methyl-4-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2,5,6,7-tetrahydro-cyclopenta[d]pyridazin-1-one; -   2-methyl-4-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2,5,6,7-tetrahydro-cyclopenta[d]pyridazin-1-one; -   2-methyl-4-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2,4a,5,6,7,7a-hexahydro-cyclopenta[d]pyridazin-1-one; -   2-methyl-4-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2,4a,5,6,7,7a-hexahydro-cyclopenta[d]pyridazin-1-one; -   2-methyl-4-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-5,6,7,8-tetrahydro-2H-phthalazin-1-one; -   4-{4-[3-(butyl-ethyl-amino)-propoxy]-phenyl}-2-methyl-5,6,7,8-tetrahydro-2H-phthalazin-1-one; -   4-[4-(3-methyl-4-oxo-3,4-dihydro-phthalazin-1-yl)-phenoxymethyl]-piperidine-1-carboxylic     acid tert-butyl ester; -   2-methyl-4-[4-(piperidin-4-ylmethoxy)-phenyl]-2H-phthalazin-1-one; -   4-[4-(1-cyclobutyl-piperidin-4-ylmethoxy)-phenyl]-2-methyl-2H-phthalazin-1-one; -   4-[4-(1-methyl-6-oxo-1,6-dihydro-pyridazin-3-yl)-phenoxymethyl]-piperidine-1-carboxylic     acid tert-butyl ester; -   2-methyl-6-[4-(piperidin-4-ylmethoxy)-phenyl]-2H-pyridazin-3-one; -   6-[4-(1-cyclobutyl-piperidin-4-ylmethoxy)-phenyl]-2-methyl-2H-pyridazin-3-one; -   6-[4-(1-isopropyl-piperidin-4-ylmethoxy)-phenyl]-2-methyl-2H-pyridazin-3-one; -   6-[4-(1-cyclopropylmethyl-piperidin-4-ylmethoxy)-phenyl]-2-methyl-2H-pyridazin-3-one; -   6-[4-(1-cyclopentyl-piperidin-4-ylmethoxy)-phenyl]-2-methyl-2H-pyridazin-3-one; -   2-methyl-6-[4-(1-methyl-piperidin-4-ylmethoxy)-phenyl]-2H-pyridazin-3-one; -   6-[4-(1-isopropyl-piperidin-4-yloxy)-phenyl]-2-methyl-2H-pyridazin-3-one; -   2-methyl-6-[4-(piperidin-4-yloxy)-phenyl]-2H-pyridazin-3-one; -   2-methyl-6-[4-(piperidin-4-yloxy)-phenyl]-2H-pyridazin-3-one; -   2-methyl-8-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-5,6-dihydro-2H-benzo[h]cinnolin-3-one; -   8-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-2-phenyl-5,6-dihydro-2H-benzo[h]cinnolin-3-one; -   2-benzyl-8-(3-piperidin-1-yl-propoxy)-5,6-dihydro-2H-benzo[h]cinnolin-3-one; -   2-isopropyl-8-(3-piperidin-1-yl-propoxy)-5,6-dihydro-2H-benzo[h]cinnolin-3-one; -   2-methyl-7-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-2H-phthalazin-1-one; -   2-methyl-7-(3-piperidin-1-yl-propoxy)-2H-phthalazin-1-one; and -   6-{3-fluoro-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-phenyl-2H-pyridazin-3-one;     and stereoisomeric forms, mixtures of stereoisomeric forms or     pharmaceutically acceptable salt forms thereof; with the compound     6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one,     or a stereoisomeric form, mixture of stereoisomeric forms, or a     pharmaceutically acceptable salt thereof being more preferred.

In a second embodiment, the compounds of formula I are selected from Examples 22 to 38, 49 to 50 and 52 to 55. In a third embodiment, the compounds are selected from Examples 12, and 56 to 61. In a fourth embodiment, the compounds are selected from Examples 1 to 3, 5 to 7, 9 to 11, 13 to 15, 18, 20, 39 to 48, and 81. In a fifth embodiment, the compounds are selected from Examples 51, and 62 to 74. In a sixth embodiment, the compounds are selected from Examples 4, 8, 16 to 17, and 19. In a seventh embodiment, the compounds are selected from Examples 75 to 78. In a eighth embodiment, the compounds are Examples 79 and 80.

In another aspect, the present invention is directed to pharmaceutically acceptable salts of the compounds described above. As used herein, “pharmaceutically acceptable salts” includes salts of compounds of the present invention derived from the combination of such compounds with non-toxic acid or base addition salts.

Acid addition salts include inorganic acids such as hydrochloric, hydrobromic, hydroiodic, sulfuric, nitric and phosphoric acid, as well as organic acids such as acetic, citric, propionic, tartaric, glutamic, salicylic, oxalic, methanesulfonic, para-toluenesulfonic, succinic, and benzoic acid, and related inorganic and organic acids.

Base addition salts include those derived from inorganic bases such as ammonium and alkali and alkaline earth metal hydroxides, carbonates, bicarbonates, and the like, as well as salts derived from basic organic amines such as aliphatic and aromatic amines, aliphatic diamines, hydroxy alkamines, and the like. Such bases useful in preparing the salts of this invention thus include ammonium hydroxide, potassium carbonate, sodium bicarbonate, calcium hydroxide, methylamine, diethylamine, ethylenediamine, cyclohexylamine, ethanolamine and the like.

In addition to pharmaceutically-acceptable salts, other salts are included in the invention. They may serve as intermediates in the purification of the compounds, in the preparation of other salts, or in the identification and characterization of the compounds or intermediates.

The pharmaceutically acceptable salts of compounds of the present invention can also exist as various solvates, such as with water, methanol, ethanol, dimethylformamide, ethyl acetate and the like. Mixtures of such solvates can also be prepared. The source of such solvate can be from the solvent of crystallization, inherent in the solvent of preparation or crystallization, or adventitious to such solvent. Such solvates are within the scope of the present invention.

The present invention also encompasses the pharmaceutically acceptable prodrugs of the compounds disclosed herein. As used herein, “prodrug” is intended to include any compounds which are converted by metabolic processes within the body of a subject to an active agent that has a formula within the scope of the present invention. Since prodrugs are known to enhance numerous desirable qualities of pharmaceuticals (e.g., solubility, bioavailability, manufacturing, etc.) the compounds of the present invention may be delivered in prodrug form. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in Prodrugs, Sloane, K. B., Ed.; Marcel Dekker New York, 1992, incorporated by reference herein in its entirety

It is recognized that compounds of the present invention may exist in various stereoisomeric forms. As such, the compounds of the present invention include both diastereomers and enantiomers. The compounds are normally prepared as racemates and can conveniently be used as such, but individual enantiomers can be isolated or synthesized by conventional techniques if so desired. Such racemates and individual enantiomers and mixtures thereof form part of the present invention.

It is well known in the art how to prepare and isolate such optically active forms. Specific stereoisomers can be prepared by stereospecific synthesis using enantiomerically pure or enantiomerically enriched starting materials. The specific stereoisomers of either starting materials or products can be resolved and recovered by techniques known in the art, such as resolution of racemic forms, normal, reverse-phase, and chiral chromatography, recrystallization, enzymatic resolution, or fractional recrystallization of addition salts formed by reagents used for that purpose. Useful methods of resolving and recovering specific stereoisomers described in Eliel, E. L.; Wilen, S. H. Stereochemistry of Organic Compounds; Wiley: New York, 1994, and Jacques, J, et al. Enantiomers, Racemates, and Resolutions; Wiley: New York, 1981, each incorporated by reference herein in their entireties.

It is further recognized that functional groups present on the compounds of Formula I may contain protecting groups. For example, the amino acid side chain substituents of the compounds of Formula I can be substituted with protecting groups such as benzyloxycarbonyl or t-butoxycarbonyl groups. Protecting groups are known per se as chemical functional groups that can be selectively appended to and removed from functionalities, such as hydroxyl groups and carboxyl groups. These groups are present in a chemical compound to render such functionality inert to chemical reaction conditions to which the compound is exposed. Any of a variety of protecting groups may be employed with the present invention. Preferred groups for protecting lactams include silyl groups such as t-butyldimethylsilyl (“TBDMS”), dimethoxybenzhydryl (“DMB”), acyl, benzyl (“Bn”), and methoxybenzyl groups. Preferred groups for protecting hydroxy groups include TBS, acyl, benzyl, benzyloxycarbonyl (“CBZ”), t-butyloxycarbonyl (“Boc”), and methoxymethyl. Many other standard protecting groups employed by one skilled in the art can be found in Greene, T. W. and Wuts, P. G. M., “Protective Groups in Organic Synthesis” 2d. Ed., Wiley & Sons, 1991.

For therapeutic purposes, the compounds of the present invention can be administered by any means that results in the contact of the active agent with the agent's site of action in the body of the subject. The compounds may be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in combination with other therapeutic agents, such as, for example, analgesics. The compounds employed in the methods of the present invention including, for example, the compounds of Formula I, I*, I**, I(a-i), and/or II, may be administered by any means that results in the contact of the active agents with the agents' site or site(s) of action in the body of a patient. The compounds of the present invention are preferably administered in therapeutically effective amounts for the treatment of the diseases and disorders described herein to a subject in need thereof.

A therapeutically effective amount can be readily determined by the attending diagnostician, as one skilled in the art, by the use of conventional techniques. The effective dose will vary depending upon a number of factors, including the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, the formulation of the active agent with appropriate excipients, and the route of administration. Typically, the compounds are administered at lower dosage levels, with a gradual increase until the desired effect is achieved.

Typical dose ranges are from about 0.01 mg/kg to about 100 mg/kg of body weight per day, with a preferred dose from about 0.01 mg/kg to 10 mg/kg of body weight per day. A preferred daily dose for adult humans includes about 25, 50, 100 and 200 mg, and an equivalent dose in a human child. The compounds may be administered in one or more unit dose forms. The unit dose ranges from about 1 to about 500 mg administered one to four times a day, preferably from about 10 mg to about 300 mg, two times a day. In an alternate method of describing an effective dose, an oral unit dose is one that is necessary to achieve a blood serum level of about 0.05 to 20 μg/ml in a subject, and preferably about 1 to 20 μg/ml.

Although the compounds of the present invention may be administered as the pure chemicals, it is preferable to present the active ingredient as a pharmaceutical composition.

Generally speaking, therapeutic compounds of this invention may be administered to a patient alone or in combination with a pharmaceutically acceptable carrier. Accordingly, the compounds of the invention, for example, compounds of Formula I, I*, I**, I(a-i), and/or II, are preferably combined with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice as described, for example, in Remington's Pharmaceutical Sciences (Mack Publishing Co., Easton, Pa., 1980), the disclosures of which are hereby incorporated herein by reference, in their entireties. The carrier(s) must be acceptable in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipient thereof. The relative proportions of active ingredient and carrier may be determined, for example, by the solubility and chemical nature of the compounds, chosen route of administration and standard pharmaceutical practice.

The compounds of the present invention may be formulated into pharmaceutical compositions by admixture with one or more pharmaceutically acceptable excipients. The excipients are selected on the basis of the chosen route of administration and standard pharmaceutical practice, as described, for example, in Remington: The Science and Practice of Pharmacy, 20^(th) ed.; Gennaro, A. R., Ed.; Lippincott Williams & Wilkins: Philadelphia, Pa., 2000. The compositions may be formulated to control and/or delay the release of the active agent(s), as in fast-dissolve, modified-release, or sustained-release formulations. Such controlled-release, or extended-release compositions may utilize, for example biocompatible, biodegradable lactide polymers, lactide/glycolide copolymers, polyoxyethylene-polyoxypropylene copolymers, or other solid or semisolid polymeric matrices known in the art.

The compositions can be prepared for administration by oral means; parenteral means, including intravenous, intramuscular, and subcutaneous routes; topical or transdermal means; transmucosal means, including rectal, vaginal, sublingual and buccal routes; ophthalmic means; or inhalation means. Preferably the compositions are prepared for oral administration, particularly in the form of tablets, capsules or syrups; for parenteral administration, particularly in the form of liquid solutions, suspensions or emulsions; for intranasal administration, particularly in the form of powders, nasal drops, or aerosols; or for topical administration, such as creams, ointments, solutions, suspensions aerosols, powders and the like.

For oral administration, the tablets, pills, powders, capsules, troches and the like can contain one or more of the following: diluents or fillers such as starch, or cellulose; binders such as microcrystalline cellulose, gelatins, or polyvinylpyrrolidones; disintegrants such as starch or cellulose derivatives; lubricants such as talc or magnesium stearate; glidants such as colloidal silicon dioxide; sweetening agents such as sucrose or saccharin; or flavoring agents such as peppermint or cherry flavoring. Capsules may contain any of the afore listed excipients, and may additionally contain a semi-solid or liquid carrier, such as a polyethylene glycol. The solid oral dosage forms may have coatings of sugar, shellac, or enteric agents. Liquid preparations may be in the form of aqueous or oily suspensions, solutions, emulsions, syrups, elixirs, etc., or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as surfactants, suspending agents, emulsifying agents, diluents, sweetening and flavoring agents, dyes and preservatives.

The compositions may also be administered parenterally. The pharmaceutical forms acceptable for injectable use include, for example, sterile aqueous solutions, or suspensions. Aqueous carriers include mixtures of alcohols and water, buffered media, and the like. Nonaqueous solvents include alcohols and glycols, such as ethanol, and polyethylene glycols; oils, such as vegetable oils; fatty acids and fatty acid esters, and the like. Other components can be added including surfactants; such as hydroxypropylcellulose; isotonic agents, such as sodium chloride; fluid and nutrient replenishers; electrolyte replenishers; agents which control the release of the active compounds, such as aluminum monostearate, and various co-polymers; antibacterial agents, such as chlorobutanol, or phenol; buffers, and the like. The parenteral preparations can be enclosed in ampules, disposable syringes or multiple dose vials. Other potentially useful parenteral delivery systems for the active compounds include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes.

Other possible modes of administration include formulations for inhalation, which include such means as dry powder, aerosol, or drops. They may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or oily solutions for administration in the form of nasal drops, or as a gel to be applied intranasally. Formulations for topical use are in the form of an ointment, cream, or gel. Typically these forms include a carrier, such as petrolatum, lanolin, stearyl alcohol, polyethylene glycols, or their combinations, and either an emulsifying agent, such as sodium lauryl sulfate, or a gelling agent, such as tragacanth. Formulations suitable for transdermal administration can be presented as discrete patches, as in a reservoir or microreservoir system, adhesive diffusion-controlled system or a matrix dispersion-type system. Formulations for buccal administration include, for example lozenges or pastilles and may also include a flavored base, such as sucrose or acacia, and other excipients such as glycocholate. Formulations suitable for rectal administration are preferably presented as unit-dose suppositories, with a solid based carrier, such as cocoa butter, and may include a salicylate.

Pharmaceutical kits useful in, for example, the treatment of pain, which comprise a therapeutically effective amount of a compound of the invention and/or other therapeutic compounds described herein, in one or more sterile containers, are also within the ambit of the present invention. Sterilization of the container may be carried out using conventional sterilization methodology well known to those skilled in the art. The sterile containers of materials may comprise separate containers, or one or more multi-part containers, as exemplified by the UNIVIAL™ two-part container (available from Abbott Labs, Chicago, Ill.), as desired. The compound of the invention and/or other therapeutic compound as described herein may be separate, or combined into a single dosage form as described above. Such kits may further include, if desired, one or more of various conventional pharmaceutical kit components, such as for example, one or more pharmaceutically acceptable carriers, additional vials for mixing the components, etc., as will be readily apparent to those skilled in the art. Instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and/or guidelines for mixing the components, may also be included in the kit.

The compounds of the present invention may be used in methods to bind histamine receptors, more preferably histamine H₃ receptors. Such binding may be accomplished by contacting the receptor with an effective amount of a compound of Formula I, I*, I**, I(a-i), and/or II. The histamine receptors may be located in the central nervous system or located peripherally to the central nervous system or in both locations. Preferably, the contacting step conducted in an aqueous medium, preferably at physiologically relevant ionic strength, pH, and the like.

In yet another aspect, the invention is directed to methods of binding histamine receptors, more preferably histamine H₃ receptors, comprising the step of administering to a patient in need thereof, an effective amount of a compound of the invention including, for example, a compound of Formula I, I*, I**, I(a-i), and/or II, or any combination thereof.

In certain preferred aspects, the methods comprise the step of administering to said patient an therapeutically effective amount of a compound of Formula I, I*, I**, I(a-i), and/or II, or any combination thereof.

In some preferred embodiments, the histamine receptors are H³ histamine receptors. In certain more preferred embodiments, the compound selectively binds H³ histamine receptors relative to H₁, H₂ and/or H₄ receptors. In certain preferred embodiments, the H³ histamine receptors are located in the central nervous system. In some other preferred embodiments, the compound of Formula I, I*, I**, I(a-i), and/or II, or any combination thereof exhibits activity toward the histamine receptors. In certain preferred embodiments, the binding agonizes the activity of the cannabinoid receptors. In other preferred embodiments, the binding antagonizes the activity of the cannabinoid receptors, more preferably as a neutral antagonist. In still other preferred embodiments, the binding inversely agonizes the activity of the cannabinoid receptors.

In yet other preferred embodiments, the compounds of Formula I, I*, I**, I(a-i), and/or II, or any combination thereof exhibit activity toward the histamine receptors in vivo. In alternatively preferred embodiments, the compounds of Formula I, I*, I**, I(a-i), and/or II, or any combination thereof, exhibit activity toward the histamine receptors in vitro.

In certain other preferred aspects of the invention, there are provided methods of treating a disease, disorder or condition that may be affected, modulated or controlled through the binding of histamine, preferably H₃ histamine receptors. More preferably these diseases, disorders, and/or conditions selected from the group consisting of narcolepsy or sleep/wake disorders, feeding behavior, eating disorders, obesity, cognition, arousal, memory, mood disorders, mood attention alteration, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease/dementia, schizophrenia, pain, stress, migraine, motion sickness, depression, psychiatric disorders, epilepsy, gastrointestinal disorders, respiratory disorders, inflammation, and myocardial infarction. The methods herein provided comprise administering to a subject in need of such treatment a therapeutically effective amount of a compound of the invention, preferably a compound of formula:

more preferably a compound of formula I, I*, I**, I(a-i), and/or II, or any combination thereof.

In certain preferred embodiments, the disorder is narcolepsy or sleep/wake disorders. Alternatively the disorder treated is attention deficit hyperactivity disorder.

As those skilled in the art will appreciate, numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically described herein, and the scope of the invention is intended to encompass all such variations.

Synthesis

The compounds of the present invention may be prepared in a number of methods well known to those skilled in the art, including, but not limited to those described below, or through modifications of these methods by applying standard techniques known to those skilled in the art of organic synthesis. All processes disclosed in association with the present invention are contemplated to be practiced on any scale, including milligram, gram, multigram, kilogram, multikilogram or commercial industrial scale.

The general routes to prepare the examples shown herein are shown in the Schemes 1 and 2. The reagents and starting materials are commercially available, or readily synthesized by well-known techniques by one of ordinary skill in the arts. All substituents in the synthetic Schemes, unless otherwise indicated, are as previously defined.

Condensation of 4-(4-methoxyphenyl)-4-oxobutyric acid or ester, or a derivative there of, with hydrazine or an N-substituted hydrazine derivative in a solvent such as ethanol or 2-propanol provided a route to 4,5-dihydropyridazinone intermediates. Keto-acid intermediates with substitution at the 4- and 5-position (Examples with R^(13/13a) and R^(14/14a)) may be readily prepared (Heterocycles, 2002, 57, 39; Indian J. Chem, 1977, 16B, 631; Chem Pharm Bull, 1980, 42, 1850; J. Med. Chem. 2003, 46, 2008). Pyridazinones with R^(13/13a) and R^(14/14a) fused with heteroaryl or cycloalkyl were readily prepared from the corresponding anhydrides. NH(N2) pyridazinones were alkylated with alkyl or substituted alkyl groups using an R¹²-halide, a base, for example K₂CO₃, Cs₂CO₃ or NaH, in an inert solvent such as DMF or CH₃CN.

In cases where R¹³ or R¹⁴ substituted 4,5-dihydropyridazinone formed a mixture of isomers, the isomers were separated by standard methods known in the art. Intermediates wherein R¹² is H may be converted to analogs wherein R¹² is aryl or heteroaryl by standard palladium or copper coupling reactions using the appropriate aryl or heteroaryl halide. The 4,5-dihydropyridazinone may be oxidized to an aromatic pyridazinone using MnO₂, CuCl₂, DDQ, selenium oxide, DMSO/base or sodium 3-nitrobenzenesulfonate in the presence of sodium hydroxide.

In Scheme 1, examples of compounds disclosed herein may be obtained by condensation of an intermediate keto acid for example, 4-(4-methoxyphenyl)-4-oxobutyric acid (or an ester derivative) with hydrazine or an n-substituted hydrazine derivative in a solvent such as ethanol or 2-propanol to produce a dihydropyridazinone intermediate. The keto-acid intermediates not commercially available are readily prepared and described using literature methods. Keto-acid intermediates with R¹³ or R¹⁴ groups in the 4 or 5-positions or fused aryl or heteroaryl groups are described (Heterocycles, 2002, 57, 39; Indian J. Chem, 1977, 16B, 631; Chem Pharm Bull, 1980, 42, 1850; J. Med. Chem. 2003, 46, 2008). The N2 position may be substituted with alkyl or substituted alkyl groups using a base, for example K₂CO₃, Cs₂CO₃ or NaH in an inert solvent such as DMF or CH₃CN. In cases where R¹³ or R¹⁴ substituted dihydropyridazinone form isomers, the individual isomers may be separated using conventional methods known to the art. R¹³ aryl or heteroaryl groups may be introduced by standard palladium or copper coupling reactions using the appropriate aryl or heteroaryl halide. Alternatively, the 4,5-position may be oxidized to the pyridizinone intermediate using for example MnO₂, CuCl₂, DDQ or selenium oxide as the oxidizing agent. The N2 nitrogen may be H, or further substituted using methods outlined previously.

As outlined in Scheme 1 and 2, the pyridizinone or dihydro pyridizinone methoxy intermediate is demethylated using BBr₃ in dichloromethane to produce the phenol. Alkylation of the phenol with bromochloropropane or a dibromoalkane intermediate in a suitable solvent such as DMF, acetone, butanone or CH₃CN with K₂CO₃ produces the halogen intermediate. Alkylation of the halide intermediate with an amine gives the target dihydropyridazinone examples of the invention. Other suitable leaving groups may be used such as mesylates as precursors to amines. Mitsunobo reactions with cyclic amino-ethers such as 4-hydroxypiperidine, 3-hydroxypyrrolidine or substituted amino alcohols produce the corresponding examples. Alkyl bridged analogs or linker group with hetero atoms can readily be prepared for example from methoxy indanones, tetralones, benzocycloheptanones, dihydro-2H-benzo[b]oxepinones, dihydro-2H-benzo[b]thiepinones, chromanones, or thiochromanones.

As outlined in Schemes 3 and 4, the pyridazinone or 4,5-dihydropyridazinone was demethylated using BBr₃ in dichloromethane to produce phenol intermediates III and IIIa. Alkylation of the phenol intermediates with 3-bromo-1-chloropropane or a dibromo intermediate in a suitable solvent such as DMF, acetone, butanone or CH₃CN with K₂CO₃ produced the corresponding alkylated intermediate. Displacement of the halide with an amine gave the target dihydropyridazinone examples of general structures V and Va.

As outlined in Scheme 5, the phenol intermediate was coupled under Mitsunobo conditions with hydroxypiperidines, pyrrolidines or azepines to give the piperidine or cyclic amine derivatives of general structure VI. Using reaction conditions described previously, examples of general structure VII was prepared.

Scheme 6 discloses an Aldol condensation route to examples wherein R¹² is H. 4-Hydroxy-acetophenone or a derivative thereof was condensed with a keto-acid, for example glycolic acid in acetic acid, and cyclized with hydrazine to give an aromatic pyridazinone (J. Med. Chem., 1989, 32, 528).

5-Aryl pyridazinone examples were synthesized as outlined in Schemes 7 and 8. Condensation of 4-methoxyphenyl acetone (R¹⁴=Me) with glyoxylic acid (Scheme 7), followed by cyclization with hydrazine hydrate or N-substituted hydrazine derivatives afforded 5-(4-methoxy-phenyl)-6-methyl-2H-pyridazin-3-one, and N—R¹² examples (Farmaco, 1996, 51, 693-688).

5-Aryl examples where R¹⁴ is H were prepared as outlined in Scheme 8 starting from 4-methoxyphenylacetaldehyde using conditions shown in Scheme 7.

Aza examples (X═N) where R¹³ and R^(13a) are each methyl were prepared as outlined in Scheme 9 by alkylation of 1-(6-chloropyridin-3-yl)ethanone with 4-hydroxy-N—Boc-piperidine and a base such as NaH, potassium tertiary butoxide, or KHMDS in DMSO, DMF or THF. A second alkylation step using potassium bis(trimethylsilyl)amide in toluene and, for example 2-bromo-2-methyl-propionic acid ethyl ester, produced the keto-ester intermediates VIII. Example 148 was produced as shown in Scheme 9 using conditions described previously.

Scheme 10 shows the route to aza (X═N) examples where R¹² is heteroaryl(For example, Example 149 (6-[6-(1-Cyclobutyl-piperidin-4-yloxy)-pyridin-3-yl]-2-pyridin-2-yl-2H-pyridazin-3-one). 6-(6-Chloropyridin-3-yl)-4,5-dihydro-2H-pyridazin-3-one intermediate IX, prepared from ethyl-4-(4-chloro-3-pyridyl)-4-oxobutyrate and hydrazine in ethanol was alkylated with 4-hydroxy-boc-piperidine and a base (KHMDS, DMSO) to intermediate X and converted to example 141 using methods described previously. Treatment of Example 141 with 2-bromopyridine in the presence of copper(I)iodide gives Example 149. Using aryl halides or heteroaryl halides gave examples where R¹² is aryl or heteroaryl.

Bridged examples (Scheme 11) were prepared using methoxy tetralones and glycolic acid in an aldol synthesis. Phenol formation and alkylations as described previously produced the N-substituted examples. Alternatively, the use of β-tetralones provided a route to pyridazinone regioisomers.

Scheme 12 shows bridged analogs where R¹² is H, prepared by varying the order of the reactions. Addition of Zn dust to the aldol/ring closure procedure gave a one-pot synthesis of the dihydropyridazinone.

The present invention will now be illustrated by reference to the following specific, non-limiting examples. Those skilled in the art of organic synthesis may be aware of still other synthetic routes to the invention compounds. The reagents and intermediates used herein are commercially available or may be prepared according to standard literature procedures.

EXAMPLES

Other features of the invention will become apparent in the course of the following descriptions of exemplary embodiments as shown below. The compounds shown herein have activity in the targets described herein at concentrations ranging from 0.1 nM to 10 μM. These examples are given for illustration of the invention and are not intended to be limiting thereof.

Example 1

Step 1.

In a 500 mL round bottom flask, 4-(4-methoxyphenyl)-4-oxobutyric acid (27 g, 132 mmol) and methylhydrazine (7.3 g, 8.5 mL, 159 mmol) in 2-propanol (150 mL) were stirred at reflux 12 h. The solvent was concentrated to about 50 mL, ether was added (˜50 mL) and the product collected by filtration, washed 1× with ether and dried under house vacuum. Yield 27 g (94%, purity >95%), mp 133-135° C. ¹H NMR (CDCl₃) δ 2.57 (m, 2H), 2.9 (m, 2H), 3.4 (s, 3H), 3.8 (s, 3H), 6.9 (d, 2H), 7.6 (d, 2H). MS m/z=218 (M+H). Step 2.

Method A: In a 1 L round bottom flask, 6-(4-methoxyphenyl)-2-methyl-4,5-dihydro-2H-pyridazin-3-one (27 g, 124 mmol) and MnO₂ (30 g, 345 mmol) in xylene (250 mL) was stirred at vigorous reflux 14 h. The reaction was cooled to rt and filtered through a pad of celite. The xylene was concentrated and the resulting yellow solid was triturated with ether/hexane (1:2) and collected to produce 20 g (75%, HPLC 98% purity) of product. The celite/MnO₂ pad was washed with CHCl₃:MeOH 9:1 (2×˜100 mL), filtered and concentrated. The residue was triturated with ether/hexane (1:2) and collected to give a second crop (4 g, 15%, 96% purity) total yield 24 g (90%). mp 109-110° C. ¹H NMR (DMSO-d₆) δ 3.75 (s, 3H), 3.85 (s, 3H), 7.0-7.05 (d, 2H, d, 1H), 7.82 (d, 2H), 8.01 (d, 1H); MS m/z=216 (M+H).

Method B: A mixture of 6-(4-methoxyphenyl)-2-methyl-4,5-dihydro-2H-pyridazin-3-one (3.27 g, 15 mmol) and Cu(II)Cl₂ (3.96 g, 2 eq., anhydrous, Acros) in 45 ml of anhydrous acetonitrile was refluxed for 2 hr. HPLC indicated the completion of the reaction (rt (product)=7.66 min, rt (SM)=7.88 min). The reaction was cooled to rt and poured into ice-water (˜100 ml) and the acetonitrile removed at reduced pressure. The resulting off-white solid was filtered off, washed with water, and then crystallized from EtOH:Et₂O to give the product (2.47 g, 76%). Step 3.

To 6-(4-methoxyphenyl)-2-methyl-2H-pyridazin-3-one (10 g, 46.3 mmol) in 15 mL DCM cooled on an ice-water bath to ˜5° C. was added 93 mL of BBr₃ (1M soln in DCM) over 5 min. The ice bath was removed and the solution stirred at rt for 4 h. The reaction was cooled on an ice-bath and saturated NH₄Cl solution (100 mL) added slowly. After the addition was complete, the DCM was removed under reduced pressure, excess water added and the product collected, washed 1× with MeOH (˜20 mL) and dried to give 9.2 g (98%): Mp 242-245° C. ¹H NMR (DMSO-d₆) δ 3.8 (s, 3H), 6.85 (d, 2H), 7.0 (d, 1H), 7.7 (d, 2H), 7.95 (d, 1H), 9.8 (s, 1H); MS m/z=203 (M+H). Step 4.

Phenol from step 3 (500 mg, 2.3 mmol), 3-bromo-1-chloropropane (720 mg, 4.6 mmol) and K₂CO₃ (950 mg) in CH₃CN (25 mL) was stirred at reflux 20 h. The reaction was filtered and concentrated. The resulting oil was dissolved in Et₂O, and washed with water, NaCl solution, dried (MgSO₄) and concentrated. The product was triturated with Et₂O-hexanes to yield 580 mg (91%) mp 186-187° C. ¹H NMR (DMSO-d₆) δ 2.2 (t, 2H), 3.7 (s, 3H), 3.8 (t, 2H), 4.15 (t, 2H), 7.0-7.1 (m, 3H), 7.8 (d, 2H), 8.0 (d, 1H). MS m/z=279 (M+H). Step 5. Example 1

6-[4-(3-Chloropropoxy)phenyl]-2-methyl-2H-pyridazin-3-one (1.5 g, 5.4 mmol), K₂CO₃ (2.2 g 16.2 mmol), NaI (805 mg, 5.4 mmol) R-methylpyrrolidine HCl (1.3 g, 10.8 mmol) in CH₃CN (30 mL) was heated under N₂ at 90° C. for 2 days. The reaction was filtered and concentrated. The residue was dissolved in EtOAc and washed with 2N Na₂CO₃ (1×), NaCl solution (1×) dried (MgSO₄) and concentrated. The product was purified by ISCO chromatography (80 g silica gel column, 95:5 DCM:MeOH). The fractions were combined and concentrated to yield 850 mg (48%) of free base. The HCl was prepared by adding a 1N HCl-ether solution to the based in ether. The product was collected, and recrystallized from CH₃CN-ether. mp 183-185° C. ¹H NMR (DMSO-d₆) δ 1.38 (d, 3H), 1.62 (m, 1H), 1.92-1.3.1 (m, 3H), 3.4 (m, 3H), 3.7 (m, 1H), 3.7 (s, 3H), 4.15 (m, 2H), 7.0-7.17 (m, 3H), 7.8 (d, 2H), 8.0 (d, 1H), 10.1 (s, 1H). MS m/z=328 (M+H).

Example 11

Step 1.

A mixture of 1-(4-hydroxyphenyl)ethanone (20.4 g, 150 mmol), K₂CO₃ (62.1 g, 3.0 eq.), and 3-bromo-1-chloropropane (29.6 mL, 2.0 eq.) in CH₃COCH₃ (200 mL) was heated to 65° C. overnight. The mixture was filtered, washed with acetone, and concentrated to dryness. The crude product was dissolved in 150 mL of CH₂Cl₂, and washed with saturated NaHCO₃, NaCl solution and dried over Na₂SO₄. Concentration to dryness under vacuum afforded product (31.5 g, 99% yield): MS m/z 213 (M+H). Step 2.

A mixture of the product from step 11 (4.6 g, 1.0 eq.) and glyoxalic acid monohydrate (4.6 g, 1.0 eq.) was stirred in 15 mL of acetic acid at 100° C. for 2 h. The solvent was evaporated and to the residue was added 25 mL of water, and cooled to 0° C. while conc. aqueous NH₄OH was added to pH 8. To this mixture, hydrazine hydrate (4.76 mL, 2 eq.) was added and heated to 100° C. for 1 h. The resulting solid was filtered, washed with water. The crude material was dissolved in CH₂Cl₂/MeOH and purified by column chromatography with CH₂Cl₂ to 10% MeOH in CH₂Cl₂; Mp 191-3° C.; MS m/z 265 (M+H). Step 3.

A mixture of the product from step 2 (5.5 g, 21 mmol), K₂CO₃ (3.5 eq, 10.1 g), 100 mg of NaI, and R-2-methylpyrrolidine hydrochloride (2 eq., 5.1 g) in 250 mL of acetonitrile was heated to 80° C. for 2 days. The reaction mixture was then filtered, washed with CH₂Cl₂ (2×50 mL), and concentrated. The residue was dissolved in 200 mL of CH₂Cl₂, and washed with saturated NaHCO₃, saturated NaCl, dried with Na₂SO₄ and concentrated. The residue was purified by ISCO graduate chromatography with 100% CH₂Cl₂ to 5% MeOH: 95% CH₂Cl₂:0.5 mL of 2-aminopropane and then to 10% MeOH: 90% CH₂Cl₂:0.5 mL of 2-aminopropane to give the product. The product was dissolved in 15 mL of MeOH and then added 30 mL of 0.5 N HCl in EtOH. Evaporation of the solvent, and crystallization from MeOH:Et₂O afforded the example 11 as the HCl salt (2.65 g, 41%): Mp 240-2° C.; MS m/z 314 (M+H).

The following examples were prepared as HCl salts unless noted using methods for example 1 and example 11. The 4,5-dihydro examples were prepared using the method for step 3 on the product from step 1. Example Structure Mp (° C.) MS m/z 2

200-201 328 (M + H) 3

118-122 356 (M + H) 4

76-77 358 (M + H) 5

60-64 (tartrate) 356 (M + H) 6

58-62 (tartrate) 342 (M + H) 7

140-142 346 (M + H) 8

140-146 375 (M + H) 9

214-222 450 (M + H) 10

230-232 408 (M + H) 81

190-191 408 (M + H) 11

240-2  314 (M + H) 12

147 354 (M + H) 13

188-190 342 (M + H) 82

76-78 342 (M + H) 14

169 344 (M + H) 15

166-7  344 (M + H) 16

145-147 330 (M + H) 17

56-58 406 (M + H) 18

228-230 404 (M + H) 19

213-215 392 (M + H) 20

82-86 390 (M + H) 84

175-178 base 364 (M + H) 85

178 dec.

Example 21

A mixture of R-1-[3-(4-bromo-phenoxy)-propyl]-2-methyl-pyrrolidine (560 mg, 1.87 mmol), 2H-pyridazin-3-one (180 mg, 1.87 mmol), K₂CO₃ (775 mg, 5.61 mmol), copper powder (120 mg, 1.87 mmol) in pyridine (75 mL) was stirred at reflux under nitrogen for 18 h. The reaction was cooled to rt and concentrated at reduced pressure. The residue was dissolved onto fluorsil for elution and purification by ISCO silica gel chromatography (95:5:1/DCM, MeOH, isopropyl amine). The fractions containing pure product were collected and concentrated. The solid was recrystallized from Et₂O-hexanes to give 210 mg of Example 21 as a white solid; Mp 106-107° C. The HCl salt was prepared by dissolving the base in MeOH and adding 1N Et₂O—HCl: Mp 175-177° C. (MeOH-Et₂O); MS m/z 314 (M+H).

Example 22

Step 1.

A solution of 3-thiophenecarboxylic acid (10 g, 78 mmol) in 250 mL of THF at 0° C. under N₂ was added 2.0 M LDA (2.2 eq., 86 mL) dropwise. After 10 min at 0° C., p-anisaldehyde (10.6 mL, 1.12 eq.) was added and the mixture was slowly warmed to room temperature overnight. The reaction was stirred for ˜14 h, after which 100 mL of ice-water was added, and the solvent was evaporated. The aqueous solution was washed with EtOAc (2×40 mL), and then added KMnO₄ (2 eq., 12.4 g) dropwise at 0° C. The ice-bath was removed and the reaction was heated to 60° C. for 3 h. The solid was collected and washed with hot water. The aqueous layer was acidified to pH ˜3, extracted with EtOAc (3×50 mL). The combined EtOAc was dried and evaporated. The crude solid was dissolved in 50 mL of EtOH, and NH₂NH₂.H₂O (1.5 eq., 1.5 mL) was added dropwise. The reaction was heated to 80° C. for 3 h, and the resulting solid was collected and washed with EtOH to give 3.6 g (36%): MS m/z 259 (M+H). Step 2.

A solution of the product from step 1 in 10 mL of DMF was added Cs₂CO₃ (2 eq. 1.95 g) and 2-iodopropane (1.2 eq., 360 uL). The reaction was heated to 80° C. for 2 h, and then filtered through celite, washed with MeOH:CH₂Cl₂ (95:5). The filtrate was concentrated and purified by silica gel flash chromatography (MeOH:CH₂Cl₂, 97:3) to afford 585 mg (65%) of the product: Mp 124-6° C.; MS m/z 301 (M+H). Step 3.

A solution of the product from step 2 (1.0 g, 3.3 mmol) in 25 mL of CH₂Cl₂ was cooled to 0° C. and BBr₃ (1M in DCM, 16.7 mL) was added dropwise. The ice-bath was removed and the reaction was stirred at rt for 1 h. The reaction mixture was then poured into 50 mL of ice cold saturated NH₄Cl solution with stirring. The resulting solid was collected, washed with water (3×15 mL), and Et₂O (2×15 mL) to give the product of step 3 (868 mg, 92%): Mp 256-257° C.; MS m/z 287 (M+H). Step 4.

A solution of the product of step 3 (858 mg, 3 mmol), K₂CO₃ (1.24 g, 3.0 eq.), and 3-bromo-1-chloropropane (0.3 mL, 1.05 eq.) in acetone:DMF (25 mL:3 mL) was heated to 80° C. overnight. The mixture was then filtered, washed with acetone, and concentrated to dryness to afford the product of step 4 (1.17 mg, 98% yield): Mp 92-4° C.; MS m/z 363 (M+H). Step 5.

A mixture of the product of step 4 (109 mg, 0.3 mmol), K₂CO₃ (3.5 eq, 145 mg), 50 mg of NaI, and R-2-methylpyrrolidine hydrochloride (1.2 eq., 44 mg) in 10 mL of acetonitrile was heated to 80° C. for 2 days. The reaction mixture was then filtered, washed with CH₂Cl₂ (2×20 mL) and concentrated. The residue was dissolved in 20 mL of CH₂Cl₂, and washed with saturated NaHCO₃ solution, saturated NaCl solution, dried with Na₂SO₄, and concentrated. The residue was purified by preparative TLC or ISCO graduate silica gel chromatography (MeOH:CH₂Cl₂:2-aminopropane; 5:95:0.5) to give the product. The product was dissolved in 5 mL of MeOH, and added 0.5 mL of 1N HCl in EtOH. Evaporation of the solvent, and crystallization from MeOH:Et₂O afforded the HCl salt of example 22 (5-isopropyl-7-(4-(3-((R)-2-methyl-pyrrolidin-1yl)propoxy)phenyl)-5H-thieno[2,3-d]pyridazin-4-one) (52 mg, 42%): Mp 123-4° C.; MS m/z 412 (M+H).

The following examples were prepared as HCl salts using methods of example 22. Example Structure Mp (° C.) MS m/z 23

158-159 426 (M + H) 24

195-196 412 (M + H) 25

100-102 440 (M + H) 26

 83 dec. 442 (M + H) 27

 9-96 442 (M + H) 28

188-190 400 (M + H) 29

144 398 (M + H) 30

283 dec. 481 (M + H) 31

106 dec. 426 (M + H) 32

151-153 412 (M + H) 33

 84 dec. 426 (M + H) 34

168-170 426 (M + H) 35

207-209 455 (M + H) 36

123 dec. 481 (M + H) 37

227-229 494 (M + H) 38

223-224 494 (M + H)

Example 39

Step 1. A solution of 2-methoxy-4-oxo-4-(4′-methoxyphenyl) butyric acid (2.22 g, 10 mmol) and hydrazine hydrate (1.5 eq., 688 μL) in 20 mL of EtOH was stirred at 80° C. overnight. The solvent was removed and the solid was collected and washed with cold EtOH to give 6-(4-methoxy-phenyl)-4-methyl-4,5-dihydro-2H-pyridazin-3-one (2.05 g, 94%): Mp 203-6° C.

Step 2. A mixture of the product from step 1 (6-(4-methoxy-phenyl)-4-methyl-4,5-dihydro-2H-pyridazin-3-one; 1.96 g, 9 mmol) and Cu(II)Cl₂ (2.48 g, 2 eq.) in of acetonitrile (15 mL) was heated to 70° C. for 2 h. The reaction was quenched with ice-water (˜100 mL), the resulting solid was collected and crystallized from isopropanol to give 1.42 g (73%) of 6-(4-methoxy-phenyl)-4-methyl-2H-pyridazin-3-one: Mp 265-7° C.; MS m/z 217 (M+H).

Step 3. The product of step 2 (6-(4-methoxy-phenyl)-2,4-dimethyl-2H-pyridazin-3-one) was prepared as described for example 22 step 2 using 6-(4-methoxy-phenyl)-4-methyl-4,5-dihydro-2H-pyridazin-3-one, MeI and Cs₂CO₃.

Example 39

6-(4-(3-Chloropropoxy)-phenyl)-2,4-dimethyl-2H-pyridazin-3-one was prepared from the product of step 3 and 3-bromo-1-chloropropane using the procedure described for Example 22 step 4. Example 39 (2,4-dimethyl-6-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one) was prepared using 6-(4-(3-chloropropoxy)-phenyl)-2,4-dimethyl-2H-pyridazin-3-one and piperidine by the methods described for example 22 step 5. The hydrochloride salt was prepared; Mp 222-3° C.; MS m/z 342 (M+H).

The following examples as HCl salts were prepared using methods described for example 1 and example 22. Example Structure Mp (° C.) MS m/z 40

175-176 342 (M + H) 41

 54-155 370 (M + H) 42

 197-198 370 (M + H) 43

190-192 418 (M + H) 44

232-233 418 (M + H) 45

232-233 418 (M + H) 46

186-187 418 (M + H) 47

207-209 404 (M + H) 48

212-214 404 (M + H) 49

216-217 378 (M + H) 50

241-242 378 (M + H) 51

253-254 364 (M + H) 52

201-203 364 (M + H) 53

238-240 392 (M + H) 54

217-218 489 (M + H) 55

216-217 489 (M + H) 56

212-214 368 (M + H) 57

214-216 368 (M + H) 58

<50 370 (M + H) 59

<50 370 (M + H) 60

156-158 382 (M + H) 61

196-198 382 (M + H)

6-(4-methoxy-phenyl)-4,5-dihydro-2H-pyridazin-3-one (1.65 g, 7.5 mmol) in 15 mL of EtOH was heated to 80° C. as 20 mL of 4% of KOH/EtOH solution was added dropwise. After 5 min., benzaldehyde (1.0 eq. 0.76 mL) was added and the mixture stirred at 80° C. for 2 h. The reaction was cooled to rt., poured into ice-H₂O (75 mL) and the resulting solid was collected and crystallized from EtOH to give 1.67 g (76%) of intermediate 4-benzyl-6-(4-methoxy-phenyl)-2H-pyridazin-3-one: MS m/z 293 (M+H). This intermediate was used to prepare examples 45 and example 46.

Step 1. A suspension of NaH (12.8 mmol, 512 mg) in DMSO (23 mL) was added 4′-methoxy-2-phenylacetophenone (12.8 mmol, 2.89 g) in 10 ml toluene dropwise under argon. After 30 minutes of stirring, ethyl bromoacetate (1.4 mL, 1 eq.) in 10 mL of toluene was added and the mixture was stirred at rt overnight. The reaction was quenched by addition of 2N HCl (4 mL), and then 60 mL of water. The mixture was extracted with CH₂Cl₂ (3×30 mL), dried over MgSO₄ and concentrated under vacuum overnight to afforded 4.0 g (99%) of 4-(4-methoxy-phenyl)-4-oxo-3-phenyl-butyric acid ethyl ester.

Step 2. A solution of 4-(4-methoxy-phenyl)-4-oxo-3-phenyl-butyric acid ethyl ester (5.0 g, 16 mmol) in EtOH:H₂O (60 mL 1:1) was stirred as 10N NaOH (16 mL) was added dropwise. The reaction was stirred at rt for 1 hr. The solvent was evaporated and the residue was diluted with water (50 mL) and extracted with CH₂Cl₂ (2×20 mL). The aqueous layer was then acidified with 3N HCl to pH 2-3, extracted with CH₂Cl₂ (3×30 mL). The CH₂Cl₂ extracts were dried over MgSO₄, and the oil was crystallized from Et₂O/MeOH to give 4.5 g (99%) of 4-(4-methoxy-phenyl)-4-oxo-3-phenyl-butyric acid: mp 157-9° C.; MS m/z 283 (M−H).

Step 3. A solution of 4-(4-methoxy-phenyl)-4-oxo-3-phenyl-butyric acid (1.5 g, 5.28 mmol) and hydrazine hydrate (1.5 eq., 363 μL) in 20 mL of EtOH was stirred at 80° C. overnight. The solvent was reduced and the solid was filtered and then washed with cold EtOH to give 6-(4-methoxy-phenyl)-5-phenyl-4,5-dihydro-2H-pyridazin-3-one (1.46 g, 99%): mp 176-7° C.; MS m/z 281 (M+H).

Examples 47 and 48 were prepared from 6-(4-methoxy-phenyl)-5-phenyl-4,5-dihydro-2H-pyridazin-3-one as described in Example 39.

Example 62

A suspension of 4-(4-hydroxy-phenyl)-2-methyl-2H-phthalazin-1-one (252 mg, 1.0 mmol) and of 4-bromomethyl)piperidine-1-carboxylic acid t-butyl ester (786 mg, 3 eq) in 1 mL of 4N NaOH and 8 mL of DMSO was stirred at rt for 24 h. The reaction was diluted with water (20 mL), extracted with EtOAc (3×10 mL), and the combined extracts were washed with NaHCO₃ solution, NaCl solution and dried over MgSO₄. The product was purified by ISCO graduate chromatography (100% CH₂Cl₂ to 95:5 CH₂Cl₂:MeOH) to afford 198 mg (50%) of 4-(4-(1(3-methyl-4-oxo-3,4-dihydro-phthalazin-1-yl)-phenoxymethyl)-piperidine-1-carboxylic acid t-butyl ester: Mp 167-9° C.; MS m/z 450 (M+H).

Example 63

A solution of example 62 (4-(4-(1(3,-methyl-4-oxo-3,4-dihydro-phthalazin-1-yl)-phenoxymethyl)-piperidine-1-carboxylic acid tert-butyl ester) (180 mg, 0.4 mmol) and 4N HCl (2 mL) in dioxane (5 mL) and water (0.5 mL) was heated to 50° C. for 2 h. The solvent was evaporated, and the product was triturated with Et₂O to give 117 mg (84%) of example 63 (2-methyl-4-(4-(piperidin-4-ylmethoxy)-phenyl)-2H-phthalazin-1-one) HCl: Mp 207-9° C.; MS m/z 350 (M+H).

Example 64

A solution of example 63 (2-methyl-4-(4-(piperidin-4-ylmethoxy)-phenyl)-2H-phthalazin-1-one) (90 mg, 0.23 mg) and NaCNBH₃ in DMF:MeOH:AcOH (3:6 mL: 0.25 mL) was stirred under N₂ as cyclobutanone (81.7 mg, 5 eq.) was added. The reaction was stirred at 60° C. for 1.5 h, quenched with 3 mL of water, extracted with CH₂Cl₂ (3×10 mL), washed with NaHCO₃, NaCl solution, dried and concentrated. The crude product was purified by silica gel chromatography using 5% MeOH: 95% CH₂Cl₂: 0.5 mL of isopropyl amine. The fractions were collected, concentrated and the product dissolved in 5 mL of MeOH, and added 0.5 mL of 1N HCl in EtOH. The solvent was evaporated, and the HCl product crystallized from MeOH-Et₂O to give example 64 (4-(4-(1-cyclobutyl-piperidin-4-ylmethoxy)-phenyl)-2-methyl-2H-phthalazin-1-one HCl)

(53 mg, 57%): Mp 256-7° C.; MS m/z 404 (M+H).

The following examples as HCl salts were prepared from 6-(4-hydroxy-phenyl)-2-methyl-2H-pyridazin-3-one using the procedures for examples 62-64. Example 65 is the base. Example Structure Mp (° C.) MS m/z 65

164-166 400 (M + H) 66

249-251 300 (M + H) 67

250-252 354 (M + H) 68

187-189 342 (M + H) 69

230-231 354 (M + H) 70

250-251 368 (M + H) 71

257-258 314 (M + H)

Example 72

A mixture of 6-(4-hydroxy-phenyl)-2-methyl-2H-pyridazin-3-one (500 mg, 2.6 mmol), triphenylphosphine (1.35 g, 5.2 mmol), 4-hydroxy-N-iPr-piperidine (745 mg, 10.4 mmol) in THF (50 mL) was added DEAD (1.1 g, 6.5 mmol) dropwise. The reaction was stirred at rt overnight, then concentrated. The product was purified by ISCO silica gel chromatography (95:5. DCM:MeOH). The HCl salt was prepared by addition of 1M Et₂O HCl to a methanol solution of the base. mp 108-110° C. MS m/z 328 (M+H).

Example 73

A solution of 6-(4-hydroxy-phenyl)-2-methyl-2H-pyridazin-3-one (1.0 mg, 4.6 mmol), triphenylphosphine (1.44 g, 5.5 mmol), 4-hydroxy-N—BOC-piperidine (1.1 mg, 5.5 mmol), in THF (40 mL) was added DEAD (0.96 g, 5.5 mmol) dropwise on an ice-batch. The batch was removed and the reaction was stirred at rt 2-days. The reaction was concentrated at reduced pressure and Et₂O (40 mL) was added and stirred 2 h and the solids removed by filtration. The solution was concentrate and the product was purified by ISCO silica gel chromatography (95:5. DCM:MeOH). The resulting 4-[4-(1-methyl-6-oxo-1,6-dihydro-pyridazin-3-yl)-phenoxy]-piperidine-1-carboxylic acid t-butyl ester was dissolved in dioxane (5 mL) and 4N HCl in dioxane (4 mL) as added and stirred 2 h. The solution was concentrated and 2N Na₂CO₃ added to pH 9. The aqueous solution was added solid sodium chloride until saturated, then extracted with EtOAc (2×50 mL), dried (MgSO₄) and concentrated. The HCl salt was prepared by addition of 1M HCl Et₂O solution to a methanol solution of the base. Mp>210° C. MS m/z 386 (M+H).

Example 74

To a solution of example 73 (0.25 g, 0.9 mmol) and cyclobutanone in MeOH (10 mL) was added HOAc (0.5 mL) then solid sodium cyanoborohydride (560 mg, 62.8 mmol). The reaction was stirred 4 h then concentrated. Na₂CO₃ solution was added, and extracted with EtOAc (2×50 mL), dried over MgSO₄, filtered and concentrated. To the residue in CH₃CN (3 mL) was added a 1N HCl/Et₂O solution and concentrated. Example 74 was recrystallized from CH₃CN-Et₂O to give 180 mg of a white solid. Mp 250-252° C. MS m/z 340 (M+H).

Example 75 Step 1

A mixture of 6-methoxy-1-tetralone (20 g, 114 mmol) and glyoxylic acid monohydrate (10.5 g, 114 mmol) was heated at 120° C. in a melt for 5 min. After slight cooling, EtOAc (100 mL) was carefully added. The solid which precipitated was collected to afford 8.5 g (30%) of hydroxyl-(6-methoxy-1-oxo-1,2,3,4-tetrahydro-naphthalen-2-yl)-acetic acid; Mp 212-214° C., MS m/z 251 (M+H).

Step 2

A solution of the product from step 1 (700 mg, 2.8 mmol) and N-methylhydrazine (0.3 mL) in 2-propanol (10 mL) was heated to reflux 18 h. The solvent was removed under vacuum and the solid was triturated with methanol (2 mL), collected and then suspended in methylene chloride (2 mL) at 0° C. BBr₃ (10 mL of 1M solution in DCM, 10 mmol) was slowly added dropwise and the ice bath removed. After 3 h at ambient temperature, saturated NH₄Cl solution (10 mL) was added. The DCM was removed under vacuum and the resulting slurry was carefully neutralized with saturated NaHCO₃ solution and washed with water. The solids were collected to afford 8-hydroxy-2-methyl-5,6-dihydro-2H-benzo[h]cinnolin-3-one (175 mg, 27%) as a white solid; m p>300° C. MS m/z 229 (M+H).

Step 3

To a slurry of the product from step 2 (166 mg, 0.7 mmol) 1-bromo-3-chloro-propane (126 mg, 0.9 mmol) and K₂CO₃ (110 mg, 0.8 mmol) in acetonitrile (5 mL) was stirred 18 h at 100° C. The solvent was removed under vacuum and the solids were partitioned between EtOAc (10 mL) and water (10 mL). The organics were washed with EtOAc (2×10 mL), dried over MgSO₄ and the solvent was removed under vacuum. Silica gel chromatography with EtOAc/hexanes as eluent afforded 196 mg of the intermediate 3-chloropropylether (88%) as a white solid. The chloro intermediate was slurred (196 mg, 0.6 mmol) in acetonitrile (4 mL) and added R-2-methyl-pyrrolidine tartrate (227 mg, 0.9 mmol), KI (20 mg, 0.1 mmol) and K₂CO₃ (355 mg, 2.4 mmol). The reaction was stirred 18 hat 100° C., and the solvent was removed under vacuum. The solids were partitioned between CH₂Cl₂ (10 mL) and water (10 mL). The water layer was washed with CH₂Cl₂ (3×10 mL). The combined organic layers were dried over Na₂SO₄ and concentrated under vacuum. Silica gel chromatography using CH₂Cl₂/MeOH (95:5) as eluent gave the product as an oil. The HCl salt was prepared from EtOH and 1M HCl in Et₂O to give 130 mg (52%) of example 75 as a white solid; Mp 192-194° C.; MS m/z 354 (M+H).

The following examples were prepared as HCl salts using the methods described for example 75. Example Structure Mp (° C.) MS m/z 76

140-142 416 (M + H) 77

206-208 438 (M + H) 78

250-252 354 (M + H)

Example 79

Step 1. A solution of 2-formyl-5-methoxy-benzoic acid (1.0 g, 6.10 mmol) and methyl hydrazine (0.481 mL, 1.5 eq.) in ethanol (15 mL) was stirred at 85° C. for 1.5 days. The solvent was removed and the solid was collected and washed with cold EtOH to give 7-methyl-2-methyl-2H-phthalazin-1-one (780 mg): MS m/z 191 (M+H).

Step 2-3. 7-(3-Chloro-propoxy)-2-methyl-2H-phthalazin-1-one was prepared from 7-methyl-2-methyl-2H-phthalazin-1-one using the procedure described in Example 22 Step 3, and Step 4.

The hydrochloride salt of example 79 (2-methyl-7-(3-(R)-2-methyl-pyrrolidin-1-yl)-propoxy)-2H-phthalazin-1-one) was prepared using the procedure as described in Example 1522 Step 5: Mp 252-3° C.; MS m/z 302 (M+H).

The following examples were prepared as HCl salts using methods of example 79. Example Structure Mp (° C.) MS m/z 79

252-253 302 (M + H) 80

251-252 302 (M + H)

Example 83

This compound was prepared using the same method as example 74 using example 73 and cyclopentanone in MeOH (10 mL)/HOAc (0.5 mL) followed by solid sodium cyanoborohydride. The reaction was stirred 4 h then concentrated. Na₂CO₃ solution was added, and extracted with EtOAc (2×50 mL), dried over MgSO₄, filtered and concentrated. Example 83 was recrystallized from CH₃CN-Et₂O to give a white solid. Mp 129-132° C. MS m/z 354 (M+H).

Example 86

Step 1.

A mixture of 1-(4-methoxyphenyl)propan-2-one (16.4 g, 100 mmol) and glyoxalic acid hydrate (9.20 g, 100 mmol) were heated to 135° C. overnight, then the water was distilled off at 120° C. for 2 h. The residue was taken up in 40 mL of ethanol with stirring as methylhydrazine (10.5 mL, 200 mmol) was added dropwise. The reaction was heated to 85° C. overnight. The solvent was evaporated and the residue was dissolved in 200 mL of methylene chloride and washed with 5% NaHCO₃ solution (2×20 mL), saturated NaCl solution, then dried over Na₂SO₄ and concentrated. The residue was purified by silica gel chromatography (2% MeOH in CH₂Cl₂) to give 5-(4-methoxyphenyl)-2,6-dimethyl-2H-pyridazin-3-one (4.2 g) MS m/z 231 (M+H). Step 2.

A solution of the product from step 1 (3.2 g, 14 mmol) in CH₂Cl₂ (40 mL) was cooled to 0° C. and BBr₃ (6.6 mL, 5.0 eq.) was added dropwise. The ice-bath was removed and the reaction was stirred at rt for 1 h, after which the reaction mixture was poured into 50 mL of ice cold saturated NH₄Cl solution with stirring. The resulting solid was filtered, and washed with water (3×15 mL) then Et₂O (2×15 mL) to give the product of step 2 (0.66 g, 22%): MS m/z 217 (M+H). Step 3.

A solution of the product from step 2 (710 mg, 3.29 mmol), K₂CO₃ (1.36 g, 3.0 eq.) and 3-bromo-1-chloropropane (0.39 mL, 1.2 eq.) in CH₃COCH₃ (30 mL) was heated to 80° C. overnight. The mixture was then filtered, washed with acetone and concentrated to dryness to afford the product of step 3 (950 mg, 98%): MS m/z 293 (M+H). Step 4.

A mixture of the product of step 3 (481 mg, 1.65 mmol), K₂CO₃ (3.5 eq, 795 mg), 50 mg of NaI, and R-2-methylpyrrolidine hydrochloride (2.0 eq., 773 mg) in acetonitrile (10 mL) was heated to 80° C. for 2 days. The reaction was then filtered, washed with CH₂Cl₂ (2×20 mL) and concentrated. The residue was dissolved in 30 mL of CH₂Cl₂ and washed with saturated NaHCO₃, saturated NaCl solution, dried with Na₂SO₄ and then concentrated. The residue was purified by preparative TLC (10% MeOH: 90% CH₂Cl₂:0.5 mL 2-aminopropane) to give the product. The product was dissolved in 10 mL of MeOH, and was added 2.5 mL of 1N HCl in EtOH. The solvents were evaporated and the product crystallized from MeOH:Et₂O to give example 86 as the HCl salt (231 mg, 41%): Mp 176-8° C.; MS m/z 342 (M+H).

Example 87

This compounds was prepared using the procedure for example 86 using the product of step 3 and piperidine to give the hydrochloride salt; Mp 210-211° C.; MS m/z 342 (M+H).

Example 88

Step 1.

A solution of 4-hydroxyphenylacetone (4.5 g, 30 mmol) and potassium carbonate (4.14 g, 3.0 eq.) in 50 mL of acetone was stirred under N₂ as 1-bromo-3-chloro-propane was added dropwise. The reaction was heated to 80° C. overnight. The mixture was then filtered through celite, washed with acetone and concentrated to afford 1-[4-(3-chloro-propoxy)phenyl]propan-2-one (6.3 g, 93% yield): MS m/z 227 (M+H). Step 2.

5-[4-(3-Chloropropoxy)phenyl]-6-methyl-2H-pyridazin-3-one was prepared from the product from step 1 using the procedure described in Example 86 step 1. Step 3.

6-Methyl-5-{4-[3-®-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2(−1-pyridazin-3-one) hydrochloride salt was prepared from 5-[4-(3-chloropropoxy)phenyl]-6-methyl-2H-pyridazin-3-one and R-2-methylpyrrolidine hydrochloride using the procedure described in Example 86 Step 4; Mp 115° C. (dec), MS m/z 329 (M+H).

Example 89

This compound was prepared using the procedure for example 88 using the product of step 2 and piperidine to give the hydrochloride salt Mp dec 123 (dec.) ° C.; MS m/z 328 (M+H).

Example 90

This compound was prepared using the procedure for example 88 to give the hydrochloride salt Mp 204-6° C.; MS m/z 342 (M+H).

Example 91

Step 1.

A solution of 4-methoxyphenyl ethanol (15.0 g, 98.2 mmol) in 150 mL of methylene chloride was stirred at 0° C. while Dess-Martin periodinane (50 g, 1.2 eq.) was added in small portions. The ice-bath was removed and the reaction was stirred at rt for 1 h. The reaction mixture was then diluted with methylene chloride (100 mL), washed with 10% sodium thiosulfate, saturated NaHCO₃ solution, water, saturated NaCl solution, and dried over Na₂SO₄. The product was purified using silica gel chromatography (100% hexanes to 20% EtOAC/hexanes) to afford 5.3 g (34%) of 4-methoxyphenyl acetaldehyde.

A suspension of glyoxalic acid hydrate (2.45 g, 26.6 mmol) and morpholine hydrochloride (3.28 g, 26.35 mmol) in dioxane (25 mL) was stirred as water (2 mL) was added. The homogeneous solution and 4-methoxyphenyl acetaldehyde (3.8 g, 25.3 mmol) was then added and the solution was stirred at reflux for 24 h. The solvent was evaporated and a solid was formed after addition of 20 mL of water. The solid was collected and washed with water to give 5.1 g (98%) of the product: MS m/z 189 (M−17+H). Step 2.

A suspension of 5-hydroxy-4-(4-methoxyphenyl)-5H-furan-2-one (2.06 g, 10 mmol) in 30 mL of ethanol was stirred as methylhydrazine (0.78 mL, 1.5 eq) was added dropwise. The reaction was heated to reflux at 85° C. for 2 h, then the solvent was reduced at reduced pressure to give a solid, which was collected and washed with cold EtOH to give 1.0 g (46%) of 5-(4-methoxy-phenyl)-2-methyl-2H-pyridazin-3-one: MS m/z 217 (M+H). Step 3.

5-(4-Hydroxyphenyl)-2-methyl-2H-pyridazin-3-one was prepared from 5-(4-methoxy-phenyl)-2-methyl-2H-pyridazin-3-one with BBr₃ using the procedure described in Example 86 Step 2; Mp 296-8° C.; MS m/z 203 (M+H). Step 4.

5-[4-(3-Chloro-propoxy)-phenyl]-2-methyl-2H-pyridazin-3-one was prepared from 5-(4-hydroxy-phenyl)-2-methyl-2H-pyridazin-3-one with 1-bromo-3-chloro-propane using the procedure described in Example 86 Step 3; Mp 90-91° C.; MS m/z 279 (M+H). Step 5.

This compound was prepared as the hydrochloride salt from 5-[4-(3-chloropropoxy)-phenyl]-2-methyl-2H-pyridazin-3-one and R-2-methylpyrrolidine using the procedure described in Example 86 Step 4; Mp 222-3° C.; MS m/z 328 (M+H).

Example 92

This compound was prepared as the hydrochloride salt using 5-[4-(3-chloropropoxy)-phenyl]-2-methyl-2H-pyridazin-3-one and piperidine using the procedure described in Example 91 Step 5; Mp 253-4° C.; MS m/z 328 (M+H).

Example 93

This compound was prepared as the hydrochloride salt using 5-[4-(3-chloropropoxy)-phenyl]-2-methyl-2H-pyridazin-3-one and azepine using the procedure described in Example 91 Step 5; Mp 247-8° C.; MS m/z 342 (M+H).

Example 94

Step 1.

A mixture of 2-(4-hydroxyphenyl)ethanol (13.82 g, 100.0 mmol) and potassium carbonate (34.0 g, 250.0 mmol) in 125.0 mL of acetone was stirred as 1-bromo-3-chloropropane (24.0 g, 150.0 mmol) was added dropwise. The reaction was stirred at 60° C. overnight, and then filtered through celite, washed with acetone and concentrated. The residue was dissolved in EtOAc (250 mL) and washed with 2N Na₂CO₃, water, and saturated NaCl solution. After drying over Na₂SO₄ the solution was concentrated to give 21 g (98%): Mp 49-50° C.; MS m/z 197 (M−H). Step 2.

A solution of Dess-Martin periodinane (20.4 g, 48.0 mmol) in 200 mL of methylene chloride was stirred as 2-[4-(3-chloropropoxy)ethanol (8.59 g, 40.0 mmol) in 60.0 mL of methylene chloride was added dropwise via addition funnel. The reaction was stirred at rt for 1 h, diluted with ether (400 mL) and poured into 200 mL of 1.3 M NaOH solution. The ether layer was separated and washed with 1.3 M NaOH solution (100 mL), water until pH 7, and dried over Na₂SO₄. The product was purified using silica gel flash chromatography with 20% Et₂O in hexane to give 6.75 g (79.3%) of [4-(3-chloro-propoxy)phenyl]acetaldehyde: MS m/z 213 (M+H). Step 3.

A suspension of glyoxalic acid hydrate (3.04 g, 33.1 mmol) and morpholine hydrochloride (4.09 g, 33.1 mmol) in dioxane (48 mL) was stirred as 4.5 mL of water was added. To the homogeneous solution [4-(3-chloropropoxy)phenyl]acetaldehyde (6.70 g, 31.5 mmol) was then added and the solution was stirred at reflux for 24 h. The solvent was evaporated and 50 mL of water was added. The solid was collected and washed with water to give 8.3 g (98%): MS m/z 251 (M−17+H). Step 4.

A solution of the product from step 3 (8.0 g, 29.8 mmol) and 2-hydrazinopyridine (9.75 g, 3.0 mmol) in 80 mL of acetic acid was stirred at 110° C. for 24 h. The solvent was evaporated and the residue was purified with ISCO Combiflash chromatography with 2% MeOH in methylene chloride. The product was crystallized from EtOH and ether to give 5.88 g (58%) of 5-[4-(3-chloropropoxy)-phenyl)-5-hydroxy-5H-furan-2-one: Mp 219-220° C.; MS m/z 391 (M+H). Step 5.

A mixture of the product from step 4, R-2-methyl-pyrrolidine benzenesulfonic acid salt (12.0 g, 51.0 mmol), potassium carbonate (8.2 g, 59.0 mmol) and sodium iodide (50 mg, 0.334 mmol) in 150.0 mL of acetonitrile was heated to 80° C. for 24 h. The reaction mixture was then filtered, washed with methylene chloride (2×20 mL) and concentrated. The residue was dissolved in 100 mL of methylene chloride and washed with saturated NaHCO₃, saturated NaCl solution, dried over Na₂SO₄ and concentrated. The residue was purified by ISCO graduate silica gel chromatography with 10% MeOH in CH₂Cl₂ with 0.5% of iPrNH₂ to give the product. The product was dissolved in MeOH and added 40.0 mL of 1N HCl in EtOH and concentrated to dryness. Crystallization using MeOH and CH₃CN afforded the HCl salt (5.45 g, 75%) Mp 219-220° C.; MS m/z 391 (M+H).

Example 95

This compound was prepared using the procedure for example 94 to give the HCl salt; Mp 266-8° C.; MS m/z 391 (M+H).

Example 96

This compound was prepared using the procedure for example 94 to give the HCl salt; Mp 230-2° C.; MS m/z 405 (M+H).

Example 97

Step 1.

A solution of the product from example 94 step 3 (2.0 g, 7.45 mmol) and hydrazine hydrate (0.59 g, 1.5 eq.) in 20 mL of EtOH was stirred at 85° C. for 2 h. The solvent was reduced and the solid was collected and washed with cold EtOH to give 1.2 g (61%) of 5-[4-(3-chloropropoxy)phenyl)-2H-pyridazin-3-one: Mp 197-9° C.; MS m/z 265 (M+H).

Step 2.

This compound was prepared from the product of step 1 (5.8 g, 17.0 mmol) and piperidine using the procedure for example 88. The hydrochloride salt of the product was prepared; Mp 249-250° C.; MS m/z 314 (M+H).

Example 98

Step 1.

A suspension of 5-hydroxy-4-(4-methoxyphenyl)-5H-furan-2-one (2.00 g, 9.7 mmol) in 15 mL of ethanol was stirred as hydrazine hydrate (0.97 g, 2.0 eq) was added in dropwise. The reaction was stirred at 85° C. overnight, and then the solvent was reduced. The solid was collected and washed with cold EtOH to give 1.7 g (87%) of 5-(4-methoxyphenyl)-2H-pyridazin-3-one: MS m/z 203 (M+H). Step 2.

A mixture of the product from step 1 (1.34 g, 6.62 mmol), copper (I) iodide (0.4 g, 2.0 mmol) and potassium carbonate (1.4 g, 9.9 mmol) in DMF (15 mL) was stirred and degassed with N₂ for 3 min. Then 2-bromo-6-methylpyridine was added dropwise. After stirred at 120° C. overnight, the mixture was filtered through celite, washed with 50 mL of CH₂Cl₂, 15% of NH₄OH solution (3×15 mL), water, saturated NaCl solution, and dried over Na₂SO₄. The residue was purified by ISCO graduate chromatography (5% MeOH in CH₂Cl₂) to give 5-(4-methoxyphenyl)-2-(6-methylpyridin-2-yl)-2H-pyridazin-3-one (0.30 g, 15%): Mp 167-8° C.; MS m/z 294 (M+H). Step 3.

This compound was prepared using the procedure described for Example 91 step 3; MS m/z=280 (M+H).

Step 4

Example 98 was prepared from the product of step 3 using procedures described in Example 91 Step 4 and Step 5; Mp 118-120° C.; MS m/z 405 (M+H).

Example 99

Example 99 was prepared as the hydrochloride salt using procedures described for Example 98; Mp 98-100° C.; MS m/z 405 (M+H).

Example 100

Example 100 was prepared as the hydrochloride salt using procedures described for Example 98; Mp 155-7° C.; MS m/z 405 (M+H).

Example 101

Example 101 was prepared as the hydrochloride salt using procedures described for Example 98; Mp 106° C. (dec.); MS m/z 419 (M+H).

Example 102 Step 1

A solution of triphenylphosphine (18.5 g, 70.6 mmol) and 40% DEAD in toluene (12.3 g, 70.6 mmol) in 125.0 mL of tetrahydrofuran was cooled to 0 oC under N₂ as a solution of 1-(4-hydroxy-phenyl)-propan-2-one (6.54 g, 43.6 mmol) and 4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester (10.7 g, 53.2 mmol) in 125.0 mL of tetrahydrofuran was added dropwise via addition funnel. After stirred at rt overnight, the solvent was evaporated. The residue was stirred in hexane/EtOAc, the solid formed was filtered. The hexane/EtOAC solution was concentrated and purified by ISCO graduate chromatography (hexane-20% EtOAc in hexane) to give 4-[4-2-oxo-propyl)-phenoxy]-piperidine-1-carboxylic acid tert-butyl ester (8.52 g, 59%).

Step 2

A mixture of 4-[4-(2-oxo-propyl)-phenoxy]-piperidine-1-carboxylic acid tert-butyl ester (7.01 g, 21.03 mmol) and glyoxalic acid hydrate (1.9 g, 21 mmol) was heated to 100° C. for 5 h. The resulting dark thick oil was stirred in 30 mL of EtOH as hydrazine hydrate (2.1 g, 42 mmol) was added. After stirred at 90° C. for 5 hr, the reaction was cooled to rt, and the solvent was evaporated. The crude product was purified by flash chromatography (10% MeOH in CH₂Cl₂), followed by trituration with ether to give 4-[4-(3-methyl-6-oxo-1,6-dihydro-pyridazin-4-yl)-phenoxy]-piperidine-1-carboxylic acid tert-butyl ester (3.25 g, 46%): Mp 184-6° C.; MS m/z 386 (M+H).

Example 102

A solution of the product from step 2 (4-[4-(3-methyl-6-oxo-1,6-dihydro-pyridazin-4-yl)-phenoxy]-piperidine-1-carboxylic acid tert-butyl ester) (7.6 g, 20 mmol) in 30 mL of dioxane and 3.0 mL of water was cooled to 0° C. as 24 mL of 4M HCl in dioxane was added dropwise. After stirring at 50° C. for 1 h, the solvent was evaporated. The white solid was triturated with ether to give 6-methyl-5-[4-(piperidin-4-yloxy)-phenyl]-2H-pyridazin-3-one HCl (6.2 g, 92%): Mp 225-7° C.; MS m/z 286 (M+H).

Example 103

A solution of example 102 (5.4 g, 18.9 mmol), sodium cyanoborohydride (2.4 g, 38 mmol) and cyclobutanone (6.6 g, 95 mmol) in 40.0 mL of DMF, 80.0 mL of MeOH and 5.0 mL of acetic acid was stirred at 60° C. for 1 h. The reaction was cooled to rt, quenched with ice-water and the solvent evaporated. The residue was diluted with 100 mL of CH₂Cl₂, washed with saturated NaHCO₃ solution (3×30 mL), water (2×20 mL), NaCl solution (30 mL) and dried over Na₂SO₄. The crude product was purified by Combiflash chromatography (CH₂Cl₂ to 10% MeOH in CH₂Cl₂ with 0.5% of iPrNH₂) to give the free base of the product. The product was then dissolved in MeOH and filtered. Then 30 mL of 1N HCl was added and the solution evaporated. The hydrochloride salt was crystallized from MeOH and Et₂O to give example 103HCl (6.03 g, 90%): Mp 296-7° C.; MS m/z 340 (M+H).

Example 104 Step 1

5-(4-methoxyphenyl)-6-methyl-2H-pyridazin-3-one was prepared from 1-(4-methoxy-phenyl)propan-2-one and glyoxalic acid and hydrazine hydrate using the procedure described in Example 86 Step 1; Mp 255-256° C.; MS m/z 203 (M+H).

Step 2

5-(4-Methoxy-phenyl)-6-methyl-2-pyridin-2-yl-2H-pyridazin-3-one was prepared from 5-(4-methoxy-phenyl)-6-methyl-2H-pyridazin-3-one and 2-bromopyridine in the presence of copper iodide using the procedure described in Example 98 Step 2; Mp 156-7° C.; MS m/z 294 (M+H).

Step 3

5-(4-Hydroxy-phenyl)-6-methyl-2-pyridin-2-yl-2H-pyridazin-3-one was prepared from 5-(4-Methoxy-phenyl)-6-methyl-2-pyridin-2-yl-2H-pyridazin-3-one and BBr₃ in CH₂Cl₂ using the procedure described in Example 91 Step 3; Mp 252-4° C.; MS m/z 280 (M+H).

Step 4

A mixture of 5-(4-hydroxyphenyl)-6-methyl-2-pyridin-2-yl-2H-pyridazin-3-one (97.7 g, 28 mmol), t-butyl 4-methanesulfonyloxypiperidine-1-carboxylic acid ester (15 g, 55 mmol) and cesium carbonate (18 g, 55 mmol) in 75 mL of DMF was stirred at 100° C. overnight. The reaction mixture was cooled to rt, filtered through celite, and concentrated. The crude product was diluted with 100 mL of CH₂Cl₂, washed with 2N NaCO₃, water, NaCl solution, then dried over Na₂SO₄, and concentrated. The product was purified by flash chromatography (5% MeOH in CH₂Cl₂) and triturated with EtOAc and hexane to give 4-[4-(3-methyl-6-oxo-1-pyridin-2-yl-1,6-dihydropyridazin-4-yl)-phenoxy]-piperidine-1-carboxylic acid tert-butyl ester (6.7 g, 72%): MS m/z 463 (M+H).

Example 104

This compound was prepared using the product from step 4 and the procedures described in Example 103 Step 3 and Step 4; HCL salt mp 285-6° C.; MZ m/z 417 (M+H).

Example 105 Step 1

A mixture of 2-(4-hydroxyphenyl)ethanol (4.15 g, 30 mmol), 4-methanesulfonyloxy-piperidine-1-carboxylic acid t-butyl ester (10.51 g, 37.6 mmol) and cesium carbonate (19.6 g, 60 mmol) in 100 mL of DMF was stirred at 100° C. overnight. The reaction mixture was cooled to rt, filtered through celite and concentrated. The crude product was diluted with 100 mL of CH₂Cl₂, washed with 2N Na₂CO₃, water, NaCl solution, dried over Na₂SO₄, and concentrated. The product was purified by flash chromatography (60% EtOAc in hexanes) to give 4-[4-(2-hydroxy-ethyl)-phenoxy]-piperidine-1-carboxylic ester (8.2 g, 59%): MS m/z 222 (M−Boc+H).

Step 2

A solution of 4-[4-(2-hydroxyethyl)-phenoxy]piperidine-1-carboxylic acid tert-butyl ester (8.10 g, 25.2 mmol) in 90 mL of CH₂Cl₂ was cooled to 0° C. as Dess-Martin periodinane (11.2 g, 26.5 mmol) was added in portions. After stirred at rt overnight, the reaction was diluted with 100 mL of CH₂Cl₂, and washed with saturated NaHCO₃ (5×100 mL), water, and dried over Na₂SO₄. Flash chromatography with 60% Et₂O in hexane gave 2.83 g (35%) of 4-[4-(2-oxo-ethyl)-phenoxy]-piperidine-1-carboxylic acid tert-butyl ester: MS m/z 220 (M−Boc+H).

Step 3

4-[4-(2-hydro-5-oxo-2,5-dihydro-furan-3-yl)-phenoxy]-piperidine-1-carboxylic acid tert-butyl ester was prepared from 4-[4-(2-oxo-ethyl)-phenoxy]-piperidine-1-carboxylic acid tert-butyl ester and glyoxalic acid hydrate using procedure described in Example 94 Step 3; MS m/z 275 (M−Boc+H).

Step 4

A solution of the product from step 3 (1.0 g, 2.7 mmol) and hydrazine hydrate (0.27 g, 5.3 mmol) in 12 mL of MeOH was stirred at 80° C. overnight. After being cooled to rt, the solvent was reduced and the solid was filtered and washed with cold EtOH to give 0.63 g (57%) of 4-[4-(6-oxo-1,6-dihydro-pyridazin-4-yl)-phenoxy]piperidine-1-carboxylic acid tert-butyl ester: Mp 222-3° C.; MS m/z 372 (M+H).

Example 105

This compound was prepared using the procedure for example 102; Mp ° C.; MS m/z 272 (M+H).

Example 106

This compound was prepared as the HCl salt using the procedure for example 103; Mp 296-8° C.; MS m/z 326 (M+H).

Example 107

This compound was prepared as the HCl salt using the procedure for example 104; Mp 277-9° C.; MS m/z 422 (M+H).

Example 108

This compound was prepared as the HCl salt using the procedure for example 98; Mp 212-3° C.; MS m/z 410 (M+H).

Example 109

Example 109 was prepared using the same procedure as Example 94 except using S-2-methylpyrrolidine HCl; Mp 218-220° C.; MS m/z 391 (M+H).

Example 110 Step 1

A solution of the intermediate from Example 102 step 1 (1.0 g, 3.0 mmol) in THF (10 mL) at −78° C. under N₂ was added KHMDS (0.5 M in toluene, 9.0 mL) dropwise. After 30 min at −78° C., ethyl bromoacetate (0.75 g, 4.5 mmol) was added drop wise. After 1 hr at −78° C., the reaction was quenched with 1 N HCl (4.0 mL), diluted with 20 mL of EtOAc and the layers separated. The EtOAc layer was washed with 5% NaHCO₃, NaCl solution, then dried over Na₂SO₄ and concentrated. To the crude solid in 10 mL of EtOH was added hydrazine hydrate (0.22 g, 0.45 mmol) and the reaction then stirred at 85° C. for 2 h. The mixture was cooled to rt, the solvent was reduced and the solid was filtered and washed with cold EtOH to give 0.65 g (56%) of 4-[4-(3-methyl-6-oxo-1,4,5,6-tetrahydro-pyridazin-4-yl)-phenoxyl]-piperidine-1-carboxylic acid tert-butyl ester: Mp 165-7° C.; MS m/z 288 (M−Boc+H).

Example 110 was prepared from the product of step 1 using procedures described in Example 102 and Example 103; Mp 178-9° C.; MS m/z 342 (M+H).

Example 111 Step 1

A suspension of 4-hydroxybenzoic acid ethyl ester (5.0 g, 30 mmol), 1-bromo-3-chloropropane (7.1 g, 45 mmol) and potassium carbonate (14 g, 100 mmol) in 50 mL of acetone using the procedure described in Example 88 Step 1 gave the product as a clear oil.

Step 2

A mixture of the product from step 1 (6.5 g, 27 mmol), R-2-methylpyrrolidine benzene sulfonic acid (16 g, 67 mmol), potassium carbonate (11 g, 80 mmol) and sodium iodide (50 mg, 0.3 mmol) in 100 mL of acetonitrile was stirred at 80° C. overnight. The reaction mixture was filtered through celite, washed with CH₂Cl₂, combined and concentrated. The residue was dissolved in CH₂Cl₂, washed with saturated NaHCO₃, water, saturated NaCl, then dried over Na₂SO₄ to give 7.5 g (96%) of 4-[3-R-2-methylpyrrolidin-1-yl-propoxy]benzoic acid ethyl ester; MS m/z 292 (M+H).

Step 3

A solution of the product from step 2 (4.0 g, 14 mmol) and 2-methylpyridine (2.6 g, 27 mmol) in 60 mL of THF was cooled to 0° C., then LiHMDS (1.0 M, 27 mmol) was added dropwise. After addition, the reaction was stirred at 45° C. overnight. The reaction was quenched with ice-water, extracted with CH₂Cl₂ (3×50 mL), combined, washed with saturated NaHCO₃, water, then dried over Na₂SO₄. Flash chromatography using 10% MeOH in CH₂Cl₂ gave the product (3.7 g, 78%); Mp 40-42° C.; MS m/z 339 (M+H).

Step 4

A mixture of sodium hydride (0.092 g, 3.8 mmoL) in 10 mL of DMSO was stirred under N₂ as the product from step 3 (1.0 g, 3.8 mmol) in 5.0 mL of DMSO was added dropwise. After the reaction was stirred for 30 min, a solution of ethyl bromoacetate (0.64 g, 8.83 mmol) in 6.0 mL of toluene was added dropwise, and the reaction was stirred at rt for 1 h. The reaction was then quenched with NH₄Cl solution and the solvent was evaporated. The residue was extracted with CH₂Cl₂ (3×20 mL), combined, washed with saturated NaHCO₃, saturated NaCl then dried over Na₂SO₄. The crude product was purified by flash chromatography using 10% MeOH in CH₂Cl₂ to give the product (0.65 g, 52%).

A solution of the ester intermediate (4-{4-[3-R-2-methyl-pyrrolidin-1-yl)-phenyl}-4-oxo-3-pyridin-2-yl-butyric acid ethyl ester) (9.2 g, 22 mmol) and hydrazine hydrate (2.2 g, 43 mmol) in 150 mL of EtOH was stirred at reflux overnight. Flash chromatography using 15% MeOH in CH₂Cl₂ with 0.5% of iPrNH₂ followed by treatment of the product with 1N HCl in EtOH gave hydrochloride of 6-{4-[3-R-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-5-pyridin-2-yl-4,5-dihydro-2H-pyridazin-3-one (6.1 g, 71%); Mp 133° C. (dec.); MS m/z 393 (M+H).

Example 112

A mixture of example 111 (0.39 g, 1.0 mmol) in 4.0 mL of water was added sodium 3-nitrobenzenesulfonate (0.18 g, 0.78 mmol) and NaOH (0.12 g, 3.0 mmol). The reaction was heated to 100° C. as 2.5 mL of EtOH was added to make the reaction homogeneous. After 2 h at 100° C., the reaction was cooled to rt. 2N HCl was added to adjust pH to ˜6, then the reaction was extracted with CH₂Cl₂ (3×20 mL), which was washed with saturated NaHCO₃, saturated NaCl, and then dried over Na₂SO₄. The product was purified by preparative TLC using 10% MeOH in CH₂Cl₂ and 0.5% of iPrNH₂ to give the product. The hydrochloride salt was prepared by treating the free base with 1N HCl in EtOH (0.14 g, 35%); Mp 234° C. (dec.); MS m/z 391 (M+H).

Example 113 Step 1

4-(4-Ethoxycarbonylphenoxy)piperidine-1-carboxylic acid tert-butyl ester was prepared from 4-hydroxybenzoic acid ethyl ester and 4-hydroxypiperidine-1-carboxylic acid tert-butyl ester using the procedure described in Example 103 step 1; Mp 76-78° C.; MS m/z 350 (M+H).

Step 2

A solution of 4-(4-ethoxycarbonylphenoxy)piperidine-1-carboxylic acid tert-butyl ester (3.5 g, 10 mmol) and 2-methylpyridine (1.9 g, 2.0 mmol) in 50 mL of THF was stirred at 0° C. as LiHMDS (1.0M, 22 mL) was added dropwise. The reaction was stirred at 45° C. overnight, then quenched with ice-water and the solvent evaporated. The residue was extracted with CH₂Cl₂ (3×30 mL), and the combined CH₂Cl₂ layers were washed with saturated NaHCO₃, saturated NaCl solution, dried over Na₂SO₄, and concentrated to give the product; Mp 138-140° C.; MS m/z 397 (M+H).

Step 3

A mixture of sodium hydride (0.21 g, 8.8 mmoL) in 10 mL of DMSO was stirred under N₂ as 4-[4-(2-pyridine-2-yl-acetyl)-phenoxy]-piperidine-1-carboxylic acid tert-butyl ester (3.50 g, 8.83 mmol) in 15 mL of DMSO was added dropwise. After 30 min, a solution of ethyl bromoacetate (1.47 g, 8.83 mmol) in 8.0 mL of toluene was added dropwise. The reaction was stirred at rt for 2 h and then quenched with saturated NH₄Cl solution, and the solvent was evaporated. The residue was extracted with CH₂Cl₂ (3×20 mL), combined, washed with saturated NaHCO₃, saturated NaCl solution and dried over Na₂SO₄. The crude product was purified by Combiflash chromatography (CH₂Cl₂ to 1% MeOH in CH₂Cl₂) to give the product (4.0 g, 94%): Mp 118-120° C.; MS m/z 483 (M+H).

Step 4

A solution of the product from step 3 (4.0 g, 8.3 mmol) and hydrazine hydrate (0.83 g, 16 mmol) in 30 mL of EtOH was stirred at 90° C. overnight. The yellow suspension was reduced to ˜15 mL of EtOH. The solid was collected and washed with cold EtOH to give the product (2.05 g, 55%): Mp 213-214° C.; MS m/z 395 (M−tBu+H).

Example 113

This compound was prepared from the product of step 4 using procedures described in Example 102 Step 3 MS m/z 351 (M+H).

Example 114

This compound was prepared using the procedure for Example 103; Mp 199° C. (dec); MS m/z 405 (M+H).

Example 115

Step 1.

A mixture of the product from Example 113 step 4 (0.3 g, 0.67 mmol) and cesium carbonate (0.65 g, 2 mmol) in 4.0 mL of DMSO was heated under air at 150° C. for 0.5 h. The reaction was cooled to rt, filtered, washed with CH₂Cl₂ (3×15 mL) and combined. The CH₂Cl₂ solution was washed with saturated NaHCO₃, water and dried over Na₂SO₄. The crude product was crystallized from MeOH and ether to give the Boc product; Mp 210-2° C.; MS m/z 449 (M+H).

6-[4-(1-Cyclobutyl-piperidin-4-yloxy)-phenyl]-5-pyridin-2-yl-2H-pyridazin-3-one was prepared from the product in step 1 using procedures described in Example 102 Step 3 and Example 103; Mp 203° C. (dec.); MS m/z 403 (M+H).

Example 116

Step 1.

A solution of 4-(4-methoxyphenyl)-2-methyl-4-oxobutyric acid (10 g, 45 mmol) and 150 mL of 48% HBr in 20 mL of AcOH was heated to 100° C. for 48 h. The solvent was evaporated and EtOH (3×30 mL) was added and evaporated to give 4-(4-methoxyphenyl)-2-methyl-4-oxobutyric acid ethyl ester (9.96 g, 93%); MS m/z 259 (M+23). Step 2.

4-[4-(3-Ethoxycarbonyl-butyryl)-phenoxy]piperidine-1-carboxylic acid tert-butyl ester was prepared using procedure described in Example 102 step 1; MS m/z 442 (M+23).

The final product 6-[4-(1-cyclobutylpiperidin-4-yloxy)phenyl]-4-methyl-4,5-dihydro-2H-pyridazin-3-one HCl was prepared from 4-[4-(3-ethoxycarbonyl-butyryl)phenoxy]-piperidine-1-carboxylic acid tert-butyl ester using procedures described in Example 102 Step 3 and Example 103; Mp 257-9° C.; MS m/z 342 (M+H).

Example 117

Step 1.

4,5-Dichloropyridazin-6-one (10 g, 60.6 mmol) and 57 wt. % hydroiodic acid in water (80 mL, 1.0 mmol) was heated to 150° C. for 24 h. The reaction was cooled to rt, the solid was washed with sodium thiosulfate. The crude product was triturated with CH₂Cl₂:MeOH (1:1) and filtered to give 5-iodo-2H-pyridazin-3-one (4.64 g, 35%).

A mixture of 5-iodo-2H-pyridazin-3-one (4.64 g, 21 mmol) and 30% formaldehyde in water was heated to reflux for overnight. The reaction was cooled to rt, and the resulting solid was filtered to give 2-hydromethyl-5-iodo-2H-pyridazin-3-one (5.2 g, 99%).

A mixture of 2-hydromethyl-5-iodo-2H-pyridazin-3-one (1.15 g, 4.56 mmol) and 2-chloro-5-pyridineboronic acid (0.72 g, 4.57 mmol), tetrakis(triphenylphosphine)-palladium(0) (0.53 g, 0.46 mmol) and potassium carbonate (1.89 g, 13.7 mmol) in 30 mL of 1,2-dimethoxyethane and 10 mL of water was degassed for 3 min, then heated to 85° C. overnight. The reaction was cooled to rt, filtered and washed with ethyl acetate. The organic layer was separated, concentrated, and triturated with ether to give 5-(6-chloropyridin-3-yl)-2H-pyridazin-3-one (0.4 g, 36%); MS m/z 208 (M+H). Step 2.

A solution of 5-(6-chloropyridin-3-yl)-2H-pyridazin-3-one (73 mg, 0.35 mmol) and 4-hydroxypiperidine-1-carboxylic acid tert-butyl ester (140 mg, 0.70 mmol) in 2.7 mL of DMSO was stirred as KOtBu in 2-methyl-2-propanol (1.0 M, 14.4 mL) was added dropwise. After stirring at 110° C. overnight, the reaction was cooled to rt, and 2 mL of water was added. The mixture was extracted with CH₂Cl₂ (3×10 mL), the extracts combined and dried over Na₂SO₄. The crude product was purified by prep. TLC with 10% MeOH in CH₂Cl₂ to give 71 mg (54%) of 4-[5-(6-oxo-1,6-dihydropyridazin-4-yl)-pyridin-2-yloxy]piperidine-1-carboxylic acid tert-butyl ester; MS m/z 273 (M−Boc−H).

Example 117 hydrochloride was prepared from the product in step 2 using procedures described in Example 102 Step 3 and Example 103; Mp 232-4° C.; MS m/z 327 (M+H).

Example 118

Step 1.

A mixture of 6-(4-methoxyphenyl)-2H-pyridazin-3-one (170 mg, 0.83 mmol), 1-bromo-2-fluoroethane (122.5 mg, 1.5 eq.), NaI (20 mg) and cesium carbonate (553 mg, 2.0 eq.) in 5 mL of CH₃CN was heated to 70° C. overnight. The reaction mixture was filtered and concentrated. The product was purified by ISCO combiflash with 50% hexane and EtOAc to give 2-(2-fluoroethyl)-6-(4-methoxyphenyl)-2H-pyridazin-3-one (200 mg, 97%); MS m/z 349 (M+H).

Example 118 hydrochloride was prepared from the product in step 1 using procedures described in Example 1 and example 86; mp 135-6° C.; MS m/z 360 (M+H).

The following compounds were prepared as HCl salts unless noted using methods for example 1, example 11 or example 91. Example Structure Mp (° C.) MS m/z 119

252-3  332 (M + H) 120

240-2  332 (M + H) 121

201-3  330 (M + H) 122

207-8  328 (M + H) 123

227-9  328 (M + H) 124

120-2  398 (M + H) 125

172-4  368 (M + H) 126

189-190 368 (M + H) 127

193-4  384 (M + H) 128

251-3  356 (M + H) 129

<200 dec. base 339 (M + H) 130

207-9 base 339 (M + H) 131

95-98 base 358 (M + H) 132

163-7 base 328 (M + H) 133

134 dec. base 354 (M + H) 134

186 dec. base 314 (M + H) 135

175 dec. base 344 (M + H) 136

148 dec. base 344 (M + H) 137

114 dec. base 328 (M + H) 138

>200 tartrate 392 (M + H) 168

76-78 base 398 (M + H) 169

87-89 base 398 (M + H) 170

121-123 base 396 (M + H) 171

128-130 base 396 (M + H)

Example 139

Step 1

To ethyl-4-(4-chloro-3-pyridyl)-4-oxobutyrate (5 g, 20.7 mmol) in ethanol (30 mL) was added hydrazine monohydrate (964 μM, 31 mmol). After overnight stirring at 80° C., the reaction was concentrated to half of the volume and the resulting yellow solid was filtered off and dried to give 3.4 g of product (77%); MS m/z 210 (M+H). Step 2

To 6-(6-chloro-pyridin-3-yl)-4,5-dihydro-2H-pyridazin-3-one (3 g, 14.4 mmol) in DMSO (40 mL) was added 4-hydroxy-boc-piperidine (2.9 g, 14.4 mmol), followed by 1M KtOBu (19 mL). After overnight stirring at 100° C. open to air, the reaction was cooled, diluted with dichloromethane and washed several times with water/brine, dried over sodium sulfate, and concentrated under vacuum to obtain 4.9 g crude product (92%); MS m/z 373 (M+H). Step 3

To 4-[5-(6-oxo-1,6-dihydro-pyridazin-3-yl)-pyridin-2-yloxy]-piperidine-1-carboxylic acid tert-butyl ester (4.9 g, 13.2 mmol) in dioxane (30 mL) was added 4N HCl/dioxane (6.6 mL, 3 mmol). After overnight stirring at 60° C., the reaction was concentrated under vacuum to obtain 4 g of product as the HCl salt (quantitative); MS m/z 327 (M+H). Step 4 Example 139

6-[6-(piperidin-4-yloxy)-pyridin-3-yl]-2H-pyridazin-3-one hydrochloride (407 mg, 1.18 mmol) in a mixture of DMF (5 mL), methanol (15 mL), and acetic acid (250 μL) was added cyclopentanone (314 μL, 3.54 mmol), followed by sodium cyanoborohydride (371 mg, 5.9 mmol). After stirring at 60° C. for 2 h, the reaction was concentrated, partitioned between dichloromethane/1N sodium carbonate, washed with water/brine, dried over sodium sulfate, and concentrated. The product was purified using prep TLC plates (9:1 dichloromethane:methanol) (25%); Mp 233-237° C.; MS m/z 341 (M+H).

Example 140

To the product from step 1 Example 139 (115 mg, 0.55 mmol) in DMSO (5 mL) was added (1-isopropanol-piperidin-4-yl)methanol (130 mg, 0.83 mmol) and 1M KtOBu (1.1 mL, 1.1 mmol). After overnight stirring at 100° C., the reaction was diluted with dichloromethane, washed with water/brine several times, dried over sodium sulfate, and concentrated. The product was purified by prep TLC plates to obtain 64 mg (35%); Mp 188-191° C.; MS m/z 329 (M+H).

The following examples were prepared using methods for example 139 Example Structure Mp (° C.) MS m/z 141

217-219 327 (M + H) 142

195-197 315 (M + H)

Example 143

Step 1

To 6-(6-chloropyridin-3-yl)-4,5-dihydro-2H-pyridazin-3-one (1.03 g, 4.93 mmol) in DMSO (40 mL) was added iodomethane (460 μL, 7.4 mmol) and cesium carbonate (3.2 g, 9.86 mmol). After overnight stirring at 100° C. open to air, the reaction was cooled, diluted with dichloromethane, washed several times with water/brine, dried over sodium sulfate, and concentrated under vacuum to obtain 835 mg product (79%); MS m/z 222 (M+H). Step 2

To 6-(6-chloro-pyridin-3-yl)-2-methyl-2H-pyridazin-3-one (3 g, 13.6 mmol) in toluene (50 mL) was added 4-hydroxy-boc-piperidine (2.7 g, 13.6 mmol) and 1M KtOBu (16.3 mL, 16.3 mmol). After overnight stirring at 80° C., the reaction was concentrated, partitioned between dichloromethane/1N sodium carbonate, washed with water/brine, dried over sodium sulfate, and concentrated. The product was purified by column chromatography (99:1 dichloromethane:methanol) to obtain 2.7 g (51%); MS m/z 387 (M+H).

Example 143-145 were synthesized using Example 139 step 3 and step 4 (deprotection and reductive amination) and Example 143 Step 1 alkylation. Example Structure Mp (° C.) MS m/z 143

154-157 355 (M + H) 144

175-180 341 (M + H) 145

113-115 369 (M + H)

Example 146

Step 1

To 3-chloro-1-propanol (1.00 g, 10.6 mmol) in 2-butanone (10.00 mL) was added R-2-methyl-pyrrolidine hydrochloride (1.93 g, 15.9 mmol), potassium carbonate (3.65 g, 26.44 mmol), and potassium iodide (1.76 g, 10.6 mmol). After overnight stirring at 100° C., the reaction was filtered, partitioned between dichloromethane/water, washed with brine, dried over sodium sulfate, and concentrated under vacuum to obtain 495 mg product (33%); MS m/z 144 (M+H).

Step 2

To 6-(6-chloro-pyridin-3-yl)-4,5-dihydro-2H-pyridazin-3-one (599 mg, 2.86 mmol) (step 1 example 139) in DMSO (15 mL) was added 3-(R)-2-methylpyrrolidin-1-yl)-propan-1-ol (495 mg, 3.46 mmol) and 1M KOtBu (5.72 mL). After overnight stirring at 110° C. open to air, the reaction mixture was cooled and poured into water, extracted with dichloromethane, washed with brine, dried over sodium sulfate, and concentrated. The product was purified using prep TLC plates (9:1 dichloromethane:methanol) to obtain 68 mg; Mp 178-181° C.; MS m/z 315 (M+H).

Example 147

This compound was prepared using the intermediate from step 1 example 139 and 3-piperidin-1-yl-propanol using methods described for example 146; Mp 155-158° C. MS m/z 315 (M+H).

Example 148

Step 1

To 4-hydroxy-boc-piperidine (1.55 g, 7.71 mmol) in DMSO (12 mL) was added 1M KtOBu (8.36 mL), followed by 1-(6-chloropyridin-3-yl)ethanone (1.00 g, 6.43 mmol). After overnight stirring at 100° C., the reaction was poured into water, extracted with dichloromethane, washed with brine, dried over sodium sulfate, and concentrated. The product was purified using a Single Step column (7:3 hexanes:ethyl acetate) to obtain 0.5 g (25%); MS m/z 321 (M+H). Step 2

To 4-(5-acetyl-pyridin-2-yloxy)-piperidine-1-carboxylic acid tert-butyl ester (1.36 g, 4.24 mmol) in THF (15 mL) at −78° C. was added 0.5M potassium bis(trimethylsilyl)amide in toluene (17 mL) and stirred for 30 min before adding 2-bromo-2-methyl-propionic acid ethyl ester (1.25 mL, 8.49 mmol) at −78° C. After overnight stirring at r.t., the reaction was quenched with 1N HCl, extracted with dichloromethane, washed with water/brine, dried over sodium sulfate, and concentrated. The product was purified using a Single Step column (7:3 hexanes:ethyl acetate) to obtain 0.458 g (25%); MS m/z 435 (M+H). Step 3

To 4-[5-(3-ethoxycarbonyl-3-methyl-butyryl-pyridin-2-yloxy]piperidine-1-carboxylic acid tert-butyl ester (0.318 g, 0.732 mmol) in 2-propanol (8 mL) was added hydrazine monohydrate (2 mL). After overnight stirring at 120° C., the reaction was partitioned between dichloromethane/water, washed with brine, dried over sodium sulfate, and concentrated under vacuum to obtain 0.235 mg product (80%); MS m/z 403 (M+H). Step 4

To 4-[5-(5,5-dimethyl-6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-pyridin-2-yloxy]-piperidine-1-carboxylic acid tert-butyl ester (0.340 g, 0.845 mmol) in dichloromethane (5 mL) was added TFA (0.700 mL). After stirring at r.t. for 3 h, the reaction was concentrated under vacuum to obtain product as the TFA salt (quantitative); MS m/z 303 (M+H).

Example 148 was prepared using the product from step 4 and cyclobutanone using the procedure for example 139 step 4; m 240-245; MS m/z 357 (M+H).

Example 149

Step 1

To example 141 (0.509 g, 1.56 mmol) in DMF (8 mL) was added potassium carbonate (0.431 g, 3.12 mmol), 2-bromopyridine (0.223 mL, 2.34 mmol), and copper(I)iodide (0.0297 g, 0.156 mmol). After stirring at 150° C. for 4 h, the reaction was cooled, diluted with dichloromethane, washed with water/brine, dried over sodium sulfate, and concentrated. The product was purified using Prep. TLC plates (9:1 dichloromethane:methanol), dissolved in methanol with 1N HCl/ether (˜2 mL) added, concentrated, and recrystallized from methanol/ether as the HCl salt to give 0.223 mg (33%); Mp 261-262° C.; MS m/z 404 (M+H).

Example 150 Step 1

To 4-(4-methoxy-phenyl)-4-oxo-butyric acid ethyl ester (4.5 g, 19.0 mmol) was added 48% HBr (50 mL). After overnight stirring at 120° C., the reaction was concentrated and ethanol was added several times and concentrated to obtain 4.18 g product (94%); MS m/z 223 (M+H).

Step 2

To triphenylphosphine (2.48 g, 9.48 mmol) in THF (25 mL) was added 40% w/w DEAD in toluene (4.00 mL, 8.95 mmol) and the reaction was cooled at 0° C. before adding a mixture of 4-hydroxy-boc-piperidine (1.44, 7.14 mmol) and 4-(4-hydroxyphenyl)-oxo-butyric acid ethyl ester (1.3 g, 5.8 mmol) in THF (25 mL). After overnight stirring at r.t., the reaction was concentrated and the product was purified using a Single Step column (7:3 hexanes:ethyl acetate) to obtain 2.17 g (91%); MS m/z 406 (M+H).

Step 3

To 4-[4-(3-ethoxycarbonyl-propionyl)-phenoxy]-piperidine-1-carboxylic acid tert-butyl ester (2.68 g, 6.61 mmol) in 2-propanol (25 mL) was added hydrazine monohydrate (0.662 g, 13.2 mmol). After overnight stirring at 120° C., the reaction was concentrated down, partitioned between dichloromethane/water, washed with brine, dried over sodium sulfate, and concentrated under vacuum to obtain 2.18 g product (88%); MS m/z 374 (M+H).

Example 150

6-[4-(piperidin-4-yloxy)-phenyl]-4,5-dihydro-2H-pyridazin-3-one trifluoroacetate was prepared using conditions for Example 148 step 4.

To 6-[4-(piperidin-4-yloxy)-phenyl]-4,5-dihydro-2H-pyridazin-3-one trifluoroacetate (6.50 g, 23.8 mmol) in DMF (10 mL), methanol (50 mL), and acetic acid (2 mL) was added cyclobutanone (5.33 mL, 71.3 mmol) and sodium cyanoborohydride (7.47 g, 119 mmol) in portions. After stirring at 60° C. for 4 h, the reaction was concentrated, diluted with dichloromethane, washed with water/brine, dried over sodium sulfate, and concentrated. The product was purified using a Single Step column (9:1 dichloromethane:methanol) and recrystallized from chloroform/ether to obtain 2.2 g (40%); Mp=196-198° C.; MS m/z 328 (M+H).

Examples 151-153 were synthesized using procedures for Example 150. Example Structure Mp (° C.) MS m/z 150

196-198 328 (M + H) 151

195-197 346 (M + H) 152

157-158 356 (M + H) 153

147-149 374 (M + H)

Example 154

To example 150 (130 mg, 3.81 mmol) in DMSO (3 mL) was added cesium carbonate (248 mg, 7.61 mmol). After stirring at 130° C. for 2 h open to air, the reaction was filtered, diluted with dichloromethane, washed with water/brine, dried over sodium sulfate, and concentrated. The product was purified using Prep. TLC plates (9:1 dichloromethane:methanol) to obtain 48 mg (37%); Mp 211-213° C.; MS m/z 340 (M+H).

Examples 155-156 were synthesized using methods for example 154. Example Structure Mp (° C.) MS m/z 154

211-213 340 (M + H) 155

215-220 326 (M + H) 156

236-238 344 (M + H)

Example 157

To example 150 (1.50 g, 4.58 mmol) in DMSO (20 mL) was added potassium carbonate (1.90 g, 13.7 mmol), 2-bromopyridine (0.872 mL, 9.16 mmol), and copper(I)iodide (0.0872 g, 0.458 mmol). After overnight stirring at 150° C. open to air, the reaction was filtered, diluted with dichloromethane, washed with water/brine, dried over sodium sulfate, and concentrated. The product was purified using a single step column (9:1 dichloromethane:methanol), dissolved in methanol and 1N HCl/ether (˜2 mL) was added, concentrated, and the product was recrystallized from methanol/ether as the HCl salt to obtain 53 mg; Mp >240° C. (dec.); MS m/z 403 (M+H).

Example 158 Step 1

To 4-[4-(3-carboxy-propionyl)-phenoxy]-piperidine-1-carboxylic acid tert-butyl ester (1.34 g, 3.55 mmol) in acetic acid (20 mL) was added 2-hydrazinopyridine (1.94 g, 17.8 mmol). After overnight stirring at 120° C., the reaction was concentrated under vacuum and the product was purified using a Single Step column (9:1 dichloromethane:methanol) to obtain 295 mg; MS m/z 351 (M+H).

Example 158 was synthesized from the product in step 1 by reductive amination described for example 150 and forming the HCl salt; Mp 263-265 MS m/z 405 (M+H).

Examples 159-167 were prepared using methods described for examples 150-157. Example Structure Mp (° C.) MS m/z 159

184-6  342 (M + H) 160

200-2  340 (M + H) 161

— 311 (M + H) 162

— 328 (M + H) 163

120-123 382 (M + H) 164

100-104 396 (M + H) 165

168-170 328 (M + H) 166

146-147 410 (M + H) 167

225-227 424 (M + H)

Example 172

Step 1

To 3-oxabicyclo[3.2.0]heptane-2,4-dione (8.00 g, 63.4 mmol) in THF (90.00 mL) at −78° C. was added 0.500 M of p-anisyl magnesium bromide (133 mL, 66.6 mmol) in THF (90 mL) dropwise. After stirring at −78° C. for 2 h, the reaction was quenched with ice cold water and concentrated. The aqueous layer was acidified and the white solid was filtered off and dried to obtain 9.72 g product (65%); MS m/z 233 (M−H). Step 2

To 2-(4-methoxy-benzoyl)-cyclobutanecarboxylic acid (10.28 g, 43.88 mmol) was added 48% hydrogen bromide in water (50 mL) and acetic acid (50 mL). After overnight stirring at 120° C., the reaction was concentrated, stirred with ethanol a few times, and the product was purified using a Single Step column (7:3 hexanes:ethyl acetate) to obtain 7.70 g (71%); MS m/z 247 (M−H)

Example 172 HCl was synthesized from the product in step 2 using procedures described for example 150; Mp 285-288° C.; MS m/z 354 (M+H)

Example 173

Step 1

To 2-(4-hydroxy-benzoyl)-cyclobutanecarboxylic acid ethyl ester (0.55 g, 2.20 mmol) in acetone (10 mL) was added potassium carbonate (0.91 g, 6.58 mmol) and 1-bromo-chloropropane (0.26 mL, 2.63 mmol). After overnight stirring at 70° C., the reaction was filtered, partitioned between dichloromethane/water, washed with brine, dried over sodium sulfate, and concentrated. The product was purified using a Single Step column (9:1 hexanes:ethyl acetate) to obtain 0.30 g (42%); MS m/z 325 (M+H). Step 2

To 2-[4-(3-chloro-propoxy)-benzoyl]-cyclobutanecarboxylic acid ethyl ester (0.300 g, 0.924 mmol) in acetonitrile (15 mL) was added (R)-2-methyl-pyrrolidine, benzenesulfonic acid salt (0.337 g, 1.38 mmol), potassium carbonate (0.383 g, 2.77 mmol), and potassium iodide (0.153 g, 0.924 mmol). After overnight stirring at 80° C., the reaction was filtered, diluted with dichloromethane, washed with water/brine, dried over sodium sulfate, and concentrated. The product was purified using a Single Step column (5% methanol/dichloromethane) to obtain 0.213 g (62%); MS m/z 374 (M+H).

Example 173 was synthesized using methods described for example 1 and example 11.

Example 176

To example 174 (0.500 g, 1.36 mmol) in DMSO (5 mL) was added cesium carbonate (0.887 g, 2.72 mmol). After overnight stirring at 140 oC open to air, the reaction was poured into water, extracted with dichloromethane, washed with water/brine, dried over sodium sulfate, and concentrated. The product was purified using Prep. TLC plates (9:1 dichloromethane:methanol); Mp=210-213° C.; MS m/z 366 (M+H). Example Structure Mp (° C.) MS m/z 172

285-288 354 (M + H) 173

218-220 342 (M + H) 174

dec. >255 368 (M + H) 175

218-219 356 (M + H) 176

210-213 366 (M + H)

Example 177

This compound was prepared using ethyl-4-(4-chloro-3-pyridyl)-4-oxobutyrate and cyclobutyl hydrazine using methods described for examples 139 and 143; Mp 146-49 MS m/z 384 (M+H).

Example 178 Method A

Step 1 4-(4-Hydroxy-phenyl)-4-oxo-butyric acid ethyl ester (3.0 g, 13.5 mmol), 1-bromo-3-chloropropane (4.2 g, 27 mmol) and K₂CO₃ (5.6 g, 41 mmol) in acetonitrile (50 mL) was stirred at reflux for 12 h. The reaction was filtered, concentrated and purified by silica gel chromatography to give 3.2 g (80%). Step 2

The product from step 1 (3.1 g, 10.4 mmol), R-2-methylpyrrolidine HCl (2.5 g, 21 mmol), KI (0.9 g) and K2CO3 (4.1 g, 2.9 mmol) in acetonitrile (75 mL) was stirred at 90° C. for 2 days. The reaction was cooled, filtered and concentrated. The residue was dissolved in Et2O (75 mL) and washed with water and NaCL solution, dried (MgSO4) and concentrated to an oil; MS m/e 348 (M+H). Step 3.

The product from step 2 (3.0 g, 8.6 mmol) and hydrazine hydrate (0.33 g, 10 mmol) in isopropanol (50 mL) was stirred at 95° C. for 24 h. The reaction was cooled to rt, concentrated and the product recrystallized from EtOAc-hexane; Mp 142-45; MS m/z 316 (M+H).

The examples in the following table were synthesized using conditions for example 178 starting with 4-(4-hydroxy-phenyl)-2,2-dimethyl-4-oxo-butyric acid ethyl ester or 4-(3-fluoro-4-hydroxy-phenyl)-4-oxo-butyric acid ethyl ester. Example Structure Mp (° C.) MS m/z 179

140-2 base 344 (M + H) 180

132-3 base 334 (M + H) 181

164-166 base

Example 182

Step 1

(4-Benzyloxy-phenyl)-trimethylsilanyloxy-acetonitrile (3.0 g, 9.63 mmol) in THF (100 mL) under a nitrogen atmosphere was added LDA (7.2 mL of 2 M in THF) at −72° C. After 0.5 h, methyl 3-methylbut-2-enoate (1.23 mL, 10.1 mmol) in 1 THF (15 mL) was added dropwise. The reaction was stirred at 0° C. for 4 h, and then saturated NH₄Cl was added. The THF was removed at reduced pressure; Et2O was added (50 mL) and washed with saturated NH4Cl, water, dried (Na2SO4), and concentrated to give an oil. The oil was dissolved in THF (50 mL) and TBAF (10.1 mL of 1 M THF solution) was added at ° 0° C. dropwise. After stirring 12 h at rt the reaction was concentrated, dissolved in Et2O and washed with water, NaCl solution and dried (MgSO4). The product was purified by silica gel chromatography (10-20% EtOAc/hexanes) to give 1.5 g; Mp 72-73.

Step 2

The product from step 1 (1.25 g, 3.83 mmol) and 10% Pd/C (0.3 g) in MeOH (50 mL) was hydrogenated on a Parr apparatus until TLC indicated completion of the reaction. The mixture was filtered, concentrated to an oil and used directly in the next step; MS m/z 204 (M−OMe).

Step 3

The product from step 2 (1.0 g, 4.2 mmol), 1-bromo-3-chloropropane (1.0 g, 8 mmol) and K₂CO₃ in acetonitrile (20 mL) was heated to reflux for 24 h. The reaction was cooled, filtered, concentrated to an oil and purified by ISCO siliga gel chromatography (10% EtOAc/hexanes) to give 0.7 g.

Step 4

The product from step 3 (0.75 g, 2.4 mmol), R-2-methylpyrrolidine benzene sulfonic acid salt (1.0 g, 5 mmol), K2CO3 (1 g, 7 mmol) and KI (0.1 g) in acetonitrile (25 mL) were heated at 90° C. for 2 days. The reaction was filtered, concentrated, dissolved in Et2O and washed with water, NaCl solution and dried (MgSO₄) to give 0.7 g as an oil; MS m/z 376 (M+H).

Example 182 Step 5

The product from step 4 (0.75 g, 2.1 mmol) and hydrazine hydrate (2.0 mL) in acetonitrile (25 mL) were heated to reflux for 24 h. The reaction was cooled, concentrated and the product recrystallized using Et₂O-hexanes to give 600 mg (71%); Mp 118-121; MS m/z 344 (M+H).

Example 183

Step 1

In a 1 neck round bottom flask equipped with a Dean-Stark trap and condenser, 4-(4-methoxyphenyl)-4-oxo-butyric acid (5.0 g, 20 mmol), 2-hydrazinopyridine (3.9 g, 36 mmol) and p-toluene sulfonic acid (0.3 g) in 100 mL benzene were heated to reflux for 2 h while water was removed. The reaction was cooled to rt, an equal volume of Et₂O was added and the product collected; Mp >300° C. This solid was dissolved in HOAc (50 mL) and heated at 100° C. for 6 h. The reaction was concentrated, dissolved in EtOAc and washed with saturated NaHCO₃ solution, water, NaCl solution and dried (MgSO₄). The solvent was concentrated to a thick oil; MS m/z 282 (M+H).

Step 2

The product from step 1 (1.25 g, 4.4 mmol) in DCM (30 mL) was added BBr₃ (30 mL, 1 M in DCM) dropwise at 0° C. After stirring 4 h at rt, the mixture was cooled to 0-5° C. on an ice-bath while saturated NH₄Cl solution (30 mL) was added dropwise. Additional water was added and the DCM was removed at reduced pressure. The solid was collected and dried to give 1.1 g (93%) of a tan solid; Mp >220° C.; MS m/z 268 (M+H).

Step 3

The product from step 3 (5.0 g, 20 mmol), 1-bromo-3-chloropropane (5.9 g, 37.4 mmol) and K₂CO₃ (7.8 g, 56 mmol) in acetonitrile (50 mL) was heated to reflux for 24 h. The reaction was cooled to rt, filtered and concentrated to a thick oil. The product was dissolved in EtOAc and washed with water, NaCl solution and dried (MgSO₄). The product was purified by ISCO silica gel chromatography (95/5/1 DCM/MeOH/1-propylamine) to give 3.7 g of a dark oil; MS m/z 344 (M+H).

Example 183 Step 4

The product from step 3 (3.7 g, 10.8 mmol), R-2-methylpyrrolidine benzene sulfonic acid salt (5.24 g, 21.5 mmol), K₂CO₃ (4.46 g, 32.3 mmol) and KI (0.9 g) in acetonitrile (50 mL) were heated to reflux for 2 days. The reaction was cooled, filtered and concentrated. The residue was purified by ISCO silica gel chromatography (95/5/1 DCM/MeOH/1-propylamine). The fractions were concentrated and the HCl salt was prepared using 2M HCl/ether and recrystallized from CH₃CN/ether; Mp 203-205° C.; MS m/z 393 (M+H).

Example 184

Step 1

A mixture of 1-(3,5-difluoro-4-methoxyphenyl)ethanone (12 g, 64.5 mmol) and 48% aqueous HBr (32 mL) was stirred at reflux for 30 h. The reaction was cooled to rt and diluted with water and the aqueous layer was extracted twice with methylene chloride. The combined organics were dried (Na₂SO₄), filtered, and concentrated to give 1-(3,5-difluoro-4-hydroxyphenyl)ethanone (10 g, 91%), mp 141-143° C.; MS m/z 171 (M−H). Step 2

A mixture of 1-(3,5-difluoro-4-hydroxyphenyl)ethanone (8.1 g, 47 mmol), 3-bromo-1-chloropropane (14.7 g, 93 mmol) and K₂CO₃ (21.3 g, 154 mmol) in acetone (120 mL) was stirred at reflux for 20 h. The reaction was cooled to rt and concentrated at reduced pressure, then partitioned between water and methylene chloride. The aqueous layer was extracted twice with methylene chloride to obtain 1-[4-(3-chloropropoxy)-3,5-difluorophenyl]ethanone (12.9 g, quantitative yield); MS m/z 249 (M+H). Step 3

A mixture of 1-(4-(3-chloropropoxy)-3,5-difluoro-phenyl]ethanone (11 g, 44.7 mmol) and glyoxalic acid monohydrate (4.2 g, 46.5 mmol) in acetic acid (16 mL) was stirred at 100° C. for 4 h. The acetic acid was evaporated at reduced pressure and diluted with water then cooled to 0° C. and neutralized with ammonium hydroxide to pH 8. To this mixture, hydrazine monohydrate (4.3 mL, 86 mmol) was added and heated at 100° C. for 1 h. The reaction was cooled to rt and the solid was filtered, then dried to give a crude product. The crude product was triturated sequentially with 5% aqueous sodium bicarbonate solution and with a mixture of methylene chloride, methanol, ether and hexane to provide relatively pure product. The product was purified by ISCO (120 g silica gel column) chromatography using 2 to 8% methanol in methylene chloride to furnish 6-[4-(3-chloropropoxy)-3,5-difluorophenyl]-2H-pyridazin-3-one (7.9 g, 59%), MS m/z 301 (M+H). Step 4

A mixture of 6-[4-(3-chloropropoxy)-3,5-difluorophenyl]-2H-pyridazin-3-one (7.9 g, 26.3 mmol), K₂CO₃ (12.7 g 91.9 mmol), NaI (144 mg, 0.96 mmol) and R-methyl-pyrrolidinium benzenesulfonate (13.4 g, 55.3 mmol) in CH₃CN (200 mL) was heated under argon at 80° C. for 35 h. The mixture was filtered over celite and concentrated at reduced pressure and partitioned between saturated aqueous sodium bicarbonate solution and methylene chloride. The aqueous layer was extracted twice with methylene chloride and the combined organics were washed with brine, dried (Na₂SO₄), and concentrated. The crude product was purified by ISCO (120 g silica gel column) chromatography using 2 to 5% methanol in methylene chloride to 10% methanol containing 0.25% ammonium hydroxide in methylene chloride to obtain 6-{3,5-difluoro-4-[3-(R)-2-methylpyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one (4.3 g). The product was precipitated using a mixture of ethanol and acetonitrile to provide a pure product (0.5 g). Mp 169-171° C.; MS m/z 350 (M+H).

Example 185

Example 185 was synthesized using the procedure for example 184; Mp 165-167° C.; MS m/z 472 (M+H).

Example 186

Step 1

A mixture of 1,3-difluoro-2-methoxybenzene (2.5 g, 17.3 mmol) and ethyl succinyl chloride (4.29 g, 26 mmol) in 1,2-dichloroethane (25 mL) was cooled to 0° C. Aluminum chloride (8 g, 60.1 mmol) was added slowly at 0° C. then stirred at rt for 2 h and quenched with ice and aqueous 2N HCl at 0° C. The aqueous layer was extracted twice with methylene chloride and the combined organics were washed with brine, dried (Na₂SO₄), filtered, and concentrated to provide a crude product. The crude product was purified by ISCO (80 g silica gel column) chromatography using 8.5% EtOAc in hexane to furnish 4-(3,5-difluoro-4-methoxyphenyl)-4-oxo-butyric acid ethyl ester (2.9 g, 61%), Step 2

A mixture of 4-(3,5-difluoro-4-methoxy-phenyl)-4-oxo-butyric acid ethyl ester (2.9 g, 10.6 mmol) and 48% aqueous HBr (15 mL) in acetic acid (30 mL) was stirred at reflux for 8 h. The reaction was cooled to rt and treated three times with ethanol and then concentrated at reduced pressure to provide a crude material. The crude material was dissolved in methylene chloride and washed with water, brine, dried (Na₂SO₄), filtered, and concentrated to afford 4-(3,5-difluoro-4-hydroxyphenyl-4-oxo-butyric acid ethyl ester (2.5 g, 92%), MS m/z 257 (M+H). Step 3

A mixture of 4-[4-(3-chloropropoxy))-4-oxo-butyric acid ethyl ester (2.5 g, 9.6 mmol), 3-bromo-1-chloropropane (1.9 mL, 18.5 mmol) and K₂CO₃ (4 g, 28.9 mmol) in acetone (25 mL) was stirred at reflux for 15 h. The reaction was cooled to rt and concentrated at reduced pressure, then partitioned between water and methylene chloride. The aqueous layer was extracted twice with methylene chloride and the combined organics were washed with brine, dried (Na₂SO₄), filtered, and concentrated to obtain a crude product. The crude product was purified by ISCO (80 g silica gel column) chromatography using 10 to 12.5% EtOAc in hexane to provide 4-[4-(3-chloro-propoxy)-3,5-difluorophenyl]-4-oxo-butyric acid ethyl ester (3.1 g, 96%). Step 4

A mixture of 4-[4-(3-chloropropoxy)-3,5-difluorophenyl]-4-oxo-butyric acid ethyl ester (5 g, 14.9 mmol), K₂CO₃ (7.2 g, 52.1 mmol), NaI (220 mg, 1.4 mmol), and Benzenesulfonate; (R)-methylpyrrolidinium (8 g, 33 mmol) in CH₃CN (110 mL) was heated under argon at 80° C. for 36 h. The reaction was concentrated and partitioned between saturated aqueous sodium bicarbonate solution and methylene chloride. The aqueous layer was extracted twice with methylene chloride and the combined organics was washed with brine, dried (Na₂SO₄), filtered, and concentrated to provide a crude material (96% purity). The crude material was purified by ISCO (80 g silica gel column) chromatography using 2% to 9% methanol in methylene chloride to 10% methanol containing 0.1% ammonium hydroxide in methylene chloride. The isolated material was dissolved in methylene chloride and washed with saturated aqueous sodium bicarbonate solution, brine, dried (Na₂SO₄), filtered, and concentrated. The isolated material was crystallized with a mixture of methylene chloride, ether and hexane to obtain 4-{3,5-difluoro-4[3-(R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4-oxo-butyric acid ethyl ester (3.97 g, 70%, 99% purity), MS m/z=384 (M+H). Step 5

A mixture of 4-{3,5-difluoro-4[3-(R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4-oxo-butyric acid ethyl ester (3.97 g, 10.4 mmol) and hydrazine monohydrate (1 mL, 20.7 mmol) in isopropanol (25 mL) was heated at 110° C. for 17 h. Isopropanol was evaporated at reduced pressure and partitioned between saturated aqueous sodium bicarbonate solution and methylene chloride. The aqueous layer was extracted twice with methylene chloride and the combined organics was washed with brine, dried (Na₂SO₄), filtered, and concentrated to provide a crude material. The crude material was purified by ISCO (80 g) chromatography using 2 to 8% methanol in methylene chloride to 110% methanol containing 0.2% ammonium hydroxide in methylene chloride. The isolated material was dissolved in methylene chloride and washed with saturated aqueous sodium bicarbonate solution, brine, dried (Na₂SO₄), filtered, and concentrated. The pure material was crystallized using a mixture of methylene chloride, ether and hexane to obtain 6-{3,5-difluoro-4-[3-(R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one (2 g, 55%, 98% purity), mp 102-104° C., MS m/z 352 (M+H).

Example 187

Step 1

To a solution of triphenylphosphine (5.79 g, 22.1 mmol) in THF (35 mL) was added 40% w/w DEAD in toluene (10 mL, 15 mmol). The mixture was cooled to 0° C. and a mixture of 4-(3,5-difluoro-4-hydroxy-phenyl)-4-oxo-butyric acid ethyl ester (example 186 step 2) (3.8 g, 14.7 mmol) and 4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester (3.6 g, 18 mmol) in THF (35 mL) was added dropwise under argon. After the addition, the cooling bath was removed and stirred at rt overnight. The reaction mixture was concentrated at reduced pressure and purified by ISCO (120 g) chromatography using 15 to 30% EtOAc in hexane to provide 4-[4-(3-ethoxycarbonyl-propionyl)-2,6-difluoro-phenoxy]-piperidine-1-carboxylic acid tert-butyl ester (3.21 g, 49% yield). Step 2

A mixture of 4-[4-(3-ethoxycarbonyl-propionyl)-2,6-difluoro-phenoxy]-piperidine-1-carboxylic acid tert-butyl ester (3.21 g, 7.27 mmol) and hydrazine monohydrate (0.7 mL, 14.1 mmol) in isopropanol (20 mL) was stirred at reflux overnight. Isopropanol was concentrated at reduced pressure and partitioned between saturated aqueous sodium bicarbonate solution and methylene chloride. The aqueous layer was extracted twice with methylene chloride and the combined organics was washed with brine, dried (Na₂SO₄), filtered, and concentrated to provide a crude material. The crude material was purified by ISCO (80 g silica gel column) chromatography using 15 to 60% EtOAc in hexane to obtain 4-[2,6-difluoro-4-(6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenoxy]-piperidine-1-carboxylic acid tert-butyl ester (0.42 g, 14%). Step 3

A solution of 4-[2,6-difluoro-4-(6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenoxy]-piperidine-1-carboxylic acid tert-butyl ester (0.42 g, 1 mmol) in methylene chloride (5 mL) was treated with trifluoro acetic acid (10 mL). The mixture was stirred at RT for 3 h and TFA was concentrated at reduced pressure to give 6-[3,5-difluoro-4-(piperidin-4-yloxy)-phenyl]-4,5-dihydro-2H-pyridazin-3-one (0.35 g, quantitative yield), MS m/z 310 (M+H). Step 4

A solution of 6-[3,5-difluoro-4-(piperidin-4-yloxy)-phenyl]-4,5-dihydro-2H-pyridazin-3-one (350 mg, 1.1 mmol) in a mixture of DMF (2 mL) and MeOH (9 mL) was stirred under argon. Cyclobutanone (0.38 mL, 5 mmol), sodium cyanoborohydride (0.53 g, 8.45 mmol) and acetic acid (0.4 mL, 7 mmol) were added sequentially and stirred at 60° C. for 3 h. The reaction mixture was concentrated at reduced pressure and partitioned between aqueous 1M sodium carbonate solution and methylene chloride. The aqueous layer was extracted twice with methylene chloride and the combined organics was washed with brine, dried (Na₂SO₄), filtered and concentrated to provide a crude product. The crude product was purified by ISCO (40 g) chromatography using 2 to 5% methanol in methylene chloride to 10% methanol containing 0.2% ammonium hydroxide in methylene chloride. The recovered product was dissolved in methylene chloride and washed with saturated aqueous sodium bicarbonate solution, brine, dried (Na₂SO₄), filtered, and concentrated to furnish a pure product. The pure product was crystallized with a mixture of methylene chloride, ethanol, ether and hexane to obtain 6-[4-(1-cyclobutyl-piperidin-4-yloxy)-3,5-difluoro-phenyl]-4,5-dihydro-2H-pyridazin-3-one (110 mg, yield), mp 162-164° C.; MS m/z 364 (M+H)

Example 188

A mixture of 6-[4-(1-cyclobutyl-piperidin-4-yloxy)-3,5-difluoro-phenyl]-4,5-dihydro-2H-pyridazin-3-one (137 mg, 0.37 mmol) and cesium carbonate (232 mg, 0.71 mmol) in dimethyl sulfoxide (5 mL) was heated at 130° C. 45 min. The mixture was cooled to rt and partitioned between water and methylene chloride. The aqueous layer was extracted twice with methylene chloride and the combined organics was washed with brine, dried (Na₂SO₄), filtered, and concentrated to provide a crude product. The crude product was purified by ISCO (40 g silica gel column) chromatography using 2% to 8% methanol in methylene chloride to 10% methanol containing 0.2% ammonium hydroxide in methylene chloride. The recovered product was dissolved in methylene chloride and washed with saturated aqueous sodium bicarbonate solution, brine, dried (Na₂SO₄), filtered, and concentrated. The product was crystallized using a mixture of ethanol, ethyl acetate, ether and hexane to give 6-[4-(1-cyclobutyl-piperidin-4yloxy)-3,5-difluoro-phenyl]-2H-pyridazin-3-one (40 mg, 29%); Mp 195-197° C.; MS m/z 362 (M+H).

Example 189

Step 1

A solution of triphenylphosphine (22.4 g, 85.2 mmol) and 40% w/w DEAD in toluene (12.6 mL, 79.9 mmol) in tetrahydrofuran (100 mL) was cooled to 0° C. A mixture of p-propiophenol (8 g, 53.3 mmol) and 4-hydroxypiperidine-1-carboxylic acid tert-butyl ester (12.9 g, 63.9 mmol) in THF (75 mL) was added dropwise at 0° C. After the addition, the cooling bath was removed and stirred at rt overnight. The reaction mixture was concentrated at reduced pressure and purified by ISCO (120 g silica gel column) chromatography using 5 to 30% EtOAc in hexane to provide an impure product (12 g). The product was again treated with triphenylphosphine and 40% w/w DEAD in toluene, after the completion, the reaction was concentrated at reduced pressure. The crude residue was triturated with a mixture of methylene chloride and hexane and filtered and the filtrate was concentrated at reduced pressure and purified by ISCO (120 g silica gel column) chromatography using 5 to 30% EtOAc in hexane to provide 4-(4-propionylphenoxy)-piperidine-1-carboxylic acid tert-butyl ester (10 g, 56%). Step 2

A solution of 4-(4-propionyl-phenoxy)-piperidine-1-carboxylic acid ethyl ester (5 g, 15 mmol) in tetrahydrofuran (40 mL) was cooled to 0° C. Lithium diisopropylamide, (2M solution in THF) (8 mL, 16.4 mmol) was added dropwise and warmed to rt for 30 min. The reaction was cooled again to 0° C. and ethyl bromoacetate (1.8 mL, 16 mmol) was added dropwise and warmed to rt for 30 min and then quenched with aqueous 1M HCl acid at 0° C. The aqueous layer was extracted twice with methylene chloride and the combined organics were washed with brine, dried (Na₂SO₄), filtered, and concentrated to give 4-[4-(3-ethoxycarbonyl-2-methyl-propionyl)-phenoxy]-piperidine-1-carboxylic acid tert-butyl ester (5.8 g, 92%), MS m/z 364 (M−55). Step 3

A mixture of crude 4-[4-(3-ethoxycarbonyl-2-methyl-propionyl)-phenoxy]-piperidine-1-carboxylic acid tert-butyl ester (9 g, 21.4 mmol) and hydrazine monohydrate (3.58 ml, 71.6 mmol) in isopropanol (70 mL) was heated at 90° C. for 2 days and concentrated at reduced pressure to give a crude residue. The crude reside was dissolved in methylene chloride and washed with saturated aqueous sodium bicarbonate solution, brine, dried (Na₂SO₄), filtered, and concentrated to give a crude product. The crude product was purified by ISCO (120 g silica gel column) chromatography using 2 to 5% methanol in methylene chloride to obtain 4-[4-(4-methyl-6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenoxy]-piperidine-1-carboxylic acid tert-butyl ester (4.4 g, 53%), MS m/z 388 (M+H) Step 4

A solution of 4-[4-(4-methyl-6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenoxy]-piperidine-1-carboxylic acid tert-butyl ester (1 g, 2.5 mmol) in methylene chloride at RT was treated with trifluoroacetic acid (3 mL, 38.9 mmol) and stirred at RT for 3 h. TFA was evaporated at reduced pressure to obtain 5-methyl-6-[4-(piperidin-4-yloxy)-phenyl]-4,5-dihydro-2H-pyridazin-3-one (0.35 g, 47%), MS m/z 288 (M+H). Step 5

A solution of 5-methyl-6-[4-(piperidin-4-yloxy)-phenyl]-4,5-dihydro-2H-pyridazin-3-one (3.2 mg, 11 mmol) in a mixture of DMF (4 mL) and MeOH (20 mL) was stirred under argon. Cyclobutanone (4.2 mL, 56 mmol), sodium cyanoborohydride (7 g, 111 mmol) and acetic acid (1.5 mL, 26 mmol) were added sequentially and stirred at 60° C. for 20 h. The reaction mixture was concentrated at reduced pressure then quenched with 1M sodium carbonate solution at 0° C. and extracted twice with methylene chloride to provide a crude product. The crude product was purified by ISCO (40 g silica gel column) chromatography using 2 to 5% methanol in methylene chloride to 10% methanol containing 0.2% ammonium hydroxide in methylene chloride. The recovered product was dissolved in methylene chloride and washed with saturated aqueous sodium bicarbonate solution, brine, dried (Na₂SO₄), filtered, and concentrated to furnish a pure product. The pure product was crystallized using from a mixture of EtOAc, ethanol, ether and hexane to obtain 6-[4-(1-cyclobutyl-piperidin-4-yloxy)-3,5-difluoro-phenyl]-4,5-dihydro-2H-pyridazin-3-one (640 mg, 17%), mp 163-165° C.; MS m/z 342 (M+H).

Example 190

Example 191

Racemic Example 189 (660 mg) was separated into two enantiomers by chiral chromatography using chiralPak and 0.1% diethylamine in methanol.

Example 190

-   R(−)-6-[4-(cyclobutyl-piperidin-4-yloxy)-phenyl-5-methyl-4,5-dihydro-2H-pyradazin-3-one     mp 188-190° C., MS m/z 342 (M+H), Hg 365=−29.2, Conc. ˜0.1 g/mL

Example 191

-   S(+)-6-[4-(cyclobutyl-piperidin-4-yloxy)-phenyl-5-methyl-4,5-dihydro-2H-pyradazin-3-one     one mp 188-190° C., MS m/z 342 (M+H), Hg 365=+30.5, Conc. ˜0.1     g/mL).

Example 192

Example 192 was synthesized from 1-(4-methoxyphenyl)butan-1-one using procedures for example 189; Mp 152-154° C.; MS m/z 356 (M+H).

Example 193

Step 1

A mixture of 4-[4-(3-ethoxycarbonyl-2-methyl-propionyl)-phenoxy]-piperidine-1-carboxylic acid tert-butyl ester (Example 189 step 2) (5.7 g, 14 mmol) and 1N NaOH (18 mL) in methanol was heated at 65° C. for 1 h. Methanol was evaporated at reduced pressure and diluted with water then cooled to 0° C. The aqueous layer was neutralized carefully with citric acid and extracted twice with methylene chloride to obtain a crude 4-[4-(3-carboxy-2-methyl-propionyl)phenoxy]-piperidine-1-carboxylic acid tert-butyl ester (4.3 g, 81%), MS m/z 390 (M−1) Step 2

A mixture of 4-[4-(3-carboxy-2-methyl-propionyl)-phenoxy]-piperidine-1-carboxylic acid tert-butyl ester (4.3 g, 11 mmol) and 2-hydrazinopyridine (1.5 g, 14 mmol) in isopropanol (45 mL) was heated in a microwave reactor (300 Watts) at 160° C. for 150 min. Isopropanol was evaporated at reduced pressure and triturated with ether (150 mL) to obtain an orange solid (3 g). The filtrate was concentrated and purified by ISCO (80 g silica gel column) chromatography using 1.5 to 3.5% methanol in methylene chloride to obtain 4-[4-(4-methyl-6-oxo-1-pyridin-2-yl-1,4,5,6-tetrahydropyridazin-3-yl)phenoxy]-piperidine-1-carboxylic acid tert-butyl ester (0.3 g), mp 164-166° C., MS m/z 465 (M+H).

Example 193 was synthesized using the product from step 2 and methods described for example 189 step 4 and step 5. Example Structure Mp (° C.) MS m/z 193

143-5 HCl 419 (M + H)

Example 194

Step 1

A solution of 4-methoxypropiophenone (24 g, 140 mmol) in tetrahydrofuran (220 mL) was cooled to 0° C. Lithium diisopropylamide, (2M solution in THF) (126 mL, 248 mmol) was added dropwise and warmed to rt for 30 min. The reaction was cooled again to 0° C. and ethyl bromoacetate (18 mL, 161 mmol) was added dropwise and warmed to rt for 30 min and then quenched with aqueous 1M HCl acid at 0° C. The aqueous layer was extracted twice with methylene chloride and the combined organics were washed with brine, dried (Na₂SO₄), filtered, and concentrated to give 4-(4-methoxyphenyl)-3-methyl-4-oxobutyric acid ethyl ester (44 g), MS m/z 205 (M−45) Step 2

A mixture of crude 4-(4-methoxy-phenyl)-3-methyl-4-oxo-butyric acid ethyl ester (44 g, 175.8 mmol), acetic acid (300 mL) and 48% aqueous HBr (150 mL) was stirred at reflux for 10 h. The reaction was cooled to rt, concentrated at reduced pressure then partitioned between methylene chloride and water and the aqueous layer was extracted three times with methylene chloride and concentrated to provide a crude material. The crude material was dissolved in ethanol (125 mL) and added amberlyst then heated at 85° C. for 15 h. The reaction mixture was filtered over celite at rt and the filtrate was concentrated at reduced pressure and then partitioned between water and methylene chloride. The aqueous layer was extracted twice with methylene chloride to furnish a crude product and the crude product was purified by ISCO (330 g silica gel column) chromatography using 20 to 30% EtOAc in hexane to obtain a mixture (19 g) of 4-(4-hydroxyphenyl)-3-methyl-4-oxo-butyric acid ethyl ester (MS m/z 235 (M−H) and p-hydroxypropiophenone. The mixture was used for the next reaction without further purification. Step 3

A mixture of 4-(4-hydroxyphenyl)-3-methyl-4-oxo-butyric acid ethyl ester (12.5 g, 52.9 mmol), 1-bromo-3-chloropropane (11.3 mL, 114.6 mmol) and K₂CO₃ (21.9 g, 159 mmol) in acetone (200 mL) was stirred at 60° C. for 15 h. The reaction was cooled to RT and filtered over celite and the filtrate was evaporated at reduced pressure to give a crude residue. The crude residue was partitioned between methylene chloride and saturated aqueous sodium bicarbonate solution and the aqueous layer was extracted twice with methylene chloride. The combined organics was washed with brine, dried (Na₂SO₄), filtered, and concentrated to provide a crude product. The crude product was purified by ISCO (330 g) chromatography using 15% EtOAc in hexane to produce 4-[4-(3-chloropropoxy)-phenyl]-3-methyl-4-oxo-butyric acid ethyl ester (9.7 g, 56%), MS m/z 267 (M−45) Step 4

A mixture of 4-[4-(3-chloro-propoxy)-phenyl]-3-methyl-4-oxo-butyric acid ethyl ester (7 g, 22 mmol), K₂CO₃ (9.3 g, 67 mmol), NaI (330 mg, 2.2 mmol), and (R)-methyl-pyrrolidinium benzenesulfonate (11 g, 47 mmol) in CH₃CN (160 mL) was heated under argon at 80° C. for 36 h. The reaction mixture was concentrated at reduced pressure and partitioned between saturated aqueous sodium bicarbonate solution and methylene chloride. The aqueous layer was extracted twice with methylene chloride and the combined organics was washed with brine, dried (Na₂SO₄), filtered, and concentrated to provide a crude material. The crude material was purified by ISCO (80 g siliga gel column) chromatography using 2% to 9% methanol in methylene chloride to 10% methanol containing 2.5 mL ammonium hydroxide in methylene chloride to afford a pure product. The pure product was dissolved in methylene chloride and washed with saturated aqueous sodium bicarbonate solution, brine, dried (Na₂SO₄), filtered, and concentrated to give 3-methyl-4-{4-R-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4-oxo-butyric acid ethyl ester (8.39 g, quantitative yield), MS m/z 362 (M+H). Step 5

A mixture of 3-methyl-4-{4-R-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4-oxo-butyric acid ethyl ester (8.39 g, 23.2 mmol) and hydrazine monohydrate (5 mL, 100 mmol) in isopropanol was heated at 100° C. for 36 h. Isopropanol was evaporated at reduced pressure and quenched with saturated aqueous sodium bicarbonate solution and extracted twice with methylene chloride. The combined organics was washed with brine, dried (Na₂SO₄), filtered, and concentrated to afford a crude product. The crude product was purified by ISCO (80 g) chromatography using 2 to 10% methanol in methylene chloride to 10% methanol containing 4 mL ammonium hydroxide in methylene chloride to afford a pure product. The pure product was dissolved in methylene chloride and washed with saturated aqueous sodium bicarbonate solution, brine, dried (Na₂SO₄), filtered, and concentrated to give 5-methyl-6-{4-[3-R-2-methyl-pyrrolidin-1-yl)propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one (6.1 g, 80%, >95% purity). The product was dissolved in a mixture of ethanol and ethyl acetate and 1M HCl (18 mL) in ether was added and the mixture was concentrated at reduced pressure. Fresh ethanol and ethyl acetate were added and concentrated under vacuum and again dissolved in ethanol and slowly added ethyl acetate, ether and hexane. After stirring for 15 min at RT solid separated, and the solid was filtered, washed with ether and dried at 85° C. in a ChemDry for 15 h to provide example 194 HCl as an off-white solid (5.8 g), mp 169-171° C., MS m/z 330 (M+H).

Example 195

Example 196

Racemic example 194 (5.8 g) of was separated into two diastereomers using chiralCel and 0.1% diethylamine in methanol.

Example 195

-   5-methyl-6-[4-[3-(R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one     HCl (2.4 g), mp 149-151° C., MS m/z 367 (M+H).

Example 196

-   5-methyl-6-[4-[3-(S)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one     HCl (2.6 g), mp 189-191° C., MS m/z 367 (M+H)

Example 197 (racemic) and example 198 (racemic) were synthesized as HCl salts using methods described for example 194. Example Structure mp (° C.) MS m/z 197

223-225 HCl 330 (M + H) 198

161-163 HCl

Example 199

Step 1

A mixture of 4-(4-methoxy-2-methyl-phenyl)-4-oxo-butyric acid (2 g, 9 mmol), acetic acid (30 mL) and 48% aqueous HBr (10 mL) was heated at 130° C. for 5.5 h. The reaction was cooled to rt and concentrated at reduced pressure and azeotrope twice with benzene to give a crude residue. The crude residue was dissolved in ethanol (25 mL) and added amberlyst then heated at 90° C. for 18 h. The reaction was filtered over celite and evaporated ethanol at reduced pressure then quenched with water and extracted twice with methylene chloride to obtain 4-(4-hydroxy-2-methyl-phenyl)-4-oxo-butyric acid ethyl ester (1.6 g, 75%). The crude material was used for the next reaction without purification. Step 2

4-[4-(3-chloro-propoxy)-2-methyl-phenyl]-4-oxo-butyric acid ethyl ester was prepared from 4-(4-hydroxy-2-methyl-phenyl)-4-oxo-butyric acid ethyl ester according to the procedure in step 3 example 184 MS m/z 267 (M−45). Step 3

4-{2-methyl-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4-oxo-butyric acid ethyl ester (0.28 g, 67%) was prepared from 4-[4-(3-chloro-propoxy)-2-methyl-phenyl]-4-oxo-butyric acid ethyl ester (0.36 g, 1.15 mmol) according to the procedure in step 4 of example 184; MS m/z 362 (M+H). Step 4

6-{(R)-2-methyl-4-[3-(2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one was prepared from 4-[4-(3-chloro-propoxy)-2-methyl-phenyl]-4-oxo-butyric acid ethyl ester (0.28 g, 0.77 mmol) according to the procedure in step 5 of example 184HCl; Mp 121-123° C.; MS m/z=330 (M+H).

Examples 200-204 were synthesized using Cu(0) coupling methods according to Example 21 or CuI/dioxane/1,2-diaminocyclohexane/Cs₂CO₃ and starting with R-1-[3-(4-bromo-phenoxy)propyl]-2-methyl-pyrrolidine or 4-(5-bromopyridin-2-yloxy)-piperidine-1-carboxylic acid tert-butyl ester. Example Structure Mp (° C.) MS m/z 200

86-9  390 (M + H) 201

168-70 fumarate 328 (M + H) 202

70-3  364 (M + H) 203

155-9 fumarate 403 (M + H) 204

87-90 391 (M + H) 262

51-55 fumarate

Example 205

Step 1

To 9.80 mL of ethyl acetate (100 mmol) in 40 mL dry THF at room temperature was added 2.0 g of 60% sodium hydride (49.9 mmol), 7.50 g of 4′-methoxyacetophenone (49.9 mmol), 100.0 mg of 18-crown-6 (0.40 mmol), and 2 drops of ethanol. After 30 minutes, the reaction was refluxed for 1 h, and then 100 mL of dry THF was added. After an additional 1 h, 30 mL THF was added. After 1 h the reaction was cooled to 0° C. and 25 mL of 10% aqueous sulfuric acid was added. The product was extracted with diethyl ether. The ether extracts were dried with Na₂SO₄, filtered, and concentrated in vacuo. The crude material was purified via silica gel chromatography eluting with 4:1 hexane:ethyl acetate to give 5.8 g of 1-(4-methoxyphenyl)butane-1,3-dione containing 30% starting material (via ¹H NMR 42% yield). Step 2

To 7.04 mL of 21% sodium ethoxide in ethanol (18.8 mmol) in 60 mL ethanol at 0° C. was added 4.70 g of 1-(4-methoxyphenyl)butane-1,3-dione (17.1 mmol) in 60 mL ethanol dropwise over 24 minutes. After 30 min a solution of 2.59 g of ethyl chloro-(hydroximino)acetate (17.1 mmol) in 30 mL ethanol was added dropwise over 6 minutes. The reaction was warmed to room temperature slowly. When TLC indicated the reaction was complete, the reaction was concentrated in vacuo. Water and saturated NaHCO₃ was added and the product extracted with ethyl acetate. The ethyl acetate extracts were dried with Na₂SO₄, filtered, and concentrated in vacuo. The crude material was purified via silica gel chromatography eluting with 8:1 hexane:ethyl acetate to give 4-(4-methoxybenzoyl)-5-methylisoxazole-3-carboxylic acid ethyl ester which was dried overnight under high vacuum to give 3.74 g (71.8%). Step 3.

A solution of 2.47 g of 4-(4-methoxybenzoyl)-5-methylisoxazole-3-carboxylic acid ethyl ester (8.54 mmol) and 0.598 mL of hydrazine monohydrate (12.0 mmol) in 18.4 mL ethanol was stirred at room temperature for 19 hours. The heterogeneous reaction was cooled in an ice bath then filtered off the white solid, washing with cold ethanol then diethyl ether. Dried on under high vacuum to give 2.06 g (92%) of 4-(4-methoxyphenyl)-3-methyl-6h-isoxazolo[3,4-d]pyridazin-7-one. Step 4

To 1.05 g of 4-(4-methoxyphenyl)-3-methyl-6h-isoxazolo[3,4-d]pyridazin-7-one (4.08 mmol) in 15 mL dry DMF was added 1.03 g of sodium ethanethiolate in 15 mL dry DMF at room temperature. The reaction was then heated at 100° C. for 2.5 h. Added water and 1M HCl until acidic. Extracted the product with diethyl ether and dried the extracts with Na₂SO₄, filtered, and concentrated in vacuo. The product was purified via silica gel chromatography eluting with 95:5 dichloromethane:methanol to give 533 mg of 4-(4-hydroxyphenyl)-3-methyl-6h-isoxazolo[3,4-d]pyridazin-7-one; Mp 268-276° C.; MS m/z 216 (M−N₂+H). Step 5

To a solution of 805 mg of triphenylphosphine (3.07 mmol) in 10 mL dry THF at 0° C. was added 1.30 mL 40% w/w diethylazodicarboxylate in toluene (8.26 mmol). After 15 min, a solution of 524 mg of 4-(4-hydroxyphenyl)-3-methyl-6h-isoxazolo[3,4-d]pyridazin-7-one (2.05 mmol) and 494 mg of 4-hydroxypiperidine-1-carboxylic acid tert-butyl ester (2.46 mmol) in 18 mL dry THF were added dropwise. The reaction was slowly warmed to room temperature. After 14 h water was added and the product was extracted with ethyl acetate. The extracts were dried with Na₂SO₄, filtered, and concentrated in vacuo. The product was purified via silica gel chromatography eluting with 1:1 hexane:ethyl acetate to give 985 mg of 4-[4-(3-methyl-7-oxo-6,7-dihydroisoxazole[3,4-d]pyridazin-4-yl)phenoxy]piperidine-1-carboxylic acid tert-butyl ester 65.4%.

Step 6

Example 206

To 980 mg of 4-[4-(3-methyl-7-oxo-6,7-dihydroisoxazole[3,4-d]pyridazin-4-yl)phenoxy]-piperidine-1-carboxylic acid tert-butyl ester (1.3 mmol) in 20 mL of dichloromethane was added 1.0 mL of trifluoroacetic acid (13 mmol). After stirring at room temperature for 3 hours, an additional 0.5 mL of trifluoroacetic acid was added. The reaction was concentrated in vacuo as monitored by TLC and concentrated and triturated with diethyl ether to give 375 mg (98% pure) (63% yield) of example 206 as an off-white solid 3-methyl-4-[4-(piperidin-4-yloxy)phenyl]-6h-isoxazolo-[3,4-d]pyridazin-7-one TFA salt. Mp 283-239° C.; MS m/z 299 (M−N₂+H).

Step 7

Example 205

To 369 mg of example 206 (3-methyl-4-[4-(piperidin-4-yloxy)phenyl]-6h-isoxazolo-[3,4-d]pyridazin-7-one trifluoroacetic acid salt) (0.838 mmol) and 84 μL acetic acid (1.5 mmol) in 6 mL dry methanol and 2 mL dry DMF at 0° C. was added 260 mg of sodium cyanoborohydride (4.2 mmol) and then 190 μL of cyclobutanone (2.5 mmol). The reaction was heated at 60° C. After 1 h, the reaction was complete as determined by LC/MS and was concentrated in vacuo. Water and 2M Na₂CO₃ was added and the product was extracted with dichloromethane. The extracts were dried with Na₂SO₄, filtered, and concentrated in vacuo. The crude product was purified via silica gel chromatography eluting with 500:15:10 dichloromethane:methanol:7N ammonia in methanol to give a colorless oil which was re-concentrated in vacuo with diethyl ether. Added diethyl ether and upon standing, a white solid formed which was triturated with ether to yield 56 mg (17%) of example 205 Mp 182.5-184.0° C.; MS m/z 353 (M−N₂+H).

Example 207

Step 1

A mixture of 5.97 g of 4′-hydroxyacetophenone (43.8 mmol), 13.0 g of 1-(3-chloropropyl)-piperidine hydrochloride (65.8 mmol), 12.70 g of potassium carbonate (91.89 mmol), and 3.28 g of sodium iodide (21.9 mmol) in 100 mL dry acetone was stirred at reflux. After 1.5 h, the reaction was cooled to room temperature, filtered and concentrated. Ethyl acetate was added and the white solid that remained was filtered off. The filtrate was concentrated in vacuo and the crude residue was purified via silica gel chromatography using a gradient of ethyl acetate then 400:20:10 ethyl acetate: 7N ammonia in methanol:methanol to yield 583 mg of 1-[4-(3-piperidin-1-ylpropoxy)phenyl]ethanone as an oil. MS m/z 265 (M+H). Step 2

To 430 μL of ethyl acetate (4.4 mmol) in 10 mL dry THF at room temperature was added 180 mg of 60% sodium hydride (4.4 mmol), 15.0 mg of 18-crown-6 (0.0568 mmol), 2 drops of ethanol, and then 578 mg (2.212 mmol) of 1-[4-(3-piperidin-1-ylpropoxy)phenyl]ethanone in 10 mL dry THF. After 30 min, the reaction was refluxed. An additional 18 mL of dry THF was added after 1.5 hours to reduce the viscosity of the reaction. After an additional 2 hours, 0.50 mL of 12.1 M aq. HCl was added to the reaction and the reaction was concentrated in vacuo. Water and saturated NaHCO₃ was added and the product extracted with ethyl acetate. The ethyl acetate extracts were dried with Na₂SO₄, filtered, and concentrated in vacuo. The crude material was purified via silica gel chromatography eluting with 500:20:12 dichloromethane:methanol: 7N ammonia in methanol to give a yellow oil which solidified to give 450 mg (66%) of 1-[4-(3-piperidin-1-ylpropoxy)-phenyl]butane-1,3-dione as a yellow solid; Mp 43.0-45.5° C.; MS m/z 304 (M+H). Step 3

To 597 μL of 21% sodium ethoxide in ethanol (1.595 mmol) in 4 mL ethanol at 0° C. was added 440 mg of 1-[4-(3-piperidin-1-ylpropoxy)phenyl]butane-1,3-dione (1.45 mmol) in 5.5 mL ethanol dropwise. After 30 min, a solution of 220 mg of ethyl chloro(hydroximino)acetate (1.45 mmol) in 3 mL ethanol was added dropwise. The reaction was warmed to room temperature slowly. After 19.5 h the reaction was concentrated in vacuo. Water and saturated NaHCO₃ was added and the product extracted with ethyl acetate. The ethyl acetate extracts were dried with Na₂SO₄, filtered, and concentrated in vacuo. The crude material was purified via silica gel chromatography eluting with 500:15:10 dichloromethane:methanol: 7N ammonia in methanol to give 300 mg (50%) of a gold oil determined to be 5-methyl-4-[4-(3-piperidin-1-ylpropoxy)benzoyl]-isoxazole-3-carboxylic acid ethyl ester; MS m/z 401 (M+H).

Step 4

Example 207

To 291.3 mg of 5-methyl-4-[4-(3-piperidin-1-ylpropoxy)benzoyl]isoxazole-3-carboxylic acid ethyl ester (0.7057 mmol) in 1.54 mL of ethanol at room temperature was added 49.4 μL of hydrazine monohydrate (0.988 mmol). After 21 h, the heterogeneous reaction was cooled to 0° C. and filtered. The white solid was washed with cold ethanol then diethyl ether and dried at 65° C. under high vacuum. Yield 120 mg (46%) of a white solid Mp 178-9; MS m/z 369 (M+H).

Example 208

Example 208 was prepared using methods described for example 207; Mp 169-70° C.; MS m/z 369 (M+H).

Example 178 Method B Step 1

In a 1 L round bottom flask, 4-(4-methoxyphenyl)-4-oxo-butyric acid (25 g, 106 mmol) in 48% HBr (125 mL) and acetic acid (250 mL) was heated to reflux 18 h. The reaction was cooled slightly and ethanaol (250 mL) was added. The solvent was concentrated under vacuum. Additional ethanol (100 mL) was added and solvent concentrated under vacuum again. The resulting oil was crystallized from ethyl acetate/hexanes to produce 8.65 g (37%). MS m/z=223 (M+H).

Step 2

In a 1 L round bottom flask, 4-(4-hydroxyphenyl)-4-oxo-butyric acid ethyl ester (8.65 g, 39.0 mmol), 1-bromo-3-chloro-propane (6.1 g, 61.0 mmol), and potassium carbonate (9.3 g, 67.1 mmol) in acetonitrile (300 mL) was heated to reflux 14 h. The reaction was cooled and the solvent concentrated under vacuum. The slurry was partitioned between methylene chloride and water, separated and dried over MgSO₄. Purification with silica gel chromatography eluting with hexanes/ethyl acetate (3:1) produced 7.9 g (68%). MS m/z 299 (M+H).

Step 3

In a 500 mL round bottom flask, 4-[4-(3-chloro-propoxy)-phenyl]-4-oxo-butyric acid ethyl ester (7.85 g, 26.3 mmol), and hydrazine monohydrate (2.55 mL, 52.7 mmol), in isopropanol (200 mL) was heated to reflux 14 h. The reaction was cooled and the solvent concentrated under vacuum. Purification with silica gel chromatography eluting with methylene chloride/methanol (95:5) produced 5.2 g (74%). MS m/z 267 (M+H).

Example 178 Step 4

In a 500 mL round bottom flask, 6-[4-(3-chloro-propoxy)-phenyl]-4,5-dihydro-2H-pyridazin-3-one (5.2 g, 19.5 mmol), benzenesulfonate (R)-2-methyl-pyrrolidinium (9.5 g, 39.0 mmol), potassium carbonate (10.8 g, 78.0 mmol), and potassium iodide (200 mg, 1.2 mmol) in acetonitrile (300 mL) was heated to reflux 14 h. The reaction was cooled and the solvent concentrated under vacuum. The slurry was partitioned between methylene chloride and water, then washed with water three times. The organics were extracted three times with 3% citric acid solution. The combined aqueous layers were basified with sat. NaHCO₃ sol. and extracted with methylene chloride, then dried over MgSO₄. Ethereal HCl was added and the solvents reduced under vacuum. Crystallization from MeOH/Et₂O produced 3.17 g (46%). Mp 221-223° C. MS m/z 316 (M+H).

Example 209 Step 1

In a 500 mL round bottom flask, 6-hydroxy-3,4-dihydro-2H-naphthalen-1-one (10 g, 61.0 mmol), 1-bromo-3-chloro-propane (9.6 g, 61.0 mmol), and potassium carbonate (9.3 g, 67.1 mmol) in acetonitrile (300 mL) was heated to reflux 14 h. The reaction was cooled and the solvent concentrated under vacuum. The slurry was partitioned between methylene chloride and water, separated, dried over MgSO₄. Purification with silica gel chromatography eluting with hexanes/ethyl acetate (3:1) produced 10.6 g (73%). Mp 85-87° C. MS m/z 239 (M+H).

Step 2

In a 100 mL round bottom flask, 6-(3-chloro-propoxy)-3,4-dihydro-2H-naphthalen-1-one (1 g, 4.2 mmol), and glyoxylic acid monohydrate (387 mg, 4.2 mmol), in acetic acid (10 mL) was heated to reflux 6 h. The reaction was cooled and hydrazine monohydrate (0.41 mL, 8.4 mmol) was added and the reaction was heated to reflux 14 h. The reaction was cooled and the solvent concentrated under vacuum. The slurry was partitioned between methylene chloride and water, separated, dried over MgSO₄. Purification with silica gel chromatography eluting with methylene chloride/methanol (95:5) produced 620 mg (51%). MS m/z 291 (M+H).

Example 209 Step 3

In a 100 mL round bottom flask, 8-(3-chloro-propoxy)-5,6-dihydro-2H-benzo[h]cinnolin-3-one (600 mg, 2.1 mmol), benzenesulfonate (R)-2-methyl-pyrrolidinium (1.02 g, 4.2 mmol), potassium carbonate (1.14 g, 8.3 mmol), and potassium iodide (10 mg, 0.06 mmol) in acetonitrile (60 mL) was heated to reflux 14 h. The reaction was cooled and the solvent concentrated under vacuum. The slurry was partitioned between methylene chloride and water, and then washed with water three times. The organics were extracted three times with 3% citric acid solution. The combined aqueous layers were basified with sat. NaHCO₃ sol. and extracted with methylene chloride, then dried over MgSO₄. Ethereal HCl was added and the solvents reduced under vacuum. Crystallization from MeOH/Et₂O produced 85 mg (11%). Mp 289-292° C. MS m/z 340 (M+H).

Example 210

Following the procedure of Example 209: Mp 253-255° C. MS m/z=328 (M+H).

Example 211

Following the procedure of Example 209: Mp 272-275° C. MS m/z=342 (M+H).

Example 212 Step 1

In a 1 L round bottom flask, 6-(3-chloro-propoxy)-3,4-dihydro-2H-naphthalen-1-one (10.0 g, 41.9 mmol), benzenesulfonate (R)-2-methyl-pyrrolidinium (13.15 g, 84.0 mmol), potassium carbonate (23.15 g, 168 mmol), and potassium iodide (100 mg, 0.6 mmol) in acetonitrile (600 mL) was heated to reflux 14 h. The reaction was cooled and the solvent concentrated under vacuum. The slurry was partitioned between methylene chloride and water, then washed with water three times. The organics were extracted three times with 3% citric acid solution. The combined aqueous layers were basified with sat. NaHCO₃ sol. and extracted with methylene chloride, then dried over MgSO₄. Ethereal HCl was added and the solvents reduced under vacuum. Crystallization from MeOH/Et₂O produced 8.75 g (65%). Mp 183-185° C. MS m/z=288 (M+H).

Example 212 Step 2

In a 250 mL round bottom flask, 6-[3-((R)-2-Methyl-pyrrolidin-1-yl)-propoxy]-3,4-dihydro-2H-naphthalen-1-one (3.0 g, 9.3 mmol), and glyoxylic acid monohydrate (1.28 g, 13.9 mmol), in acetic acid (60 mL) was heated to reflux 3 h. The reaction was cooled and zinc dust (1.21 g, 18.5 mmol) was added and the reaction was heated to reflux 14 h. The reaction was cooled and diluted with water (120 mL). The mixture was basified to pH 8 with NH₄OH and then hydrazine monohydrate (0.93 mL, 18.5 mmol) was added. The reaction was heated to reflux 2 h. The reaction was cooled and re-basified with NaHCO₃, then extracted with methylene chloride three times. The organics were dried over MgSO₄, then ethereal HCL was added. The solvents were removed under vacuum and the product was crystallized with MeOH/ether to produce 1.16 g (33%). Mp 193-195° C. MS m/z 342 (M+H).

Example 213 Step 1

In a 250 mL round bottom flask, 1-(4-hydroxy-2-methoxy-phenyl)ethanone (5.0 g, 30.0 mmol), 1-bromo-3-chloro-propane (3.27 mL, 33.1 mmol), and potassium carbonate (4.75 g, 33.1 mmol) in acetonitrile (100 mL) was heated to reflux 14 h. The reaction was cooled and the solvent concentrated under vacuum. The slurry was partitioned between methylene chloride and water, separated, dried over MgSO₄. Purification with silica gel chromatography eluting with hexanes/ethyl acetate (3:1) produced 6.18 g (85%). Mp 51-53° C. MS m/z 243 (M+H).

Step 2

In a 250 mL round bottom flask, 1-[4-(3-chloro-propoxy)-2-methoxy-phenyl]-ethanone (6.18 g, 25.5 mmol), benzenesulfonate (R)-2-methyl-pyrrolidinium (12.4 g, 50.9 mmol), potassium carbonate (14.1 g, 102 mmol), and potassium iodide (20 mg, 0.12 mmol) in acetonitrile (100 mL) was heated to reflux 14 h. The reaction was cooled and the solvent concentrated under vacuum. The slurry was partitioned between methylene chloride and water, then washed with water three times. The organics were extracted three times with 3% citric acid solution. The combined aqueous layers were basified with sat. NaHCO₃ sol. and extracted with methylene chloride, then dried over MgSO₄. The solvents were removed under vacuum to produce 4.25 g (57%) of oil. MS m/z 292 (M+H).

Example 213 Step 3

In a 100 mL round bottom flask, 1-{2-methoxy-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-ethanone (4.24 g, 14.5 mmol), and glyoxylic acid monohydrate (2.01 g, 21.8 mmol), in acetic acid (20 mL) was heated to reflux 3 h. The reaction was cooled and diluted with water (40 mL). The mixture was basified to pH 8 with NH₄OH and then hydrazine monohydrate (1.41 mL, 29.1 mmol) was added. The reaction was heated to reflux 2 h. The reaction was cooled and re-basified with NaHCO₃, then extracted with methylene chloride three times. The organics were dried over MgSO₄, then ethereal HCL was added. The solvents were removed under vacuum and the product was crystallized with MeOH/ether to produce 500 mg (9%). Mp 182-186° C. MS m/z 344 (M+H).

Example 214

Following the procedure of Example 213: Mp 220-222° C. MS m/z 332 (M+H).

Example 215

In a 50 mL round bottom flask, 6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one (250 mg, 0.71 mmol), 2-bromopyridine (105 μL, 1.07 mmol), copper(I)iodide (13.6 mg, 0.07 mmol), and potassium carbonate (296 mg, 2.14 mmol) in dimethylformamide (10 mL) was heated to reflux 14 h. The reaction was cooled and water (20 mL) was added. The sticky solids were filtered off and then partitioned between methylene chloride and water, separated, and dried over MgSO₄. Purification with silica gel chromatography eluting with methylene chloride/methanol (95:5) produced 10 mg (2.4%) oil. MS m/z 391 (M+H).

Example 216 Step 1

In a 500 mL round bottom flask ethyl 2-pyridylacetate (2.0 g, 12.1 mmol), and 60% sodium hydride (508 mg, 12.7 mmol) in dimethylformamide (50 mL) was stirred 1 h. 2-Bromo-1-[4-(3-chloro-propoxy)-phenyl]-ethanone (3.53 g, 12.1 mmol) was then added in dimethylformamide (50 mL) via dropping funnel. The reaction was stirred 14 h. Water (300 mL) was added and the organics were extracted three times with ethyl acetate, and then dried over MgSO₄. Purification with silica gel chromatography eluting with hexanes/ethyl acetate (3:1) produced 2.8 g (62%). MS m/z 376 (M+H).

Step 2

In a 100 mL round bottom flask, 4-[4-(3-chloro-propoxy)-phenyl]-4-oxo-2-pyridin-2-yl-butyric acid ethyl ester (2.77 g, 7.4 mmol), benzenesulfonate (R)-2-methyl-pyrrolidinium (3.59 g, 14.7 mmol), potassium carbonate (4.07 g, 29.5 mmol), and potassium iodide (100 mg, 0.6 mmol) in acetonitrile (100 mL) was heated to reflux 14 h. The reaction was cooled and the solvent concentrated under vacuum. The slurry was partitioned between methylene chloride and water, and then washed with water 3 times. The organics were chromatographed through silica gel with methylene chloride/methanol (95:5) eluent. Ethereal HCl was added to make the bis HCl salt and produce 960 mg (28%) of an amorphous solid. MS m/z 425 (M+H).

Example 216 Step 3

In a 50 mL round bottom flask, 4-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4-oxo-2-pyridin-2-yl-butyric acid ethyl ester (950 mg, 1.84 mmol), and hydrazine monohydrate (204 μL, 4.2 mmol), in acetic acid (20 mL) was heated to reflux 14 h. The reaction was cooled and the solvent concentrated under vacuum. The slurry was partitioned between methylene chloride and NaHCO₃ sol., extracted three times, and then dried over MgSO₄. Purification with silica gel chromatography eluting with methylene chloride/methanol (95:5) produced 250 mg (33%). Ethereal HCl was added to a methanol solution to produce crystals. Mp 231-233° C. MS m/z 393 (M+H).

Example 217

In a 10 mL round bottom flask, 6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4-pyridin-2-yl-4,5-dihydro-2H-pyridazin-3-one (120 mg, 0.31 mmol), and cesium carbonate (197 mg, 0.62 mmol), in dimethylsulfoxide (3 mL) was heated to 135° C. 3 h. The reaction was cooled and the slurry was partitioned between methylene chloride and water extracted three times, and then dried over MgSO₄. Purification with silica gel chromatography eluting with methylene chloride/methanol (95:5), followed by HCl salt formation produced 120 mg (33%). Mp 157-161° C. MS m/z 391 (M+H).

Example 218 Step 1

In a 50 mL round bottom flask, 6-methoxy-3,4-dihydro-1H-naphthalen-2-one (1.0 g, 5.68 mmol), and glyoxylic acid monohydrate (523 mg, 5.68 mmol), in acetic acid (10 mL) was heated to reflux 3 h. The reaction was cooled and diluted with water (20 mL). The mixture was basified to pH 8 with NH₄OH and then hydrazine monohydrate (0.55 mL, 11.4 mmol) was added. The reaction was heated to reflux 2 h. The reaction was cooled and re-basified with NaHCO₃, then extracted with methylene chloride three times. The organics were dried over MgSO₄, and the solvents were removed under vacuum to produce 1.1 g (85%). mp dec. 270° C. MS m/z=229 (M+H). Step 2

In a 100 mL round bottom flask, 8-methoxy-5,6-dihydro-3H-benzo[f]cinnolin-2-one (1.05 g, 4.61 mmol) in methylene chloride (3 mL) was cooled to 0° C. Boron tribromide (23 ml of a 1M sol. in methylene chloride) was added and the reaction warmed to ambient temperature for 4 h. Re-cooled to 0° C. and sat. NH₄Cl sol. (23 mL) was added. The solvents were removed under vacuum and water was added. Solids were filtered off and washed with cold methanol to produce 587 mg (59%). Mp >300° C. MS m/z 215 (M+H). Step 3

In a 50 mL round bottom flask, 8-hydroxy-5,6-dihydro-3H-benzo[f]cinnolin-2-one (575 mg, 2.69 mmol), 1-bromo-3-chloro-propane (0.27 mL, 2.69 mmol), and potassium carbonate (371 mg, 2.69 mmol) in acetonitrile (20 mL) was heated to reflux 14 h. The reaction was cooled and the solvent concentrated under vacuum. The slurry was partitioned between methylene chloride and water, separated, dried over MgSO₄. Purification with silica gel chromatography eluting with methylene chloride/methanol (95:5) produced 106 mg (14%) as an amorphous solid. MS m/z 291 (M+H).

Example 218 Step 4

In a 25 mL round bottom flask, 8-(3-chloro-propoxy)-5,6-dihydro-3H-benzo[f]cinnolin-2-one (100 mg, 0.34 mmol), benzenesulfonate (R)-2-methyl-pyrrolidinium (168 mg, 0.68 mmol), potassium carbonate (190 mg, 1.36 mmol), and potassium iodide (1 mg, 0.006 mmol) in acetonitrile (10 mL) was heated to reflux 14 h. The reaction was cooled and the solvent concentrated under vacuum. The slurry was partitioned between methylene chloride and water, and then washed with water 3 times. The organics were chromatographed through silica gel with methylene chloride/methanol (95:5) eluent to produce 10 mg (9%). Mp 225° C. (dec.). MS m/z 340 (M+H).

Example 219 Step 1

In a 500 mL round bottom flask, diethyl azodicarboxylate (16.9 g, 97.3 mmol) and triphenylphosphine (25.5 g, 97.3 mmol) in tetrahydrofuran (200 mL) were cooled to 0° C. 1-(2-Fluoro-4-hydroxy-phenyl)-ethanone (10.0 g, 64.9 mmol) and 4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester (15.67 g, 77.9 mmol) in tetrahydrofuran (100 mL) were added. The reaction was warmed to ambient temperature 14 h. The solvents were concentrated under vacuum and methylene chloride (100 mL) and hexanes (500 mL) were added. The solids were filtered off. The mother liquor was concentrated under vacuum and chromatographed through silica gel with hexanes/ethyl acetate (7:3) as eluent to produce 17.5 g (80%). Mp 72-73° C.

Step 2

In a 250 mL round bottom flask, 4-(4-acetyl-3-fluoro-phenoxy)-piperidine-1-carboxylic acid tert-butyl ester (4.0 g, 12 mmol) in tetrahydrofuran (00 mL) were cooled to −78° C. Lithium diisopropylamide (1.4 g, 13 mmol) was added and stirred 30 min. then warmed to 0° C. Re-cooled to −78° C. and ethyl bromoacetate (1.4 mL, 13 mmol) in tetrahydrofuran (25 mL) was added. The reaction warmed to ambient temperature over 14 h. The reaction was quenched with NH₄Cl sol. and the solvents were concentrated under vacuum. The reaction was chromatographed through silica gel with hexanes/ethyl acetate (7:3) as eluent to produce 4.10 g (82%) of oil.

Step 3

In a 250 mL round bottom flask, 4-[4-(3-ethoxycarbonyl-propionyl)-3-fluoro-phenoxy]-piperidine-1-carboxylic acid tert-butyl ester (4.1 g, 9.68 mmol), and hydrazine monohydrate (0.97 mL, 19.4 mmol), in isopropanol (100 mL) was heated to reflux 14 h. The reaction was cooled and the solvent concentrated under vacuum. Purification with silica gel chromatography eluting with methylene chloride/methanol (95:5) produced 945 mg (25%). Mp 146-148° C. MS m/z 392 (M+H).

Step 4

In a 10 mL round bottom flask, 4-[3-fluoro-4-(6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenoxy]-piperidine-1-carboxylic acid tert-butyl ester (410 mg, 1.0 mmol) in trifluoroacetic acid (3 mL) was stirred 2 h. The solvent concentrated under vacuum to produce 420 mg (100%) of the salt as an oil. MS m/z=292 (M+H).

Example 219 Step 5

In a 25 mL round bottom flask, 6-[2-fluoro-4-(piperidin-4-yloxy)-phenyl]-4,5-dihydro-2H-pyridazin-3-one trifluoroacetic acid salt (420 mg, 1.0 mmol) was dissolved in methanol (10 mL), N,N-dimethylformamide (4 mL), and acetic acid (0.4 mL). Cyclobutanone (0.23 mL, 3.0 mmol), and then sodium cyanoborohydride (0.32 g, 5.0 mmol) were added. The reaction was heated to 60° C. for 2 h. The reaction was cooled and diluted with methylene chloride and NaHCO₃ sol. to pH 9. The organics were extracted three times and the solvent concentrated under vacuum. Purification with silica gel chromatography eluting with methylene chloride/methanol (95:5) followed by salt formation with ethereal HCl produced 210 mg (54%). Mp >300° C. MS m/z 346 (M+H).

Example 220

Following the procedure of Example 219: Mp >300° C. MS m/z=354 (M+H).

Example 221 Step 1

In a 10 mL round bottom flask, 4-[3-fluoro-4-(6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenoxy]-piperidine-1-carboxylic acid tert-butyl ester (525 mg, 1.34 mmol), and cesium carbonate (874 mg, 2.68 mmol), in dimethylsulfoxide (5 mL) was heated to 135° C. 3 h. The reaction was cooled and the slurry was partitioned between methylene chloride and water extracted three times, and then dried over MgSO₄. Purification with silica gel chromatography eluting with methylene chloride/methanol (95:5) produced 500 mg (93%). Mp 117-119° C. MS m/z 390 (M+H).

Example 221 Step 2

Following the final two steps of Example 219: Mp >300° C. MS m/z 344 (M+H).

Example 222

Following the procedure of Example 221: Mp >300° C. MS m/z 340 (M+H).

Example 223

Step 1.

To a round-bottom flask was added 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenol (11.0 g, 50 mmol), 1-bromo-3-chloropropane (9.88 mL, 100 mmol), potassium carbonate (20.7 g, 150 mmol), and acetonitrile (100 mL). The reaction mixture was heated to reflux for 24 h. The reaction was cooled to room temperature and was filtered. The filtrate was concentrated to give crude 2-[4-(3-chloro-propoxy)-phenyl]-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane. This material was used for next step without purification.

Step 2.

To a round-bottom flask was added crude 2-[4-(3-chloro-propoxy)-phenyl]-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane, (R)-2-methyl-pyrrolidine, benzenesulfonic acid salt (24.3 g, 100 mmol), sodium iodide (7.49 g, 50 mmol), potassium carbonate (20.7 g, 150 mmol) and acetonitrile (100 mL). The reaction was heated to reflux for 2.5 days and was cooled to room temperature. The reaction was diluted with methylene chloride (100 mL) and was filtered. The filtrate was concentrated. Purification by column chromatography (5% MeOH in CH₂Cl₂) to give 11.3 g (65%, 2 steps) of (R)-2-methyl-1-{3-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenoxy]-propyl}-pyrrolidine.

Step 3.

To a round-bottom flask was added 2-hydroxymethyl-5-iodo-2H-pyridazin-3-one (2.28 g, 9.05 mmol), (R)-2-methyl-1-{3-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenoxy]-propyl}-pyrrolidine (3.28 g, 9.50 mmol), tetrakis(triphenylphosphine)palladium(0) (2.1 g, 1.8 mmol), potassium carbonate (6.25 g, 45.2 mmol), 1,2-dimethoxyethane (80 mL), and water (40 mL). The reaction mixture was flushed with nitrogen for 30 min and was heated to reflux for 48 h. After cooled to room temperature, the reaction was filtered. The organic layer was separated and concentrated. Purification by column chromatography (CH₂Cl₂:MeOH:iPrNH=9:1:0.1) to give 3.31 g (63.5%) of example 223 (5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one).

The following examples were prepared using the procedure for example 223. Example Structure Mp (° C.) MS m/z 223

160-163 314 (M + H) 224

183-185 358 (M + H) 225

154-156 328 (M + H) 226

130-133 328 (M + H) 227

145-148 328 (M + H) 228

160-163 328 (M + H) 229

175-180 472 (M + H) 230

 139-40.5 HCl 372 (M + H) 231

186-8 HCl 328 (M + H) 232

185-97 (dec.) HCl 372 (M + H) 233

112-113 328 (M + H) 234

119.5-123.5 HCl

Example 235

Step 1.

To a stirred solution of 4,5-dichloropyridazin-6-one (5.00 g, 30.3 mmol) and N,N-diisopropylethylamine (7.92 mL, 45.5 mmol) in methylenechloride (50 mL) was added slowly, bromomethyl methyl ether (4.79 mL, 60.6 mmol) at room temperature (water-bath). The reaction was stirred for 22 h and was then concentrated. Purification by column chromatography (1% MeOH in CH₂Cl₂) gave 4.74 g (74.8%) of 4,5-dichloro-2-methoxymethyl-2H-pyridazin-3-one.

Step 2.

To a stirred solution of 4,5-dichloro-2-methoxymethyl-2H-pyridazin-3one (1.00 g, 4.78 mmol) in 1,4-dioxane (25 mL) at room temperature was added sodium methoxide (271 mg, 5.02 mmol). After 19 h, the reaction was added additional 271 mg of sodium methoxide and was continued to stir for 6 h. The reaction was filtered and the filtrate was concentrated to give 915 mg (93% crude) 5-chloro-4-methoxy-2-methoxymethyl-2H-pyridazin-3-one.

Step 3.

To a round-bottom flask was added 5-chloro-4-methoxy-2-methoxymethyl-2H-pyridazin-3-one (902 mg, 4.41 mmol), (R)-2-methyl-1-{3-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenoxy]-propyl}-pyrrolidine (1.67 g, 4.85 mmol), tetrakis(triphenylphosphine)palladium(0) (510 mg, 0.44 mmol), potassium carbonate (2.34 g, 22.0 mmol), 1,2-dimethoxyethane (15 mL) and water (15 mL). The reaction mixture was flushed with nitrogen for 30 min and was then heated to reflux for 21 h. After cooled to room temperature, the reaction was extracted with CH₂Cl₂ (100 mL, 50 mL). The combined organic layers were washed with water (50 mL), brine, dried (Na₂SO₄), and concentrated. Purification by column chromatography (5% MeOH in CH₂Cl₂) to give 744 mg (43.6%) of example 235 (4-methoxy-2-methoxymethyl-5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one) as an oil. MS m/z 388 (M+H).

Example 236

Step 1.

To a stirred solution of 4,5-dichloro-2-methoxymethyl-2H-pyridazin-3one (500 mg, 2.39 mmol) in methanol (12 mL) at room temperature was added sodium methoxide (258 mg, 4.78 mmol). After stirred for 2 h, the reaction was concentrated. To this residue was added water (20 mL), then extracted with CH₂Cl₂ (2×50 mL). The combined organic layer was dried (Na₂SO₄) and concentrated to give 480 mg (98%) 4-chloro-5-methoxy-2-methoxymethyl-2H-pyridazin-3-one.

Step 2.

To a round-bottom flask was added 4-chloro-5-methoxy-2-methoxymethyl-2H-pyridazin-3-one (480 mg, 2.34 mmol), (R)-2-methyl-1-{3-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenoxy]-propyl}-pyrrolidine (890 mg, 2.60 mmol), tetrakis(triphenylphosphine)palladium(0) (270 mg, 0.23 mmol), potassium carbonate (1.24 g, 11.7 mmol), 1,2-dimethoxyethane (15 mL), and water (15 mL). The reaction mixture was flushed with nitrogen for 20 min and was then heated to reflux for 24 h. After cooled to room temperature, the reaction was extracted with CH₂Cl₂ (2×50 mL). The combined organic layers was washed brine, dried (Na₂SO₄), and concentrated. Purification by column chromatography (8% MeOH in CH₂Cl₂) to give 250 mg (26%) example 236 (5-methoxy-2-methoxymethyl-4-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one). Mp 44-45° C. MS m/z 388 (M+H).

Example 237

To a round-bottom flask was added example 231 (5-Methoxy-2-methoxymethyl-4-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one) (1.07 g, 2.76 mmol), methanol (10 mL), and concentrated HCl solution (10 mL). The reaction was heated to reflux for 3 days. After cooled to room temperature, the reaction was neutralized with 10 N NaOH then 5% NaOH solution to pH 7. The reaction was concentrated and the residue was washed with CH₂Cl₂ (100 mL). The CH₂Cl₂ layer was concentrated. Purification by column chromatography (15% MeOH in CH₂Cl₂) to give 350 mg (37%) of 5-methoxy-4-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one. The product was converted to its hydrochloride salt. Mp 135-140. MS m/z 344 (M+H).

Example 238

Step 1.

To a round-bottom flask was added 1-[4-(3-chloro-propoxy)-phenyl]-ethanone (10.0 g, 47.0 mmol), morpholine (6.15 mL, 70.5 mmol), sodium iodide (7.05 g, 47.0 mmol), potassium carbonate (19.5 g, 141 mmol), and acetonitrile (100 mL). The reaction mixture was heated to reflux for 23 h. The reaction was cooled to room temperature and was diluted with methylene chloride (100 mL). The reaction was filtered and the filtrate was concentrated. Purification by column chromatography (2% MeOH in CH₂Cl₂) to give 10.5 g (85%) of 6-[4-(3-morpholin-4-yl-propoxy)-phenyl]-2H-pyridazin-3-one.

Step 2.

To a round-bottom flask was added 6-[4-(3-morpholin-4-yl-propoxy)-phenyl]-2H-pyridazin-3-one (5.00 g, 19.0 mmol), oxo-acetic acid, hydrate (3.51 g, 38.1 mmol), and acetic acid (15 mL). The reaction was heated to 111° C. for 2.5 h. After cooled to 0° C., the reaction was added water (25 mL) and NH₄OH solution until pH˜6. To this solution was added hydrazine hydrate (2.76 mL, 57.0 mmol) and was heated to reflux for 20 h (during which additional 3 eq of hydrazine hydrate was added). The reaction was cooled to room temperature and concentrated. Purification by column chromatography (20% MeOH in CH₂Cl₂) gave 2.53 g (42%) of example 238 6-[4-(3-morpholin-4-yl-propoxy)-phenyl]-2H-pyridazin-3-one.

The following examples were prepared. Example Structure Mp (° C.) MS m/z 238

156-159 316 (M + H) 239

156-158 314 (M + H) 240

154-157 300 (M + H) 241

<50 314 (M + H) 242

95-98 328 (M + H)

Example 243

Step 1.

To a round-bottom flask was added phenol (5.0 g, 53.1 mmol), 1-bromo-3-chloropropane (5.52 mL, 55.8 mmol), potassium carbonate (22.0 g, 159 mmol), and acetonitrile (100 mL). The reaction mixture was heated to reflux for 15 h. To this reaction was then added (R)-2-methyl-pyrrolidine hydrochloride (12.9 g, 106 mmol) and sodium iodide (7.96 g, 53.1 mmol) at room temperature. The reaction was continued to reflux for 24 h. After cooled to room temperature, the reaction was filtered through a pad of Celite eluted with CH₂Cl₂ (100 mL). The filtrate was concentrated. Purification by column chromatography (5% MeOH in CH₂Cl₂) to give 9.02 g (77%) of (R)-2-methyl-1-(3-phenoxy-propyl)-pyrrolidine.

Step 2.

To a stirred solution of (R)-2-methyl-1-(3-phenoxy-propyl)-pyrrolidine (1.10 g, 5.02 mmol) and 3-oxa-bicyclo[3.1.0]hexane-2,4-dione (562 mg, 5.02 mmol) in 1,2-dichloroethane (25 mL) at 0° C. was added aluminum trichloride (2.01 g, 15.0 mmol) in small portions. The reaction was heated at 80° C. for 18 h. After cooled to room temperature, the reaction was added crushed ice followed by concentrated HCl solution to break down the complex. The water layer was separated from the organic layer. To this water solution was added hydrazine hydrate (1 mL, 20.6 mmol) and was heated to reflux for 4 h. The reaction was cooled to room temperature and concentrated. Purification by column chromatography (10% MeOH in CH₂Cl₂) gave 1.38 g (76%) of example 243 (5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one).

The following examples were synthesized. The racemic isomers of example 243 were separated into two enantiomers example 246 and example 247 and example 244 were separated into two enantiomers example 248 and example 249 by chiral chromatography using chiralPak and 0.1% diethylamine in methanol. Example Structure Mp (° C.) MS m/z 243

136-139 HCl 328 (M + H) 244

79-81 340 (M + H) 245

112-115 342 (M + H) 246 single isomer

210-211 HCl 328 (M + H) 247 single isomer

197-198 HCl 328 (M + H) 248 single isomer

186-187 340 (M + H) 249 single isomer

Examples 250-254 were prepared as HCl salts following the method of example 243 and example 244. Example Structure Mp (° C.) MS m/z 250

246-248 368 (M + H) 251

110-112 382 (M + H) 252

243-245 354 (M + H) 253

147-149 434 (M + H) 254

110-121 422 (M + H) 260

264-266 HCl 368 (M + H) 261

288-290 HCl

Example 255

Step 1

4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenol (1.00 g, 4.50 mmol) and anhydrous potassium carbonate (2.20 g, 15.90 mmol) were taken up in racemic epibromohydrin (45 mL).

Reaction mixture was refluxed for 12 h. Potassium carbonate was filtered off and epibromohydrin was evaporated under vacuum. Purification of the product using ISCO silica gel chromatography (hexanes/ethyl acetate 9:1) gave a white solid 1.25 g.

Step 2

The product from step 1 (0.50 g, 1.80 mmol) and piperidine (0.23 g, 2.70 mmol) were dissolved in EtOH and refluxed for 5 h. The solvent was evaporated and the product was purified by ISCO silica gel chromatography eluting with EtOAc/MeOH 9:1 to give product as a white solid 0.49 g (75%).

Step 3

THF anhydrous 15 mL was added to Pd(OAc)₂ (0.08 g, 0.35 mmol) and triphenylphosphine (0.38 g, 1.40 mmol) under N₂. The reaction was stirred for 5 min and 3,6-dichloropyridazine (1.00 g, 6.70 mmol) was added and reaction mixture was stirred for another 5 min. The product from step 2 (1-piperidin-1-yl-3-[4-(4,4,5,5-tetramethyl-[1,3,2]-dioxaborolan-2-yl)phenoxy]-propan-2-ol) (0.49 g, 1.35 mmol) in 9 mL of anhydrous THF and 5 mL of EtOH was added dropwise, followed by 15 mL of saturated NaHCO₃.

The reaction mixture was heated at 82° C. overnight. The solvent was removed and the residue was taken up in methylene chloride and washed with H₂O and saturated NaCl, dried over Na₂SO₄ and was evaporated. The product was purified by ISCO silica gel chromatography eluting with EtOAc/MeOH 9:1 to obtain 0.22 g (46%).

Step 4

The product from step 3 (0.18 g, 0.50 mmol) in 7 mL of glacial acetic acid and NaOAc (0.02 g, 0.25 mmol) was heated to 115° C. for 2 h. The solvent was coevaporated with toluene and the residue was taken up in MeOH and catalytic amount of K₂CO₃ was added. After 1 h at reflux, the solvent was evaporated and the product was purified by ISCO silica gel chromatography eluting with EtOAc/MeOH 9:1 to give a white solid 0.09 g (82%); Mp 185° C.; MS m/z 330 (M+H).

Example 256

Example 256 was synthesized using the method for example 255 to give a white solid 0.07 g (54%); Mp 153° C.; MS m/z 330 (M+H).

Example 257

Example 257 was synthesized using the method for example 256 except using (S)-(+)-epichlorohydrin to give example 257 as a white solid 0.16 g (46%); Mp 156° C.; MS m/z 330 (M+H).

Example 258

Example 258 was synthesized using the method for example 256 except using (R)-(−)-epichlorohydrin to give example 258 as a white solid 0.16 g, (44%); Mp 147° C.; MS m/z 330 (M+H).

Example 259

Example 259 was synthesized using the method for example 255 using (R)-(−)-epichlorohydrin to give example 259 as a white solid 0.14 g, (48%); Mp 167° C.; MS m/z 330 (M+H).

Utility

The compounds of the present invention are useful, inter alia, as therapeutic agents. Particularly, the compounds are useful for interacting with the H₃ receptor. In one embodiment, the present invention provides a method for treating or preventing diseases and disorders, such as those disclosed herein, which comprises administering to a subject in need of such treatment or prevention a therapeutically effective amount of a compound of the present invention.

In an additional embodiment, the present invention provides a method for inhibiting H₃ activity comprising providing a compound of the present invention in an amount sufficient to result in effective inhibition. Particularly, the compounds of the present invention can be administered to treat such diseases and disorders such as narcolepsy or sleep/wake disorders, feeding behavior, eating disorders, obesity, cognition, arousal, memory, mood disorders, mood attention alteration, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease/dementia, schizophrenia, pain, stress, migraine, motion sickness, depression, psychiatric disorders, epilepsy, gastrointestinal disorders, respiratory disorders (such as asthma), inflammation, and myocardial infarction. In certain embodiments, the compounds can be administered to treat narcolepsy or sleep/wake disorders, obesity, cognition, attention deficit hyperactivity disorder (ADHD), and dementia. In other embodiments, the compounds can be administered to treat narcolepsy or sleep/wake disorders, or they can used to treat obesity, or they can used to treat cognition, or they can used to treat attention deficit hyperactivity disorder (ADHD), or they can used to treat dementia.

The inhibition of enzymatic activity by the compounds of the present invention can be determined using, for example, the following assays as set forth below. They are not intended, nor are they to be construed, as limiting the scope of the disclosure.

Rat H₃ Assays:

Cell line development and membrane preparation. The rat H₃ receptor cDNA was PCR amplified from reverse-transcribed RNA pooled from rat thalamus, hypothalamus, striatum and prefrontal cortex with a sequence corresponding to bp #338-1672 of Genbank file #NM_(—)053506, encoding the entire 445-amino-acid rat histamine H₃ receptor. This was engineered into the pIRES-neo3 mammalian expression vector, which was stably transfected into the CHO-A3 cell line (Euroscreen, Belgium), followed by clonal selection by limiting dilution. Cells were harvested and cell pellets were frozen (−80° C.). Cell pellets were resuspended in 5 mM Tris-HCl, pH 7.5 with 5 nM EDTA and a cocktail of protease inhibitors (Complete Protease Inhibitior Tablets, Roche Diagnostics). Cells were disrupted using a polytron cell homogenizer and the suspension was centrifuged at 1000×g for 10 minutes at 4° C. The pellet was discarded and the supernatant centrifuged at 40,000×g for 30 min at 4° C. This membrane pellet was washed in membrane buffer containing 50 mM Tris-HCl, pH 7.5 with 0.6 mM EDTA, 5 mM MgCl₂ and protease inhibitors, recentrifuged as above and the final pellet resuspended in membrane buffer plus 250 mM sucrose and frozen at −80° C.

Radioligand Binding. Membranes were resuspended in 50 mM Tris HCl (pH 7.4), 5 mM MgCl₂, 0.1% BSA. The membrane suspensions (10 μg protein per well) were incubated in a 96 well microtiter plate with [³H]-N-alpha-methylhistamine (approximately 1 nM final concentration), test compounds at various concentrations (0.01 nM-30 μM) and scintillation proximity beads (Perkin Elmer, FlashBlueGPCR Scintillating Beads) in a final volume of 80 μl for 4 hours at room temperature, protected from light. Non-specific binding was determined in the presence of 10 μM clobenpropit. Radioligand bound to receptor, and therefore in proximity to the scintillation beads, was measured using a MicroBeta scintillation counter.

GTPγS Binding. Membranes were resuspended in 20 mM HEPES pH 7.4 containing: 1 mM EDTA, 0.17 mg/ml dithiothreitol, 100 mM NaCl, 30 μg/ml saponin and 5 mM MgCl₂. For measurement of inverse agonist activity, increasing concentrations of test compounds were incubated in a 96 well microtiter plate with 10 μg/well membrane protein, 5 μM GDP, scintillation proximity beads (Perkin Elmer, FlashBlueGPCR Scintillating Beads) and [³⁵S]-GTPγS (0.1 nM final concentration). Following incubation for 45 minutes in the dark at room temperature, the microtiter plate was centrifuged at 1000×g for 5 minutes and radioactivity bound to the membranes was counted using a MicroBeta scintillation counter. Non-specific binding was measured in the presence of 10 μM GTP. A decrease in bound [³⁵S]-GTPγS is indicative of H₃ receptor inverse agonist activity in this assay. Antagonist activity of test compounds was determined in a similar experiment under the following conditions. Membranes were resuspended in 20 mM HEPES pH 7.4 containing: 1 mM EDTA, 0.17 mg/ml dithiothreitol, 200 mM NaCl, 30 μg/ml saponin and 20 mM MgCl₂. The membranes were incubated at 10 μg/well membrane protein in a microtiter plate with increasing concentrations of test compounds, 20 μM GDP, scintillation proximity beads and [³⁵S]-GTPγS (0.11 nM final concentration) plus 30 nM R-alpha-methylhistamine. The microtiter plates were incubated and processed as described above. A decrease in R-alpha-methylhistamine stimulated [³⁵S]-GTPγS binding is indicative of H₃ receptor antagonist activity in this assay.

Human H₃ Assays:

Methods: CHO cells stably expressing the human H₃ receptor (GenBank: NM_(—)007232) were harvested and cell pellets were frozen (−80° C.). Cell pellets were resuspended in 5 mM Tris-HCl, pH 7.5 with 5 nM EDTA and a cocktail of protease inhibitors (Complete Protease Inhibitior Tablets, Roche Diagnostics). Cells were disrupted using a polytron cell homogenizer and the suspension was centrifuged at 1000×g for 10 minutes at 4° C. The pellet was discarded and the supernatant centrifuged at 40,000×g for 30 min at 4° C. This membrane pellet was washed in membrane buffer containing 50 mM Tris-HCl, pH 7.5 with 0.6 mM EDTA, 5 mM MgCl₂ and protease inhibitors, recentrifuged as above and the final pellet resuspended in membrane buffer plus 250 mM sucrose and frozen at −80° C.

Radioligand Binding. Membranes were resuspended in 50 mM Tris HCl (pH 7.4), 5 mM MgCl₂, 0.1% BSA. The membrane suspensions (10 μg protein per well) were incubated in a 96 well microtiter plate with [³H]-N-alpha-methylhistamine (approximately 1 nM final concentration), test compounds at various concentrations (0.01 nM-30 μM) and scintillation proximity beads (Perkin Elmer, FlashBlueGPCR Scintillating Beads) in a final volume of 80 μl for 4 hours at room temperature, protected from light. Non-specific binding was determined in the presence of 10 μM clobenpropit. Radioligand bound to receptor, and therefore in proximity to the scintillation beads, was measured using a MicroBeta scintillation counter.

GTPγS Binding. Membranes were resuspended in 20 mM HEPES pH 7.4 containing: 1 mM EDTA, 0.17 mg/ml dithiothreitol, 100 mM NaCl, 30 μg/ml saponin and 5 mM MgCl₂. For measurement of inverse agonist activity, increasing concentrations of test compounds were incubated in a 96 well microtiter plate with 10 μg/well membrane protein, 5 μM GDP, scintillation proximity beads (Perkin Elmer, FlashBlueGPCR Scintillating Beads) and [³⁵S]-GTPγS (0.1 nM final concentration). Following incubation for 45 minutes in the dark at room temperature, the microtiter plate was centrifuged at 1000×g for 5 minutes and radioactivity bound to the membranes was counted using a MicroBeta scintillation counter. Non-specific binding was measured in the presence of 10 μM GTP. A decrease in bound [³⁵S]-GTPγS is indicative of H₃ receptor inverse agonist activity in this assay. Antagonist activity of test compounds was determined in a similar experiment under the following conditions. Membranes were resuspended in 20 mM HEPES pH 7.4 containing: 1 mM EDTA, 0.17 mg/ml dithiothreitol, 200 mM NaCl, 30 μg/ml saponin and 20 mM MgCl₂. The membranes were incubated at 10 μg/well membrane protein in a microtiter plate with increasing concentrations of test compounds, 20 μM GDP, scintillation proximity beads and [³⁵S]-GTPγS (0.1 nM final concentration) plus 30 nM R-alpha-methylhistamine. The microtiter plates were incubated and processed as described above. A decrease in R-alpha-methylhistamine stimulated [³⁵S]-GTPγS binding is indicative of H₃ receptor antagonist activity in this assay.

Other assays that may be used in connection with the present invention are set forth below. Examples of the present invention can be tested in the following in vivo models:

Evaluation of Wake Promoting Activity in Rats

The methodology utilized for evaluating wake promoting activity of test compounds is based on that described by Edgar and Seidel, Journal of Pharmacology and Experimental Therapeutics, 283:757-769, 1997, and incorporated herein in its entirety by reference. Compounds of the invention either have demonstrated or are expected to demonstrate utility for wake promoting activity.

Dipsogenia Model: Inhibition of histamine agonist-induced water drinking in the rat. Histamine, and the H₃-selective agonist (R)-α-methylhistamine (RAMH) induce water drinking behavior in the rat when administered either peripherally or centrally (Kraly, F. S., June, K. R. 1982 Physiol. Behav. 28: 841.; Leibowitz, S. F. 1973 Brain Res. 63:440; Ligneau X., Lin, J-S., Vanni-Mercier G., Jouvet M., Muir J. L., Ganellin C. R., Stark H., Elz S., Schunack W., Shwartz, J-C. 1998 J Pharmcol. Exp. Ther. 287:658-66.; Clapham, J. and Kilpatrick G. J. 1993 Eur. J. Pharmacol. 232:99-103) an effect which is blocked by H₃ receptor antagonists thioperamide and ciproxifan. Compounds of the invention either have demonstrated or are expected to block RAMH induce water drinking behavior.

Novel object discrimination: Novel object discrimination (NOD; also referred to as novel object recognition) is an assay for short-term visual recognition memory that was first described by Ennaceur and Delacour (Ennaceur, A. and Delacour, J. (1988) Behav Brain Res 31: 47-59).

Social recognition: Social recognition (SR) is an assay for short-term social (olfactory) memory that was first described by Thor and Holloway (1982). Thor, D. and Holloway, W. (1982) J Comp. Physiolog Psychcol 96: 1000-1006.

Table A lists the Human and H₃ binding data for Examples 1-78 and 81 of the present invention. TABLE A H3 Pyridazinone Binding data Human H₃ Rat H₃ Example Ki nM Ki nM 1 A A 2 A B 3 A A 4 A A 5 A A 6 A A 7 A A 8 A A 9 A A 10 A B 81 A A 11 A A 12 A A 13 A A 14 A A 15 B C 16 A A 17 A A 18 A A 19 A A 20 A A 21 A C 22 A A 23 A B 24 A A 25 B D 26 A D 27 D D 28 A B 29 A A 30 A C 31 A B 32 A A 33 A B 34 A A 35 B B 36 B D 37 A B 38 A A 39 A A 40 A A 41 A A 42 B B 43 A A 44 A B 45 A A 46 A B 47 A A 48 A A 49 A A 50 A A 51 A D 52 A A 53 A A 54 A A 55 A A 56 A A 57 A A 58 A A 59 A A 60 A A 61 A A 62 D D 63 D D 64 A B 65 D D 66 D D 67 B D 68 A B 69 B D 70 B B 71 B C 72 A A 73 C D 74 A A 75 A A 76 A A 77 A B 78 A A 79 80 Binding constants (K_(i)) for Examples 1 to 78 and 81 in the Human H₃ and Rat H₃ methods described herein are expressed by letter descriptor to indicate the following ranges: A is 0.1-100 nM; B is 101-500 nM; C is 501-1000 nM; and D is >1000 nM.

Table B lists the Human and Rat H₃ binding data for Examples 82-262 of the present invention. The Example number in the Table correspond to the Actual Example numbers in the Examples Section. TABLE B H3 Pyridazinone Binding data human H3 rat H3 Ki Example Ki (nM) (nM) 81 A A 82 A A 83 A A 84 A A 85 A A 86 A A 87 A A 88 A A 89 A A 90 A 5 91 A A 92 A A 93 A A 94 A A 95 A A 96 A A 97 A A 98 A A 99 A A 100 A A 101 A A 102 D D 103 A A 104 A A 105 D D 106 A A 107 A A 108 A A 109 A A 110 A A 111 A A 112 A 113 D D 114 A A 115 A A 116 A A 117 A A 118 A A 119 A A 120 A B 121 A A 122 A A 123 A A 124 A A 125 B C 126 B C 127 C C 128 A A 129 A B 130 B B 131 A A 132 A A 133 A A 134 A A 135 B B 136 A B 137 A A 138 A A 139 A A 140 B C 141 A A 142 A B 143 A C 143 A A 144 A A 145 A A 146 A A 147 A B 148 A A 149 A A 150 A A 151 A A 152 A A 153 A A 154 A A 155 A A 156 A A 157 A A 158 A A 159 D D 160 B B 161 D D 162 C D 163 A A 164 A A 165 D D 166 A A 167 A A 168 A A 169 A A 170 A A 171 A A 172 A A 173 A A 174 A A 175 A A 176 A A 177 A A 178 A A 179 A A 180 A A 181 A B 182 A A 183 A A 184 A A 185 A A 186 A A 187 A A 188 A A 189 A A 190 A A 191 A A 192 4 A 193 A A 194 A A 195 A A 196 A A 197 A A 198 A A 199 A A 200 A A 201 A B 202 A A 203 A A 204 A A 205 B B 206 D D 207 A A 208 A A 209 A A 210 A A 211 A A 212 A A 213 B B 214 A A 215 A A 216 A A 217 A A 218 A A 219 A A 220 A A 221 A A 222 A A 223 A A 224 A A 225 A A 226 A A 227 A A 228 A B 229 A C 230 A A 231 A A 232 A A 233 A B 234 A A 235 A A 236 A A 237 A A 238 D D 239 A A 240 A A 241 B B 242 A B 243 A A 244 A A 245 A A 246 A A 247 A A 248 A A 249 A A 250 A A 251 A A 252 A A 253 A A 254 A A 255 B B 256 A B 257 A A 258 A A 259 B B 260 A A 261 A A 262 A B Binding constants (K_(i)) for Examples 1 to 78 and 81 in the Human H₃ and Rat H₃ methods described herein are expressed by letter descriptor to indicate the following ranges: A is 0.1-100 nM; B is 101-500 nM; C is 501-1000 nM; and D is >1000 nM.

Compounds of the invention either have demonstrated or are expected to demonstrate inhibition of H₃ and thereby for utility for treatment of the indications described herein.

Publications cited throughout this disclosure are incorporated in their entirety herein by reference.

REFERENCES

-   Alguacil L. F.; Perez-Garcia C. Histamine H₃ Receptor: A potential     drug target for the treatment of central nervous systems disorders.     Current Drug Targets—CNS & Neurological Disorders 2003, 2, 303-131. -   Arrang, J. M.; Garbarg, M.; Schwartz, J. C., Auto-inhibition of     brain histamine release mediated by a novel class (H₃) of histamine     receptor. Nature 1983, 302, (5911), 832-7. -   Celanire, S.; Wijtmans, M.; Talaga, P.; Leurs, R.; de Esch, I. J.,     Keynote review: histamine H₃ receptor antagonists reach out for the     clinic. Drug Discov Today 2005, 10, (23-24), 1613-27. -   Chazot P. L.; Hann V. H₃ histamine receptor isoforms: New     therapeutic targets in the CNS? Current Opinions in Investigational     Drugs 2001, 2, 1428-1431. -   Chen Z. Effect of histamine H₃-receptor antagonist clobenprobit on     spatial memory of radial maze performance in rats. Acta Pharmacol     Sin 2000, 21, 905-910. -   Esbenshade, T. A.; ox, G. B.; Cowart, M. D. Histamine H₃ receptor     antagonists: Preclinical promise for treating obesity and cognitive     disorders. Molecular interventions 2006, 6, 77-88. -   Fox G. B.; Pan J. B.; Esbenshade T. A.; Bennani Y. L.; Black L. A.;     Faghih R.; Hancock A. A.; Decker M. W. Effects of histamine H₃     receptor ligands GT-2331 and ciproxifan in a repeated acquisition     response in the spontaneously hypertensive rat pup. Behav. Brain     Res. 2002, 131, 151-161. -   Fox G. B.; Pan J. B.; Radek R. J.; Lewis A. M.; Bitner R. S.;     Esbenshade T. A.; Faghih R.; Bennani Y. L.; Williams W.; Yao B. B.     Decker M. W.; Hancock A. A. Two novel and selective nonimidazole H₃     receptor Antagonists A-304121 and A-317920: II. In vivo behavioral     and neurophysiological characterization. J. Pharmacol. Exper. Ther.     2003, 305, 897-908. -   Hancock, A. A.; Esbenshade, T. A.; Krueger, K. M.; Yao, B. B.,     Genetic and pharmacological aspects of histamine H₃ receptor     heterogeneity. Life Sci 2003, 73, (24), 3043-72. -   Hancock, A. A.; Fox, G. B. Perspectives on cognitive domains, H₃     receptor ligands and neurological disease. Expert Opin. Investig.     Drugs, 2004, 13, 1237-1248. -   Komater V. A.; Browman K. E.; Curzon P.; Hancock A. A., Decker M.     W.; Fox B. H₃ receptor blockade by thioperamide enhances cognition     in rats without inducing locomotor sensitization. Psychopharmacology     2003, 167, 363-372. -   Leurs R.; Blandina P.; Tedford C.; Timmerman H. Therapeutic     potential of histamine H₃ receptor agonists and antagonists. Trends     in Pharmacology 1998, 19, 177-183. -   Leurs, R.; Bakker, R. A.; Timmerman, H.; de Esch, I. J., The     histamine H₃ receptor: from gene cloning to H₃ receptor drugs. Nat     Rev Drug Discov 2005, 4, (2), 107-20. -   Lin, J. S.; Sakai, K.; Vanni-Mercier, G.; Arrang, J. M.; Garbarg,     M.; Schwartz, J. C.; Jouvet, M., Involvement of histaminergic     neurons in arousal mechanisms demonstrated with H₃-receptor ligands     in the cat. Brain Res 1990, 523, (2), 325-30. -   Lloyd G. K.; Williams M. Neuronal nicotinic acetylcholine receptors     as novel drug targets. J Pharmacol Exp Ther. 2000, 292, 461-467. -   Monti, J. M.; Jantos, H.; Ponzoni, A.; Monti, D., Sleep and waking     during acute histamine H₃ agonist BP 2.94 or H₃ antagonist     carboperamide (MR16155) administration in rats.     Neuropsychopharmacology 1996, 15, 31-5. -   Orsetti M.; Ferretti C.; Gamalero S. R.; Ghi P. Histamine     H₃-receptor blockade in the rat nucleus basalis magnocellularis     improves place recognition memory. Psychopharmacology 2002, 159,     133-137. -   Parmentier R.; Ohtsu H.; Djebbara-Hannas Z.; Valatx J-L.; Watanabe     T.; Lin J-S. Anatomical, physiological, and pharmacological     characteristics of histidine decarboxylase knock-out mice: evidence     for the role of brain histamine in behavioral and sleep-wake     control. J. Neurosci. 2002, 22, 7695-7711. -   Passani, M. B.; Lin, J. S.; Hancock, A.; Crochet, S.; Blandina, P.,     The histamine H₃ receptor as a novel therapeutic target for     cognitive and sleep disorders. Trends Pharmacol Sci 2004, 25,     618-25. -   Repka-Ramirez M. S, New concepts of histamine receptors and actions.     Current Allergy and Asthma Reports 2003, 3, 227-231. -   Ritz A.; Curley J.; Robertson J.; Raber J. Anxiety and cognition in     histamine H₃ receptor −/− mice. Eur J Neurosci 2004, 19, 1992-1996. -   Rouleau, A.; Heron, A.; Cochois, V.; Pillot, C.; Schwartz, J. C.;     Arrang, J. M., Cloning and expression of the mouse histamine H₃     receptor: evidence for multiple isoforms. J Neurochem 2004, 90,     1331-8. -   Vanni-Merci G.; Gigout S.; Debilly G.; Lin J. S. Waking selective     neurons in the posterior hypothalamus and their response to     histamine H₃-receptor ligands: an electrophysiological study in     freely moving cats. Behav Brain Res 2003, 144, 227-241. -   Witkin, J. M.; Nelson, D. L., Selective histamine H₃ receptor     antagonists for treatment of cognitive deficiencies and other     disorders of the central nervous system. Pharmacol Ther 2004, 103,     1-20. -   Yao, B. B.; Sharma, R.; Cassar, S.; Esbenshade, T. A.; Hancock, A.     A., Cloning and pharmacological characterization of the monkey     histamine H₃ receptor. Eur J Pharmacol 2003, 482, (1-3), 49-60. 

1. A compound according to formula I*:

or a stereoisomeric form, mixture of stereoisomeric forms, or a pharmaceutically acceptable salt thereof; wherein: X and X^(a) are each independently CH or N; Y is S(O)_(q), O, or NR¹⁵; R¹ is NR¹⁰R¹¹ or a 4- to 9-membered heterocycloalkyl ring containing 1 or 2 nitrogen atoms and optionally substituted with 1 to 3 R²⁰ groups; R² is

wherein: when X and X^(a) are both CH, then R² is meta or para to the Y—(CHR⁴)_(m)—R¹ group; and when either X or X^(a) are N, then R² is para to the Y—(CHR⁴)_(m)—R¹ group; each R³ is: independently H, F, Cl, Br, I, OR²¹, NR²³R²⁴, NO₂, CN, CF₃, C₁-C₆alkyl, C(═O)R²¹, CO₂R²¹, or C(═O)NR²³R²⁴; or when R³ is ortho to R², and R² is (i), (ii), (iv), (vi), or (ix), then R³ and R¹⁴ taken together may form —(CH₂)_(s)—, —CH₂Z-, -ZCH₂—, -ZCH₂CH₂— or CH₂CH₂Z-; wherein Z is O, S(O)_(y), or NR²⁷; or when R³ is ortho to R², and R² is (iv), (v), or (viii), then R³ and R¹³ taken together may form —(CH₂)_(s)—, —CH₂Z-, -ZCH₂—, -ZCH₂CH₂— or CH₂CH₂Z-; or when R³ is ortho to R², and R² is (viii), then R³ and R^(13b) taken together may form —(CH₂)_(s)—, —CH₂Z-, -ZCH₂—, -ZCH₂CH₂— or CH₂CH₂Z-; or when R¹³ is ortho to X^(a) and R² is ortho to R³ and meta to X^(a), then R² and R³ taken together may form:

each R⁴ is independently H, C₁-C₆alkyl, or OR²¹, wherein the alkyl group is optionally substituted with 1 to 3 R²⁰ groups; R¹⁰ and R¹¹ are each independently H, C₁-C₆alkyl, or C₃-C₆cycloalkyl, wherein the alkyl or cycloalkyl group is optionally substituted with 1 to 3 R²⁰ groups; R² is H, C₁-C₆alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocycloalkyl, C(═O)R²⁷, or CO₂R²⁷, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, or heterocycloalkyl group is optionally substituted with 1 to 3 R²⁰ groups; R¹³ and R¹⁴ are each independently H, C₁-C₆alkyl, aryl, arylalkyl C₁-C₆alkoxyl, S(═O)_(y)—C₁-C₆alkyl, cycloalkyl, heterocycloalkyl, or heteroaryl; R^(13a), R^(13b), R^(13c), and R^(14a) are each independently H, C₁-C₆alkyl; or R¹³ and R¹⁴, taken together with the carbon atoms through which they are connected form a fused phenyl, thienyl, pyrrolyl, oxazolyl, pyridinyl, or C₃-C₆cycloalkyl ring; or R^(13b) and R¹⁴, or R¹³ and ^(14a), or R^(13b) and ^(14a), or R^(13c) and R^(14a), taken together with the carbon atoms through which they are connected form a fused C₃-C₆cycloalkyl ring; or R¹³ and R^(13a), or R¹⁴ and R^(14a), taken together with the carbon atom to which they are attached form a C₃-C₈cycloalkyl ring; provided that no more than one pair of R¹³ and R¹⁴R^(13b) and R¹⁴, R¹³ and R^(14a), R^(13b) and R^(14a), R^(13c) and R^(14a), R¹³ and R^(13a), and R¹⁴ and R^(14a) are taken together with the carbon atoms through which they are connected or to which they are attached to form a ring; and wherein the fused phenyl, thienyl, pyrrolyl, oxazolyl, pyridinyl, or cycloalkyl ring is optionally substituted with 1 to 3 R²⁰ groups; R¹⁵ is H, C₁-C₆ alkyl, C(═O)R²⁵, CO₂R²⁵; R²⁰ at each occurrence is independently, H, F, Cl, Br, I, OR²¹, OR²², NR²³R²⁴, NHOH, NO₂, CN, CF₃, C₁-C₆ alkyl optionally substituted with OR²⁶, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₇cycloalkylC₀-C₄alkyl, 3- to 7-membered heterocycloalkylC₀-C₄alkyl, phenyl, 5- or 6-membered heteroarylC₀-C₄alkyl, arylalkyl, (═O), C(═O)R²¹, CO₂R²¹, OC(═O)R²¹, C(═O)NR²³R²⁴, NR²⁷C(═O)R²¹, NR²⁷C(═O)OR²¹, OC(═O)NR²³R²⁴, NR²⁷C(═S)R²¹, or S(O)_(q)R²¹; each R²¹ is independently H, C₁-C₆alkyl, aryl, or arylalkyl; each R²² is independently the residue of an amino acid after the hydroxyl group of the carboxyl group is removed; each R²³ and R²⁴ is independently selected from H, C₁-C₆alkyl, and aryl, or R²³ and R²⁴, together with the nitrogen atom to which they are attached, form a 3 to 7 membered heterocyclic ring optionally substituted with ═O; R²⁵ is C₁-C₆alkyl, aryl, or alkylaryl; R²⁶ is H, C₁-C₆alkyl, aryl, or alkylaryl; R²⁷ is H or C₁-C₆alkyl; m is 1, 2, 3, 4, or 5 when R¹ is attached via a nitrogen atom, and m is 0, 1, 2, 3, 4, or 5 when R¹ is attached via a carbon atom; n is 1, 2, or 3; q is 0, 1, or 2; s is 1, 2, or 3; and y is 0, 1, or 2; provided that: (1) the compound is other than 6-[4-(3-Diethylamino-propoxy)-phenyl]-4,5-dihydro-2H-pyridazin-3-one; and (2) when X^(a) and X are each CH, Y is O, n is 0, each R⁴ is H, m is 2, 3, or 4, R¹ is methylamino, hydroxyethylamino, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, and R² is para to the Y—(CHR⁴)_(m)—R¹ group, then R² is other than 4,5-dihydro-2H-pyridazin-3-one-6-yl.
 2. A compound according to claim 1, wherein at least one of X and X_(a) is CH.
 3. A compound according to claim 1, wherein X and X_(a) are each CH.
 4. A compound according to claim 2, wherein Y is O.
 5. A compound according to claim 1, wherein R¹ is a 4- to 9-membered heterocycloalkyl ring containing 1 or 2 nitrogen atoms.
 6. A compound according to claim 5, wherein R¹ is a 4- to 9-membered heterocycloalkyl ring containing 1 nitrogen atom.
 7. A compound according to claim 6, wherein R¹ is a piperidine or pyrrolidine ring, optionally substituted.
 8. A compound according to claim 7, wherein the piperidine or pyrrolidine ring is attached to Y through a ring nitrogen atom.
 9. A compound according to claim 8, wherein the piperidine or pyrrolidine ring is substituted with one or two alkyl groups.
 10. A compound according to claim 7, wherein the piperidine ring is attached to Y through a ring carbon atom.
 11. A compound according to claim 10, wherein the piperidine ring is N-substituted with cycloalkyl.
 12. A compound according to claim 11, wherein the piperidine ring is N-substituted with cyclobutyl.
 13. A compound according to claim 1, wherein R² is para to the Y—(CHR⁴)_(m)—R¹ group.
 14. A compound according to claim 13, wherein R² is (i), (ii), (iv), (vi), (viii), or (ix).
 15. A compound according to claim 13, wherein R¹³ and R¹⁴, taken together with the carbon atoms through which they are connected form a fused phenyl, thienyl, oxazolyl, pyridinyl, or C₃-C₆cycloalkyl ring; or R^(13b) and R¹⁴, or R¹³ and ^(14a), or R^(13b) and ^(14a), or R^(13c) and R^(14a), taken together with the carbon atoms through which they are connected form a fused C₃-C₆cycloalkyl ring; or R¹³ and R^(13a), or R¹⁴ and R^(14a), taken together with the carbon atom to which they are attached form a C₃-C₈cycloalkyl ring; provided that no more than one pair of R¹³ and R¹⁴, R^(13b) and R¹⁴, R¹³ and R^(14a), R^(13b) and R^(14a), R^(13c) and R^(14a), R¹³ and R^(13a), and R¹⁴ and R^(14a) are taken together with the carbon atoms through which they are connected or to which they are attached to form a ring; and wherein the fused phenyl, thienyl, pyrrolyl, oxazolyl, pyridinyl, or cycloalkyl ring is optionally substituted with 1 to 3 R²⁰ groups.
 16. A compound according to claim 14, wherein when R² is (vi), (viii), or (ix), and when R¹³ and R¹⁴, R^(13b) and R¹⁴, or R¹³ and ^(14a) or R^(13b) and ^(14a), or R^(13c) and R^(14a), taken together with the carbon atoms through which they are connected form a fused C₃-C₆cycloalkyl ring; or R¹³ and R^(13a), or R¹⁴ and R^(14a), taken together with the carbon atom to which they are attached form a C₃-C₈cycloalkyl ring; then the cycloalkyl ring is a is C₃-C₄cycloalkyl ring.
 17. A compound according to claim 1, wherein R¹² is H, C₁-C₆alkyl, cycloalkyl, aryl, arylalkyl, or heteroaryl.
 18. A compound according to claim 17, wherein R¹² is H or heteroaryl.
 19. A compound according to claim 18, wherein when R¹² is heteroaryl, said heteroaryl is pyridinyl or thienyl.
 20. A compound according to claim 14, wherein R² is (iv).
 21. A compound according to claim 20, wherein R² is (iv), R¹² is H or heteroaryl, and R¹³ and R¹⁴ are each H or alkyl.
 22. A compound according to claim 21, wherein R² is (iv), R¹² is heteroaryl, and R¹³ and R¹⁴ are each H or alkyl.
 23. A compound according to claim 1, wherein R² is:


24. A compound according to claim 4, wherein R¹³, R¹⁴R^(13a), R^(13b), R^(13c), and R^(14a) are each independently H or C₁-C₆alkyl.
 25. A compound according to claim 24, wherein at least one of R¹³, R¹⁴R^(13a), R^(13b), R^(13c), and R^(14a) is C₁-C₆alkyl.
 26. A compound according to claim 1, wherein R¹⁴ is heteroaryl.
 27. A compound according to claim 4, wherein at least one R³ is F, Cl, Br, or C₁-C₆alkyl.
 28. A compound according to claim 1, wherein R⁴ is H, alkyl or alkoxyl.
 29. A compound according to claim 28, wherein R⁴ is H or alkyl.
 30. A compound according to claim 1, wherein R⁴ is H or C₁alkyl.
 31. A compound according to claim 1, wherein m is 0 or 1 when R¹ is attached to Y through a ring carbon atom.
 32. A compound according to claim 31, wherein m is
 0. 33. A compound according to claim 10, wherein m is 0 or 1 when R¹ is attached to Y through a ring carbon atom.
 34. A compound according to claim 1, wherein m is 3 when R¹ is attached to Y through a ring nitrogen atom.
 35. A compound according to claim 9, wherein m is 3 when R¹ is attached to Y through a ring nitrogen atom.
 36. A compound according to claim 1, wherein s is
 2. 37. A compound according to claim 1, wherein n is 0 or
 1. 38. A compound according to claim 9, wherein R¹ is:


39. A compound according to claim 38, wherein R¹ is:


40. A compound according to claim 38, wherein R²⁰ is F, Cl, CF₃, NR²³R²⁴, or C₁-C₆alkyl optionally substituted with OR²⁶, cycloalkylC₀-C₄alkyl, or heterocycloalkylC₀-C₄alkyl.
 41. A compound according to claim 40, wherein R²⁰ is C₁-C₆alkyl optionally substituted with OR²⁶.
 42. A compound according to claim 1, wherein R²³ and R²⁴ are each independently C₁-C₆alkyl.
 43. A compound according to claim 1, wherein Y—(CHR¹⁴)_(m)—R¹ is:


44. A compound according to claim 4, wherein R² is (iii) and one of R¹³ cyclopropyl.
 45. A compound according to claim 1, wherein when R⁴ is OR²¹, R²¹ is H or C₁-C₆alkyl.
 46. A compound according to claim 14, wherein R² is:


47. A compound according to claim 16, wherein R² is:


48. A compound according to claim 47, wherein R² is:


49. A compound according to claim 14, wherein R² is:

and R^(13a) and R¹³ are each independently C₁-C₃ alkyl.
 50. A compound according to claim 20, wherein R² is:

and R¹² is C₁-C₆ alkyl, aryl, arylalkyl, or heteroaryl.
 51. A compound according to claim 50, wherein R¹² is thienyl or pyridinyl.
 52. A compound according to claim 51, wherein R¹² is pyridin-2-yl.
 53. A compound according to claim 1, selected from the group consisting of: 2-methyl-6-{4-[(R)-2-methyl-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 6-[4-(1-cyclopentyl-piperidin-4-yloxy)-phenyl]-2-methyl-2H-pyridazin-3-one; 6-{3,5-difluoro-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-methyl-2H-pyridazin-3-one; 6-{3-chloro-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-methyl-2H-pyridazin-3-one; 2,6-dimethyl-5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 2,6-dimethyl-5-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 6-methyl-5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 6-methyl-5-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 5-[4-(3-azepan-1-yl-propoxy)-phenyl]-6-methyl-2H-pyridazin-3-one; 2-methyl-5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 2-methyl-5-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 5-[4-(3-azepan-1-yl-propoxy)-phenyl]-2-methyl-2H-pyridazin-3-one; 5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-pyridin-2-yl-2H-pyridazin-3-one; 5-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2-pyridin-2-yl-2H-pyridazin-3-one; 5-[4-(3-azepan-1-yl-propoxy)-phenyl]-2-pyridin-2-yl-2H-pyridazin-3-one; 2-methyl-5-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 2-(6-methyl-pyridin-2-yl)-5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 2-(3-methyl-pyridin-2-yl)-5-{4-[3-((R)-2-methylpyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 6-methyl-5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-pyridin-2-yl-2H-pyridazin-3-one; 6-methyl-2-(3-methyl-pyridin-2-yl)-5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 6-methyl-5-[4-(piperidin-4-yloxy)-phenyl]-2H-pyridazin-3-one; hydrochloride; 5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-6-methyl-2H-pyridazin-3-one; 5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-6-methyl-2-pyridin-2-yl-2H-pyridazin-3-one; 5-[4-(piperidin-4-yloxy)-phenyl]-2H-pyridazin-3-one; 5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-2H-pyridazin-3-one; 5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-6-methyl-2-thiophen-3-yl-2H-pyridazin-3-one; 6-methyl-5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-thiophen-3-yl-2H-pyridazin-3-one; 5-{4-[3-((S)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-pyridin-2-yl-2H-pyridazin-3-one; 5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-6-methyl-4,5-dihydro-2H-pyridazin-3-one; 6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-5-pyridin-2-yl-4,5-dihydro-2H-pyridazin-3-one; 6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-5-pyridin-2-yl-2H-pyridazin-3-one; 6-[4-(piperidin-4-yloxy)-phenyl]-5-pyridin-2-yl-4,5-dihydro-2H-pyridazin-3-one; 6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-5-pyridin-2-yl-4,5-dihydro-2H-pyridazin-3-one; 6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-5-pyridin-2-yl-2H-pyridazin-3-one; 6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-4-methyl-4,5-dihydro-2H-pyridazin-3-one; 5-[6-(1-cyclobutyl-piperidin-4-yloxy)-pyridin-3-yl]-2H-pyridazin-3-one; 2-(2-fluoro-ethyl)-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 6-{3-fluoro-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 6-[3-fluoro-4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 4-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one; 4-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 4-methyl-6-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 4-{4-[3-((S)-2-hydroxymethyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-methyl-5,6,7,8-tetrahydro-2H-phthalazin-1-one; 2-methyl-4-{3-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2,5,6,7-tetrahydro-cyclopenta[d]pyridazin-1-one; 2-methyl-4-[3-(3-piperidin-1-yl-propoxy)-phenyl]-2,5,6,7-tetrahydro-cyclopenta[d]pyridazin-1-one; 4-{3-[3-((S)-2-hydroxymethyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-methyl-2,5,6,7-tetrahydro-cyclopenta[d]pyridazin-1-one; 2-isopropyl-5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 2-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-5-(6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile; 2-[3-(piperidin-1-yl)-propoxy]-5-(6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile; 2-(2-hydroxyethyl)-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 6-{4-[(S)-2-methyl-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 4-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2,5,6,7-tetrahydro-cyclopenta[d]pyridazin-1-one; 6-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 6-[3-methoxy-4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 6-{3-methoxy-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3- one; 6-[2-methyl-4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-pyrimidin-2-yl-2H-pyridazin-3-one; 6-[6-(1-cyclopentyl-piperidin-4-yloxy)-pyridin-3-yl]-2H-pyridazin-3-one; 6-[6-(1-isopropyl-piperidin-4-ylmethoxy)-pyridin-3-yl]-2H-pyridazin-3-one; 6-[6-(1-cyclobutyl-piperidin-4-yloxy)-pyridin-3-yl]-2H-pyridazin-3-one; 6-[6-(1-isopropyl-piperidin-4-yloxy)-pyridin-3-yl]-2H-pyridazin-3-one; 6-[6-(1-cyclopentyl-piperidin-4-yloxy)-pyridin-3-yl]-2-methyl-2H-pyridazin-3-one; 6-[6-(1-cyclobutyl-piperidin-4-yloxy)-pyridin-3-yl]-2-methyl-2H-pyridazin-3-one; 6-[6-(1-cyclobutyl-piperidin-4-yloxy)-pyridin-3-yl]-2-isopropyl-2H-pyridazin-3-one; 6-{6-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-pyridin-3-yl}-2H-pyridazin-3-one; 6-[6-(3-piperidin-1-yl-propoxy)-pyridin-3-yl]-2H-pyridazin-3-one; 6-[6-(1-cyclobutyl-piperidin-4-yloxy)-pyridin-3-yl]-4,4-dimethyl-4,5-dihydro-2H-pyridazin-3-one; 6-[6-(1-cyclobutyl-piperidin-4-yloxy)-pyridin-3-yl]-2-pyridin-2-yl-2H-pyridazin-3-one; 6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-4,5-dihydro-2H-pyridazin-3-one; 6-[4-(1-cyclobutyl-piperidin-4-yloxy)-3-fluoro-phenyl]-4,5-dihydro-2H-pyridazin-3-one; 6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-4,4-dimethyl-4,5-dihydro-2H-pyridazin-3-one; 6-[4-(1-cyclobutyl-piperidin-4-yloxy)-3-fluoro-phenyl]-4,4-dimethyl-4,5-dihydro-2H-pyridazin-3-one; 6-[4-(1-cyclopentyl-piperidin-4-yloxy)-phenyl]-2H-pyridazin-3-one; 6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-2H-pyridazin-3-one; 6-[4-(1-cyclobutyl-piperidin-4-yloxy)-3-fluoro-phenyl]-2H-pyridazin-3-one; 6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-2-pyridin-2-yl-2H-pyridazin-3-one; 6-[4-(piperidin-4-yloxy)-phenyl]-2-pyridin-2-yl-4,5-dihydro-2H-pyridazin-3-one; 6-[4-((R)-1-cyclohexyl-pyrrolidin-3-yloxy)-phenyl]-4,5-dihydro-2H-pyridazin-3-one; 6-[4-((R)-1-cyclohexyl-pyrrolidin-3-yloxy)-phenyl]-2H-pyridazin-3-one; 6-[4-((R)-1-cyclobutyl-pyrrolidin-3-yloxy)-phenyl]-2H-pyridazin-3-one; 6-[4-((R)-1-cyclopentyl-pyrrolidin-3-yloxy)-phenyl]-4,5-dihydro-2H-pyridazin-3-one; 2-cyclobutyl-6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-4,5-dihydro-2H-pyridazin-3-one; 2-cyclobutyl-6-[4-(1-cyclopentyl-piperidin-4-yloxy)-phenyl]-4,5-dihydro-2H-pyridazin-3-one; 2-cyclobutyl-6-[4-(piperidin-4-yloxy)-phenyl]-4,5-dihydro-2H-pyridazin-3-one; 6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-2-(2,2,2-trifluoro-ethyl)-4,5-dihydro-2H-pyridazin-3-one; 6-[4-(1-cyclopentyl-piperidin-4-yloxy)-phenyl]-2-(2,2,2-trifluoro-ethyl)-4,5-dihydro-2H-pyridazin-3-one; 6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-(2,2,2-trifluoro-ethyl)-4,5-dihydro-2H-pyridazin-3-one; 6-{4-[3-piperidin-1-yl-propoxy]-phenyl}-2-(2,2,2-trifluoro-ethyl)-4,5-dihydro-2H-pyridazin-3-one; 6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-(2,2,2-trifluoro-ethyl)-2H-pyridazin-3-one; 6-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2-(2,2,2-trifluoro-ethyl)-2H-pyridazin-3-one; 5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.2.0]oct-4-en-2-one; 5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.2.0]oct-4-en-2-one; 4-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-2,4a,5,6,7,7a-hexahydro-cyclopenta[d]pyridazin-1-one; 4-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2,4a,5,6,7,7a-hexahydro-cyclopenta[d]pyridazin-1-one; 4-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-2,5,6,7-tetrahydro-cyclopenta[d]pyridazin-1-one; 2-cyclobutyl-6-[6-(1-cyclobutyl-piperidin-4-yloxy)-pyridin-3-yl]-4,5-dihydro-2H-pyridazin-3-one; 6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one; 4,4-dimethyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one; 6-{3-fluoro-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one; 6-[3-fluoro-4-(3-piperidin-1-yl-propoxy)-phenyl]-4,5-dihydro-2H-pyridazin-3-one; 5,5-dimethyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one; 6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-pyridin-2-yl-4,5-dihydro-2H-pyridazin-3-one; 6-{3,5-difluoro-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 6-{3,5-dibromo-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 6-{3,5-difluoro-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one; 6-[4-(1-cyclobutyl-piperidin-4-yloxy)-3,5-difluoro-phenyl]-4,5-dihydro-2H-pyridazin-3-one; 6-[4-(1-cyclobutyl-piperidin-4-yloxy)-3,5-difluoro-phenyl]-2H-pyridazin-3-one; 6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one; (R)-6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one; (S)-6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one; 6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-5-ethyl-4,5-dihydro-2H-pyridazin-3-one; 6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-5-methyl-2-pyridin-2-yl-4,5-dihydro-2H-pyridazin-3-one; 5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one racemate; 5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one diastereomer; 5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one diastereomer; 5-methyl-6-[4-(3-piperidin-1-yl-propoxy)-phenyl]-4,5-dihydro-2H-pyridazin-3-one; 5-methyl-6-[4-(3-pyrrolidin-1-yl-propoxy)-phenyl]-4,5-dihydro-2H-pyridazin-3-one; 6-{(R)-2-methyl-4-[3-(2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one; 2-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-6-phenyl-2H-pyridazin-3-one; 6-methyl-2-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 2-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-phthalazin-1-one; 2-[6-(1-cyclobutyl-piperidin-4-yloxy)-pyridin-3-yl]-6-phenyl-2H-pyridazin-3-one; 2-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-6-pyridin-3-yl-2H-pyridazin-3-one; 4-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3-methyl-6H-isoxazolo[3,4-d]pyridazin-7-one; 3-methyl-4-[4-(piperidin-4-yloxy)-phenyl]-6H-isoxazolo[3,4-d]pyridazin-7-one; 3-methyl-4-[4-(3-piperidin-1-yl-propoxy)-phenyl]-6H-isoxazolo[3,4-d]pyridazin-7-one; 3-methyl-4-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-6H-isoxazolo[3,4-d]pyridazin-7-one; 8-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-5,6-dihydro-2H-benzo[h]cinnolin-3-one; 5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 5-ethyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 8-[3-(2-methyl-pyrrolidin-1-yl)-propoxy]-4,4a,5,6-tetrahydro-2H-benzo[h]cinnolin-3-one; 6-{2-methoxy-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 6-{2-fluoro-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-pyridin-2-yl-2H-pyridazin-3-one;; 6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4-pyridin-2-yl-4,5-dihydro-2H-pyridazin-3-one; 6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4-pyridin-2-yl-2H-pyridazin-3-one; 8-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-5,6-dihydro-3H-benzo[f]cinnolin-2-one; 6-[4-(1-cyclobutyl-piperidin-4-yloxy)-2-fluoro-phenyl]-4,5-dihydro-2H-pyridazin-3-one; 8-(1-cyclobutyl-piperidin-4-yloxy)-4,4a,5,6-tetrahydro-2H-benzo[h]cinnolin-3-one; 6-[4-(1-cyclobutyl-piperidin-4-yloxy)-2-fluoro-phenyl]-2H-pyridazin-3-one; 6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-5-methyl-2H-pyridazin-3-one; 5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 2-methoxymethyl-5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 5-{4-[(S)-2-methyl-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 5-{4-[(R)-2-methyl-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 5-[4-((S)-2-methyl-3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 5-[4-((R)-2-methyl-3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 5-{3,5-dibromo-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 2-methoxymethyl-5-{2-methyl-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 5-{2-methyl-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 2-methoxymethyl-5-[2-methyl-4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 5-[2-methyl-4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 5-[4-(1-cyclobutyl-piperidin-4-yloxy)-2-methyl-phenyl]-2-methoxymethyl-2H-pyridazin-3-one; 4-methoxy-2-methoxymethyl-5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 5-methoxy-2-methoxymethyl-4-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 5-methoxy-4-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 6-[4-(3-morpholin-4-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 6-{4-[3-((S)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 6-[4-(3-pyrrolidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 6-{4-[3-(cyclobutyl-methyl-amino)-propoxy]-phenyl}-2H-pyridazin-3-one; 6-{4-[3-(cyclopentyl-methyl-amino)-propoxy]-phenyl}-2H-pyridazin-3-one; 5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; 5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; 5-{4-[(S)-2-methyl-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; 5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one single isomer; 5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one single isomer; 5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one single isomer; 5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one single isomer; 5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3-ethyl-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; 5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3-isopropyl-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; 5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3-methyl-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; 5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3-(4-fluoro-phenyl)-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; 5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3-(2,2,2-trifluoro-ethyl)-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; 6-[4-(2-hydroxy-3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 6-{4-[2-hydroxy-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 6-{4-[(S)-2-hydroxy-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 6-{4-[(R)-2-hydroxy-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 6-[4-((R)-2-hydroxy-3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 5-[4-(1-cyclopentyl-piperidin-4-yloxy)-phenyl]-3-methyl-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; 5-[4-(1-cyclopentyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; and 6-cyclopropyl-2-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; or a stereoisomeric form, mixture of stereoisomeric forms, or a pharmaceutically acceptable salt thereof.
 54. A compound according to claim 53, wherein the compound is selected from the group consisting of: 5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-6-methyl-2H-pyridazin-3-one; 6-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one; 6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-4,4-dimethyl-4,5-dihydro-2H-pyridazin-3-one; 6-[4-(1-cyclobutyl-piperidin-4-yloxy)-3-fluoro-phenyl]-4,4-dimethyl-4,5-dihydro-2H-pyridazin-3-one; 6-[6-(1-cyclobutyl-piperidin-4-yloxy)-pyridin-3-yl]-4,4-dimethyl-4,5-dihydro-2H-pyridazin-3-one; 5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-pyridin-2-yl-2H-pyridazin-3-one; 5-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2-pyridin-2-yl-2H-pyridazin-3-one; 6-{4-[(S)-2-Methyl-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 4,4-dimethyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one; 5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; 5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; 5-{4-[(S)-2-methyl-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; 5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; 5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; 5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; 5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; 5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.2.0]oct-4-en-2-one; 5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one one diastereomer; 5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one one diastereomer; 5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one; and 6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; or a stereoisomeric form, mixture of stereoisomeric forms, or a pharmaceutically acceptable salt thereof.
 55. A compound according to claim 54, wherein the compound is selected from the group consisting of: 5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-pyridin-2-yl-2H-pyridazin-3-one; 5-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2-pyridin-2-yl-2H-pyridazin-3-one; 6-{4-[(S)-2-methyl-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 4,4-dimethyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one; 5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; 5-;[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; 5-{4-[(S)-2-methyl-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; 5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; 5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; 5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; 5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; 5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.2.0]oct-4-en-2-one; 5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one one diastereomer; 5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one one diastereomer; 5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one; and 6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; or a stereoisomeric form, mixture of stereoisomeric forms, or a pharmaceutically acceptable salt thereof.
 56. A compound according to claim 55, wherein the compound is selected from the group consisting of: 4,4-dimethyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one; 5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; 5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; 5-{4-[(S)-2-methyl-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; 5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; 5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; 5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; 5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one; 5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.2.0]oct-4-en-2-one; 5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one one diastereomer; 5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one one diastereomer; 5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one; and 6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; or a stereoisomeric form, mixture of stereoisomeric forms, or a pharmaceutically acceptable salt thereof.
 57. A compound according to claim 55, wherein the compound is 6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one, or a stereoisomeric form, mixture of stereoisomeric forms, or a pharmaceutically acceptable salt thereof.
 58. A pharmaceutical composition comprising a compound of claim 1 or a stereoisomeric form, mixture of stereoisomeric forms, or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.
 59. A method for treating a disorder selected from the group consisting of narcolepsy or sleep/wake disorders, feeding behavior, eating disorders, obesity, cognition, arousal, memory, mood disorders, mood attention alteration, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease/dementia, schizophrenia, pain, stress, migraine, motion sickness, depression, psychiatric disorders, epilepsy, gastrointestinal disorders, respiratory disorders, inflammation, and myocardial infarction in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound according to formula I*:

or a stereoisomeric form, mixture of stereoisomeric forms, or a pharmaceutically acceptable salt thereof. wherein: X and X^(a) are each independently CH or N; Y is S(O)_(q), O, or NR¹⁵; R¹ is NR¹⁰R¹¹ or a 4- to 9-membered heterocycloalkyl ring containing 1 or 2 nitrogen atoms and optionally substituted with 1 to 3 R²⁰ groups; R² is

wherein: when X and X^(a) are both CH, then R² is meta or para to the Y—(CHR⁴)_(m)—R¹ group; and when either X or X^(a) are N, then R² is para to the Y—(CHR⁴)_(m)—R¹ group; each R³ is: independently H, F, Cl, Br, I, OR²¹, NR²³R²⁴, NO₂, CN, CF₃, C₁-C₆alkyl, C(═O)R²¹, CO₂R²¹, or C(═O)NR²³R²⁴; or when R³ is ortho to R², and R² is (i), (ii), (iv), (vi), or (ix), then R³ and R¹⁴ taken together may form —(CH₂)_(s)—, —CH₂Z-, -ZCH₂—, -ZCH₂CH₂— or CH₂CH₂Z-; wherein Z is O, S(O)_(y), or NR²⁷; or when R³ is ortho to R², and R² is (iv), (v), or (viii), then R³ and R¹³ taken together may form —(CH₂)_(s)—, —CH₂Z-, -ZCH₂—, -ZCH₂CH₂— or CH₂CH₂Z-; or when R³ is ortho to R², and R² is (viii), then R³ and R^(13b) taken together may form —(CH₂)_(s)—, —CH₂Z-, -ZCH₂—, -ZCH₂CH₂— or CH₂CH₂Z-; or when R³ is ortho to X^(a) and R² is ortho to R³ and meta to X^(a), then R² and R³ taken together may form:

each R⁴ is independently H, C₁-C₆alkyl, or OR²¹, wherein the alkyl group is optionally substituted with 1 to 3 R²⁰ groups; R¹⁰ and R¹¹ are each independently H, C₁-C₆alkyl, or C₃-C₆cycloalkyl, wherein the alkyl or cycloalkyl group is optionally substituted with 1 to 3 R²⁰ groups; R¹² is H, C₁-C₆alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocycloalkyl, C(═O)R²⁷, or CO₂R²⁷, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, or heterocycloalkyl group is optionally substituted with 1 to 3 R²⁰ groups; R¹³ and R¹⁴ are each independently H, C₁-C₆alkyl, aryl, arylalkyl C₁-C₆alkoxyl, S(═O)_(y)—C₁-C₆alkyl, cycloalkyl, heterocycloalkyl, or heteroaryl; R^(13a), R^(13b), R^(13c), and R^(14a) are each independently H, C₁-C₆alkyl; or R¹³ and R¹⁴, taken together with the carbon atoms through which they are connected form a fused phenyl, thienyl, pyrrolyl, oxazolyl, pyridinyl, or C₃-C₆cycloalkyl ring; or R^(13b) and R¹⁴, or R¹³ and ^(14a), or R^(13b) and ^(14a), or R^(13c) and R^(14a), taken together with the carbon atoms through which they are connected form a fused C₃-C₆cycloalkyl ring; or R¹³ and R^(13a), or R¹⁴ and R¹³, taken together with the carbon atom to which they are attached form a C₃-C₈cycloalkyl ring; provided that no more than one pair of R¹³ and R¹⁴, R^(13b) and R¹⁴, R¹³ and R^(14a), R^(13b) and R^(14a), R^(13c) and R^(14a), R¹³ and R^(13a), and R¹⁴ and R^(14a) are taken together with the carbon atoms through which they are connected or to which they are attached to form a ring; and wherein the fused phenyl, thienyl, pyrrolyl, oxazolyl, pyridinyl, or cycloalkyl ring is optionally substituted with 1 to 3 R²⁰ groups; R¹⁵ is H, C₁-C₆ alkyl, C(═O)R²⁵, CO₂R²⁵; R²⁰ at each occurrence is independently, H, F, Cl, Br, I, OR²¹, OR²², NR²³R²⁴, NHOH, NO₂, CN, CF₃, C₁-C₆ alkyl optionally substituted with OR²⁶, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₇cycloalkylC₀-C₄alkyl, 3- to 7-membered heterocycloalkylC₀-C₄alkyl, phenyl, 5- or 6-membered heteroarylC₀-C₄alkyl, arylalkyl, (═O), C(═O)R²¹, CO₂R²¹, OC(═O)R²¹, C(═O)NR²³R²⁴, NR²⁷C(═O)R², NR²⁷C(═O)OR²¹, OC(═O)NR²³R²⁴, NR²⁷C(═S)R²¹, or S(O)_(q)R²¹; each R²¹ is independently H, C₁-C₆alkyl, aryl, or arylalkyl; each R²² is independently the residue of an amino acid after the hydroxyl group of the carboxyl group is removed; each R²³ and R²⁴ is independently selected from H, C₁-C₆alkyl, and aryl, or R²³ and R²⁴, together with the nitrogen atom to which they are attached, form a 3 to 7 membered heterocyclic ring optionally substituted with ═O; R²⁵ is C₁-C₆alkyl, aryl, or alkylaryl; R²⁶ is H, C₁-C₆alkyl, aryl, or alkylaryl; R²⁷ is H or C₁-C₆alkyl; m is 1, 2, 3, 4, or 5 when R¹ is attached via a nitrogen atom, and m is 0, 1, 2, 3, 4, or 5 when R¹ is attached via a carbon atom; n is 1, 2, or 3; q is 0, 1, or 2; s is 1, 2, or 3; and y is 0, 1, or
 2. 60. The method of claim 59 wherein the disorder is narcolepsy or sleep/wake disorders.
 61. The method of claim 59 wherein the disorder is attention deficit hyperactivity disorder.
 62. A compound according to claim 1 having the structure:

and stereoisomeric forms, mixtures of stereoisomeric forms or pharmaceutically acceptable salt forms thereof, wherein: X and X^(a) are each independently CH or N; Y is selected from S(O)_(q), O, and NR¹⁵; R¹ is NR¹⁰R¹¹ or a 4 to 9 membered heterocycloalkyl ring containing 1 or 2 nitrogen atoms and optionally substituted with 1 to 3 R²⁰ groups; R² is

wherein: when X and X^(a) are both CH, then R² is meta or para to the Y—(CHR⁴)_(m)—R¹ group; and when either X or X^(a) are N, then R² is para to the Y—(CHR⁴)_(m)—R¹ group; R³ is: at each occurrence is independently, H, F, Cl, Br, I, OR²¹, NR²³R²⁴, NO₂, CN, CF₃, C₁-C₆ alkyl, C(═O)R²¹, CO₂R²¹, or C(═O)NR²³R²⁴; or when R³ is ortho to R², then R³ and R¹⁴ can combine to form —(CH₂)_(s)—, —CH₂Z-, CH₂CH₂Z-; wherein Z is O, S(O)_(y), NR²⁷; or when R³ is ortho to X^(a) and R² is ortho to R³ and meta to X^(a), then R² and R³ combine to form:

R⁴ is H, C₁-C₆ alkyl, or OR²¹, wherein the alkyl group is optionally substituted with 1 to 3 R²⁰ groups; R¹⁰ and R¹¹ are each, independently H or C₁-C₆ alkyl, wherein the alkyl group is optionally substituted with 1 to 3 R²⁰ groups; R¹² is H, C₁-C₆ alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocycloalkyl, C(═O)R²⁷, or CO₂R²⁷, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, and heterocycloalkyl groups are optionally substituted with 1 to 3 R²⁰ groups; R¹³ and R¹⁴ are independently H, C₁-C₆ alkyl, aryl, or arylalkyl or R¹³ and R¹⁴ can combine to form a fused phenyl, thienyl, pyrrolyl, cyclopentyl or cyclohexyl ring; wherein the phenyl, thienyl, pyrrolyl, cyclopentyl or cyclohexyl rings are optionally substituted with 1 to 3 R²⁰ groups; R¹⁵ is H, C₁-C₆ alkyl, C(═O)R²⁵, CO₂R²⁵; R²⁰ at each occurrence is independently, H, F, Cl, Br, I, OR²¹, OR²², NR²³R²⁴, NHOH, NO₂, CN, CF₃, C₁-C₆ alkyl optionally substituted with OR²⁶, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₇ cycloalkyl, 3-7 membered heterocycloalkyl, phenyl, 5 or 6 membered heteroaryl, arylalkyl, (═O), C(═O)R²¹, CO₂R²¹, OC(═O)R²¹, C(═O)NR²³R²⁴, NR²⁷C(═O)R²¹, NR²⁷C(═O)OR²¹, OC(═O)NR²³R²⁴, NR²⁷C(═S)R²¹, or S(O)_(q)R²¹; R²¹ at each occurrence is independently H, C₁-C₆ alkyl, aryl, or arylalkyl; R²² at each occurrence is independently the residue of an amino acid after the hydroxyl group of the carboxyl group is removed; R²³ and R²⁴ at each occurrence are each independently selected from H, C₁-C₆ alkyl, and aryl, or R²³ and R²⁴, together with the nitrogen atom to which they are attached, form a 3 to 7 membered heterocyclic ring optionally substituted with ═O; R²⁵ is C₁-C₆ alkyl, aryl, or alkylaryl; R²⁶ is H, C₁-C₆ alkyl, aryl, or alkylaryl; R²⁷ is H or C₁-C₆ alkyl; m is 1, 2, 3, 4, or 5 when R¹ is attached via a nitrogen atom, and m is 0, 1, 2, 3, 4, or 5 when R¹ is attached via a carbon atom; n is 0, 1, 2, or 3; q is 0, 1, or 2; s is 1, 2, or
 3. 63. The compound of claim 62 wherein the compounds are selected from: 2-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 2-methyl-6-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 2-isopropyl-6-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 2-isopropyl-6-[4-(3-piperidin-1-yl-propoxy)-phenyl]-4,5-dihydro-2H-pyridazin-3-one; 2-isopropyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 2-ethyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 6-{3-fluoro-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-methyl-2H-pyridazin-3-one; 2-(2,4-dichloro-benzyl)-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one; 2-(3,5-dichloro-phenyl)-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 6-[3-fluoro-4-(3-piperidin-1-yl-propoxy)-phenyl]-2-phenyl-2H-pyridazin-3-one; 6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 4-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2,5,6,7-tetrahydro-cyclopenta[d]pyridazin-1-one; 2-methyl-6-{4-[(S)-2-methyl-3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 6-{4-[3-((S)-2-hydroxymethyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-methyl-2H-pyridazin-3-one; 6-{4-[3-((R)-2-hydroxymethyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-methyl-2H-pyridazin-3-one; 2-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one; 2-benzyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one; 2-benzyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-phenyl-2H-pyridazin-3-one; 6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-phenyl-2H-pyridazin-3-one; 2-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 5-Isopropyl-7-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-5H-thieno[2,3-d]pyridazin-4-one; 7-{4-[3-(2,5-dimethyl-pyrrolidin-1-yl)-propoxy]-phenyl}-5-isopropyl-5H-thieno[2,3-d]pyridazin-4-one; 5-isopropyl-7-[4-(3-piperidin-1-yl-propoxy)-phenyl]-5H-thieno[2,3-d]pyridazin-4-one; 7-{4-[3-(3,3-dimethyl-piperidin-1-yl)-propoxy]-phenyl}-5-isopropyl-5H-thieno[2,3-d]pyridazin-4-one; 5-isopropyl-7-{4-[3-((S)-2-methoxymethyl-pyrrolidin-1-yl)-propoxy]-phenyl}-5H-thieno[2,3-d]pyridazin-4-one; 5-isopropyl-7-{4-[3-((R)-2-methoxymethyl-pyrrolidin-1-yl)-propoxy]-phenyl}-5H-thieno[2,3-d]pyridazin-4-one; 7-[4-(3-diethylamino-propoxy)-phenyl]-5-isopropyl-5H-thieno[2,3-d]pyridazin-4-one; 5-isopropyl-7-[4-(3-pyrrolidin-1-yl-propoxy)-phenyl]-5H-thieno[2,3-d]-pyridazin-4-one; 5-isopropyl-7-{4-[3-(4-pyrrolidin-1-yl-piperidin-1-yl)-propoxy]-phenyl}-5H-thieno[2,3-d]pyridazin-4-one; 7-{4-[3-((2R,5R)-2,5-dimethyl-pyrrolidin-1-yl)-propoxy]-phenyl}-5-isopropyl-5H-thieno[2,3-d]pyridazin-4-one; 7-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-5-propyl-5H-thieno[2,3-d]pyridazin-4-one; 7-{4-[3-((2R,5R)-2,5-dimethyl-pyrrolidin-1-yl)-propoxy]-phenyl}-5-propyl-5H-thieno[2,3-d]pyridazin-4-one; 7-{4-[3-(4-methyl-piperidin-1-yl)-propoxy]-phenyl}-5-propyl-5H-thieno[2,3-d]pyridazin-4-one; 7-{4-[3-(4-dimethylamino-piperidin-1-yl)-propoxy]-phenyl}-5-propyl-5H-thieno[2,3-d]pyridazin-4-one; 5-propyl-7-{4-[3-((S)-2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-propoxy]-phenyl}-5H-thieno[2,3-d]pyridazin-4-one; 5-(4-chloro-benzyl)-7-[4-(3-piperidin-1-yl-propoxy)-phenyl]-5H-thieno[2,3-d]pyridazin-4-one; 5-(4-chloro-benzyl)-7-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-5H-thieno[2,3-d]pyridazin-4-one; 2,4-dimethyl-6-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 2,4-dimethyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 2-isopropyl-4-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 2-isopropyl-4-methyl-6-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 2-benzyl-4-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 2-benzyl-4-methyl-6-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 4-benzyl-2-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; 4-benzyl-2-methyl-6-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 2-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-5-phenyl-2H-pyridazin-3-one; 2-methyl-5-phenyl-6-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 2-methyl-4-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-phthalazin-1-one; 2-methyl-4-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-phthalazin-1-one; 2-methyl-4-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-2H-phthalazin-1-one; 2-methyl-4-[4-(3-pyrrolidin-1-yl-propoxy)-phenyl]-2H-phthalazin-1-one; 4-[4-(3-azepan-1-yl-propoxy)-phenyl]-2-methyl-2H-phthalazin-1-one; 2-(4-chloro-benzyl)-4-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H-phthalazin-1-one; 2-(4-chloro-benzyl)-4-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2H-phthalazin-1-one; 2-methyl-4-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2,5,6,7-tetrahydro-cyclopenta[d]pyridazin-1-one; 2-methyl-4-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2,5,6,7-tetrahydro-cyclopenta[d]pyridazin-1-one; 2-methyl-4-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2,4a,5,6,7,7a-hexahydro-cyclopenta[d]pyridazin-1-one; 2-methyl-4-[4-(3-piperidin-1-yl-propoxy)-phenyl]-2,4a,5,6,7,7a-hexahydro-cyclopenta[d]pyridazin-1-one; 2-methyl-4-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-5,6,7,8-tetrahydro-2H-phthalazin-1-one; 4-{4-[3-(butyl-ethyl-amino)-propoxy]-phenyl}-2-methyl-5,6,7,8-tetrahydro-2H-phthalazin-1-one; 4-[4-(3-methyl-4-oxo-3,4-dihydro-phthalazin-1-yl)-phenoxymethyl]-piperidine-1-carboxylic acid tert-butyl ester; 2-methyl-4-[4-(piperidin-4-ylmethoxy)-phenyl]-2H-phthalazin-1-one; 4-[4-(1-cyclobutyl-piperidin-4-ylmethoxy)-phenyl]-2-methyl-2H-phthalazin-1-one; 4-[4-(1-methyl-6-oxo-1,6-dihydro-pyridazin-3-yl)-phenoxymethyl]-piperidine-1-carboxylic acid tert-butyl ester; 2-methyl-6-[4-(piperidin-4-ylmethoxy)-phenyl]-2H-pyridazin-3-one; 6-[4-(1-cyclobutyl-piperidin-4-ylmethoxy)-phenyl]-2-methyl-2H-pyridazin-3-one; 6-[4-(1-isopropyl-piperidin-4-ylmethoxy)-phenyl]-2-methyl-2H-pyridazin-3-one; 6-[4-(1-cyclopropylmethyl-piperidin-4-ylmethoxy)-phenyl]-2-methyl-2H-pyridazin-3-one; 6-[4-(1-cyclopentyl-piperidin-4-ylmethoxy)-phenyl]-2-methyl-2H-pyridazin-3-one; 2-methyl-6-[4-(1-methyl-piperidin-4-ylmethoxy)-phenyl]-2H-pyridazin-3-one; 6-[4-(1-isopropyl-piperidin-4-yloxy)-phenyl]-2-methyl-2H-pyridazin-3-one; 2-methyl-6-[4-(piperidin-4-yloxy)-phenyl]-2H-pyridazin-3-one; 2-methyl-6-[4-(piperidin-4-yloxy)-phenyl]-2H-pyridazin-3-one; 2-methyl-8-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-5,6-dihydro-2H-benzo[h]cinnolin-3-one; 8-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-2-phenyl-5,6-dihydro-2H-benzo[h]cinnolin-3-one; 2-benzyl-8-(3-piperidin-1-yl-propoxy)-5,6-dihydro-2H-benzo[h]cinnolin-3-one; 2-isopropyl-8-(3-piperidin-1-yl-propoxy)-5,6-dihydro-2H-benzo[h]cinnolin-3-one; 2-methyl-7-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-2H-phthalazin-1-one; 2-methyl-7-(3-piperidin-1-yl-propoxy)-2H-phthalazin-1-one; and 6-{3-fluoro-4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-phenyl-2H-pyridazin-3-one; and stereoisomeric forms, mixtures of stereoisomeric forms or pharmaceutically acceptable salt forms thereof.
 64. A pharmaceutical composition comprising a compound of claim 62 and one or more pharmaceutically acceptable excipients.
 65. A method for treating a disorder selected from the group consisting of narcolepsy or sleep/wake disorders, feeding behavior, eating disorders, obesity, cognition, arousal, memory, mood disorders, mood attention alteration, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease/dementia, schizophrenia, pain, stress, migraine, motion sickness, depression, psychiatric disorders, epilepsy, gastrointestinal disorders, respiratory disorders, inflammation, and myocardial infarction, comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of claim
 62. 66. The method of claim 65 wherein the disorder is narcolepsy or sleep/wake disorders.
 67. The method of claim 65 wherein the disorder is attention deficit hyperactivity disorder. 